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Abstract
Development of a transgenic mouse model of hereditary pancreatitis.
Tejinderjit Singh Atliwal
Hereditaiy pancreatitis, a rare autosomal dominant condition, presents with 
recurrent episodes of acute pancreatitis and usually progresses to chronic 
pancreatitis with patients at an increased risk of developing pancreatic 
adenocarcinoma. The majority of patients are carriers of either the R122H or N29I 
mutation in the cationic trypsinogen gene (PRSS1), one of the most abundant 
digestive enzymes produced by the pancreas. The mutations are thought to 
increase autoactivation of the proenzyme cationic trypsinogen to trypsin within 
the acinar cell, initiating a digestive enzyme cascade leading to pancreatitis, A 
genetically modified mouse model expressing wild type (wt) or mutant human 
PRSS1 may be exploited to study the molecular events in hereditary pancreatitis.
To investigate this, two transgenic mouse models were developed to either 
inducibly or constitutively express wt or mutant human PRSS1 tagged with a 
haemaglutinin motif to aid identification. In the inducible model, transgenic 
animals treated with tetracycline would enable binding of OptrtTA (optimised 
reversed Tet transcription activator) inducing the expression of PRSS1-based 
transgenes specifically in the acinar cells of the pancreas. In the constitutive 
model, expression of PRS SI-based transgenes is driven by the acinar cell specific 
rat elastase I promoter. Prior to generation of transgenic strains, expression 
constructs were created and tested by transient transfection of human cell lines 
that showed expression of the recombmant proteins. In addition, enzymatic 
activity of tagged human PRS SI was demonstrated using an in vitro trypsin assay.
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Chapter 1
1 INTRODUCTION
1.1 The Pancreas
1.1.1 Anatomy
The pancreas originates from the primitive digestive tube, which is formed 
by a single layer of endodenn. Two epithelial buds, referred to as the 
dorsal pancreas and ventral pancreas, coalesce to fonn a single organ 
(Edlund 2002). It is a retroperitoneal organ, located against the posterior 
abdominal wall and its anterior surface is covered by peritoneum. The 
pancreas weighs 60 to 150g in adults and is divided into regions that are 
described as the head and uncinate process, neck, body, and tail 
(Sinnatamby 2000). The portion of the gland that secretes pancreatic juice 
drains initially into small ductules that coalesce into a single duct 
(pancreatic duct of Wirsung), which usually joins the common bile duct to 
form the ampulla of Vater. The ampulla opens through the duodenal 
papilla, and its orifice is encircled by the sphincter of Oddi (Sinnatamby 
2000).
1.1.2 Physiology
Functionally, the pancreas is a mixed endocrine-exocrine gland secreting 
its products straight into the blood stream or in the duodenum respectively. 
The endocrine pancreas is made up of honnone producing cells organised
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into clusters known as islets of Langerhans dispersed throughout the 
pancreas (Madsen, Jensen et al. 1996), The islets are made up of four cell 
types (a cells, |3 cells, 6 cells and PP cells) each producing a particular 
hormone (glucogen, insulin, somatostatin and pancreatic polypeptide 
respectively). The hormones secreted by the endocrine cells regulate 
nutrient metabolism, in particular, (3 cells produce insulin to maintain 
glucose homeostasis (Madsen, Jensen et al. 1996). The exocrine pancreas, 
which represents 85% of the gland, consists of the ductal tree and the 
secretory acinar cells (Ganong 2001).
1.1.3 Acinar Cell
The acinar cell, the most numerous cell type in the pancreas, is a classic 
protein producing and secreting cell (Palade 1975). Digestive enzymes (i.e. 
proteases, amylase, lipase etc) which are required for digestion of protein, 
carbohydrates and lipids, are synthesized as inactive precursors or 
proenzymes by ribosomes at the rough endoplasmic reticulum, found at the 
basal and lateral aspects of the acinar* cell (Caro and Palade 1964). The 
enzymes are separated from constitutive and lysosomal proteins within the 
Golgi apparatus and packaged into condensing vacuoles (Fig 1.1). The 
enzymes are sorted further within the immature condensing vacuoles by 
pH dependant aggregation with exclusion of constitutive proteins, thus 
resulting in the formation of mature concentrated zymogen granules, which 
store the enzymes at the apical pole, until secretion is mitiated (Douglas
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and Rubin 1961). The internal milieu of the acinar cell is tightly regulated 
by homeostatic mechanisms in order to maintain, amongst others, a 
constant pH and cytosolic calcium concentration (Pandol 2005). Under 
physiological conditions the cytosolic calcium concentration of the acinar 
cell is approximately 0.1 pM compared to ImM in the extracellular fluid 
and lOOpM in the intracellular organelles, for instance the endoplasmic 
reticulum (Argent, Case et al. 1982). The relative concentrations are 
maintained by active pumping of calcium out of the cytosol by ATP 
dependant transporters (Mogami, Nakano et al. 1997). Regulation of pH is 
less well understood, but homeostasis is largely achieved by active 
transportation of hydrogen ions by a H+-ATPase pump (Muallem and 
Loessberg 1990). Rodent acinar cells have a cytosolic pH between 6.77 
and 7.28 compared to an extracellular pH which may vary between 7.2 and 
7.5 (Williams and Dimagno 2009). The pH of the secretory pathway is 
mildly acidic (~pH 6.8) in the Golgi complex, whilst the condensing 
vacuoles are more acidic (~pH 6.5) and the mature zymogen granules are 
neutral (Orci, Ravazzola et al. 1987). Lysosomes are acidic with a pH of 
5.0 (Williams and Dimagno 2009).
The acinar cells secrete the contents of the zymogen granules in response 
to several neurohormonal regulators released in response to the ingestion 
of food (Williams 2006). The principle secretagogues, acetylcholine (ACh) 
and cholecystokinin (CCK), activate the inositol 1,4,5 triphosphate (IP3) /
3
diacyl glycerol signalling pathway which leads to a oscillatory rise in 
cytosolic Ca2+ (Thom, Gerasimenko et al. 1994) and triggers zymogen 
granule exocytosis (Tsunoda, Stuenkel et al. 1990). Other than IPs, the 
secondary messengers nicotinic acid adenine dinucleotide phosphate and 
cyclic adenosine dinucleotide phosphate ribose also regulate Ca2+- 
dependant exocytosis (Cancela, Van Coppenolle et al. 2002). The 
proenzymes travel through the ductules which merge into small ducts and 
finally into the main pancreatic duct, to enter the duodenum (Rinderknecht 
1986), Here the enteropeptidase, enterokinase (PRSS7; OMIM 606635), 
secreted by the brush border of the duodenum activates trypsinogen to 
trypsin by proteolytic cleavage of an eight amino acid peptide, trypsin­
activating peptide (TAP), from the C terminus (Rinderknecht, Engeling et 
al. 1974). Trypsin in turn activates the other pancreatic proteases in a 
similar mamier (Rinderknecht 1986).
1.1.4 Ductal Bicarbonate Secretion
Once the acinar cells have secreted the proenzymes, they are carried into 
the duodenum in a bicarbonate rich pancreatic juice. The bicarbonate is 
secreted by ductal cells upon stimulation by secretin (Femandez-Salazar, 
Pascua et al. 2004). Approximately two litres of isotonic, bicarbonate rich, 
pancreatic juice enters the duodenum daily, and has a pH of 8 - 8.5 
(Stuenkel, Machen et al. 1988). This raises the pH of the acid chyme 
entering the duodenum, from the stomach, towards neutral and thus
4
creating an optimal environment for pancreatic enzymes to function 
(Rinderknecht 1986).
5
Fig 1.1 Acinar Cell
A schematic diagram of an acinar cell showing the synthesis and 
processing pathway of proteins from the endoplasmic reticulum (ER), 
through the cell. The secretory pathway comprises of immature 
condensing vacuoles (CV) and mature zymogen granules (ZG) for 
storage of proenzymes, which are released by exocytosis. A separate 
pathway transports enzymes to lysosomes (LYS). With permission from 
(van Acker, Perides et al. 2006)
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1.2 Proteases
1.2.1 Pancreatic proteases
Pancreatic proteases account for approximately 80% of the enzymes, by 
weight, secreted by the pancreas (Whitcomb and Lowe 2007). They, along 
with proteases secreted at other sites in the gastrointestinal tract, are 
responsible for the digestion of ingested proteins to provide the body with 
the source for essential amino acids (Whitcomb and Lowe 2007). 
Pancreatic proteases can be divided into serine proteases, which are 
endopeptidases, and metalloproteinases (i.e. caboxypeptidases), which are 
exopeptidases (Whitcomb and Lowe 2007).
1.2.2 Serine Proteases
The serine protease family consists of trypsins along with elastase and 
chymotrypsins (Teich, Hoffineister et al. 2000). The term arises due to the 
enzymes having a preserved serine residue at position 195, based on the 
chymotrypsin numbering system (Teich, Hoffineister et al. 2000). To 
clarify the previous statement, the amino acid sequence of these enzymes 
can be described using the chymotrypsin numbering system or the codon 
numbering system. The chymotrypsin numbering system aligns all serine 
proteases to centre on the serine 195 residue of the chymotrypsin molecule 
whilst the codon nomenclature numbers the first codon (methionine) as 
codon 1 (Keim, Teich et al. 2000). To avoid confusion, it was agreed in 
2000 that the codon system is the preferred one when describing the amino
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acid positions of trypsinogen (Teich, Hoffmeister et al 2000). The codon 
system will be used in this thesis unless specifically stated. Serine 
proteases are composed of a single peptide which folds to give a highly 
homologous 3D structure consisting of 2 globular domains connected by a 
single chain known as the autolysis loop, as shown using x-ray 
crystallography (Gaboriaud, Serre et al. 1996), though the specificity 
pocket varies from one protease to the other, in order to allow hydrolysis of 
particular peptide bonds (Gaboriaud, Serre et al. 1996). Trypsins hydrolyse 
at the site of basic amino acids (lysine and arginine), whilst the 
chymotrypsins hydrolyse at the site of aromatic amino acids 
(phenylalanine, tyrosine and tryptophan) and the elastases cleave the bond 
after neutral small amino acids (alanine, serine and glycine). The catalytic 
site is formed by histidine at position 57, aspartic acid at position 102 and 
serine at position 195 (chymotrypsin numbering system) and the specificity 
pocket is determined by the amino acids at positions 189, 216 and 226 
(Craik, Largman et al. 1985) (Fig 1.2).
The serine proteases and the carboxypeptidases digest the polypeptides 
entering the small bowel from the stomach. As described above, the 
enzymes reach the small bowel in their inactive form and here trypsinogen 
is activated to trypsin by the action of the brush border hydro lyase, 
enterokinase (Rinderknecht 1986) (Fig 1.3). Typsin is considered a key
Signal peptide TAP
PRSS1
PRSS2
PRSS3
mnplliltfvaaala-apfddddk-ivggync eensvpyqvs 
mnllliltfvaaava-apfddddk-ivggyic eensvpyqvs 
mnpflilafvgaava-vpfddddk-ivggytc eenslpyqvs
Insgyhfcgg 50
Insgyhfcgg
Insgshfcgg
siineqwvvs 
siiseqwvvs 
sliseqwvvs
aglcyksriq vrlgehniev 
aglcyksriq vrlgehniev 
aa|cyktriq vrlgehnikv
legneqfina 
legneqfina 
legneqfina
akiirhpqyd
akiirhpkyn
akiirhpkyn
100
rktlnnBiml 
srtldnlill 
rdt Idnekiml
iklssravin
iklsspavin
iklsspavin
arvstislpt
srvsaislpt
arvstislpt
appatgtkcl
appaagtesl
appaagtecl
isgwgntass 150
isgwgntlss
isgwgntlsf
gadypdelqc
gadypdelqc
gadypdelkc
Idapvlsqak ceasypgkit 
Idapvlsqae ceasypgkit 
Idapvltqae ckasypgkit
snmfcvgfle ggkBscqgdB 200 
nnmfcvgfle ggkBscqgdl 
nsmfcvgfle ggk|scqrd|
ggpvvcngql
ggpvvsngel
ggpvvcngql
qgvvswldgc aqknkpBvyt 
qgivswBygc aqknrpBvyt 
qgvvswphgc awknrpjvyt
kvynyvkwik ntiaans 
kvynyvdwik dtiaans 
kvynyvdwik dtiaans
247
Fig 1.2 Human Trypsinogen sequences
The amino acid sequence of the three human pancreatic trypsinogens; 
PRSS1, PRSS2 and PRSS3. Each sequence begins with the pre-pro­
peptide or signal peptide that is cleaved after transport to the ER. The 
proenzyme is packaged into zymogen granules ready for secretion. In 
the duodenum, enterokinase cleaves the trypsinogen activating peptide 
(TAP), converting trypsinogen to the active trypsin. The (-) shows the 
position of cleavage and the conserved residues within the catalytic site 
are highlighted in blue whilst the amino acids determining substrate 
specificity are highlighted red.
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enzyme as it activates the proenzymes including chymotrypsinogen, 
proelastase and procarboxypeptidase, whilst also being able to activate 
trypsinogen and thus start an autocatalytic chain reaction (Rinderknecht 
1986) (Fig 1.3). This property gives trypsin a central role in protein 
digestion and led to it being implicated in the pathophysiology of acute 
pancreatitis (Whitcomb, Gorry et al. 1996).
1.2.3 Trypsinogens
Trypsin and its inactive fonn, trypsinogen, have been well characterised 
and extensively studied. Trypsinogen was crystallized from bovine 
pancreas in 1936 (Northrop and Kunitz 1932) and later partially isolated 
from human pancreas by Buck et al in 1962 (Buck, Bier et al. 1962). It is 
the most abundant enzyme produced by the exocrine pancreas, making up 
19% of the protein in pancreatic juice (Whitcomb and Lowe 2007). It is 
secreted from the pancreas as a 28 kDa polypeptide (Scheele, Bartelt et al. 
1981).
There are three isoforms of trypsinogen produced within the human 
pancreatic acinar cell encoded by similar genetic sequences (Rowen, Koop 
et al. 1996) resulting in a 247 amino acid polypeptide, including a 15 
amino acid signalling peptide (pre-proenzyme), and an 8 amino acid 
peptide (proenzyme), trypsinogen activation peptide (TAP) (Sahin-Toth 
2006) (Fig 1.2).
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On the basis of their isoelectric points and electrophoretic mobility, the 
proenzyme isoforms are known as cationic trypsinogen, anionic 
trypsinogen and mesotrypsinogen respectively (Scheele, Bartelt et al. 
1981). Cationic trypsinogen accounts for approximately two thirds of all 
tiypsin activity (Rinderknecht, Renner et al. 1979) and has historically 
been termed trypsinogen 1 (Figarella, Clemente et al. 1969) and 
trypsinogen 3 (Scheele, Bartelt et al. 1981). The cDNA was named TYRI 
(Emi, Nakamura et al. 1986) and the gene T4 (Rowen, Koop et al. 1996) 
with the Unigene name and symbol of protease, serine 1, and PRSS1 
(OUm 276000).
Anionic trypsinogen is the second most abundant form produced in the 
pancreas, making up about one third of trypsin activity (Figarella, Negri et 
al. 1975; Guy, Lombardo et al. 1978). It has historically been tenned 
trypsinogen 2 (Figarella, Clemente et al. 1969) and trypsinogen 1 (Scheele, 
Bartelt et al. 1981), whilst its cDNA was named TYRII (Emi, Nakamura et 
al. 1986) and the gene T8 (Rowen, Koop et al. 1996). Its Unigene name 
and symbol are protease, serine 2, and PRSS2 (OMIM 601564).
The third isoform is mesotrypsinogen (PRSS3), which is secreted in 
relatively low amounts (Rinderknecht, Renner et al. 1984). It is, however, 
unique from the other two isoforms due to its resistance to trypsin 
inhibitors such as the Kazal type pancreatic secretory tiypsin inhibitor 
(PSTI or by the Unigene term, serine protease inhibitor, Kazal-type, 1
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(SPINK1)) and the Kunitz type soybean trypsin inhibitor (SBTI) 
(Rinderknecht, Renner et al. 1984; Nyaruhucha, Kito et al. 1997). This 
property is regarded to arise from the presence of arginine at position 198 
in place of the highly conserved glycine (Szmola, Kukor et al. 2003). This 
change renders mesotrypsin resistant to protease inhibitors and disrupts its 
ability to cleave protein substrates (Szmola, Kukor et al. 2003). 
Interestingly, it has been observed that mesotrypsin is able to degrade 
trypsin inhibitors leading to speculation that its physiological role may 
have evolved in diets rich in these inhibitors (Sahin-Toth 2005).
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Trypsinogen
Enterokinase
(autoactivation)
Trypsin (wt)
Mesotrypsin 
Chymotrysin C 
Trypsin
► EnzymesProenzymes
Pancreas ............. ► Autodigestion
Fig 1.3 Activation of Trypsinogen
In the intestine trypsinogen is activated by enterokinase into trypsin, 
which can then activate other proenzymes to aid digestion of proteins in 
the diet. Within the cell activation of trypsinogen is inhibited by storage 
within zymogen granules, and tight control of intracellular calcium and 
pH levels. Pancreatic secretory trypsin inhibitor (PSTI or SPINK 1) 
within the cell can inhibit 20% of activated trypsin. Inappropriate 
intracellular activation of trypsinogen that overwhelms these protective 
machanism may cause a chain reaction leading to acute pancreatitis. With 
permission from (Whitcomb, Gorry et al. 1996)
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Most of the genes (eight) encoding for the members of the trypsinogen 
family are located on the long arm of chromosome 7q35 with the exception 
of the mesotrypsinogen gene, which is located on chromosome 9pl3 
(Rowen, Koop et al. 1996; Rowen, Williams et al. 2005). The genes for 
PRSS1 and PRSS2 lie near the 3’ end of the T-cell receptor beta locus 
(Rowen, Koop et al. 1996), flanking two pseudogenes and also trypsinogen 
C, which may be functional, but no corresponding cDNA has been 
identified. These five trypsinogens are highly homologous with a sequence 
homology of at least 90% and consisting of 5 exons each spanning ~3.6kb 
(Rowen, Koop et al. 1996). A further two pseudogenes and a relic gene lie 
at the 5’ end of the locus (Rowen, Koop et al. 1996).
1.2.4 Trypsinogen Activation and Degradation 
The first evidence of enzyme activity in pancreatic juice came from the 
laboratory’s of Ivan Pavlov, recipient of the Noble prize in medicine or 
physiology in 1904. Pavlov established a method of constructing 
permanent pancreatic fistulae in dogs by stitching a patch of duodenum, on 
which the pancreatic duct opens, onto the abdominal wall (Pavlov), hi this 
way, whenever the dog was fed a flow of pancreatic juice was obtained, 
trickling from the duct over the small patch of mucous membrane and into 
a funnelled receiver tied to the belly of the animal.
The experiments to assess proteolytic activity of the pancreatic juice, 
especially with regards to trypsin, were at odds with earlier work by Pavlov
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and his pupil. The reason for this became apparent when Chepovalnikow 
showed that the pancreatic juice obtained by Pavlov’s procedure contained 
only small portions of trypsin, but a large amount of trypsinogen, and this 
latter substance needed for its conversion into trypsin the interaction of a 
body contained in the succus entericus (Chepovalnikov 1899), and called 
by Pavlov ‘enterokinase’. According to Pavlov, enterokinase acts as a 
‘ferment of ferments’, converting trypsinogen into trypsin just as trypsin 
converts other enzymes into their activated products (Pavlov).
Delezenne, working in the Pastern* institute, found that pancreatic juice 
drawn with a cannula in the duct, so to avoid contact with the patch of 
mucosa membrane forming the floor of the fistula, was free from trypsin 
(Delezenne 1901). He also proposed a different explanation of the action of 
enterokinase on trypsinogen from the hypothesis of Pavlov. Based on the 
interaction between antibody and the complement, Delezenne regarded 
enterokinase binding trypsinogen, thus creating the activated enzyme. 
Further work in the field demonstrated that, consistent with Pavlov’s 
hypothesis, enterokinase cleaves a protein moiety resulting in the activation 
of trypsin (Bayliss and Starling 1905; Mellanby and Woolley 1912).
Early work to describe tire biochemical characteristic of cationic and 
anionic trypsinogen relied on purification of these enzymes from native 
pancreatic juice or autolysed pancreatic extracts (Guy, Lombardo et al. 
1978).
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These studies indicated that the catalytic and proteolytic properties of the 
two human trypsins were equivalent (Colomb, Guy et al. 1978). 
Furthermore, both cationic and anionic trypsinogen were found to be 
susceptible to spontaneous autocatalytic activation (autoactivation) at pH 8 
and the rate of autoactivation increased with increasing calcium 
concentration (Colomb, Figarella et al. 1979). Cationic trypsinogen was 
reported to autoactivate faster than anionic trypsinogen in all conditions 
except at pH 5.6 and lOmM Ca2+, where it was found to be stable for a 
prolonged period (Colomb and Figarella 1979). In the absence of calcium 
at pH 5.6 cationic trypsinogen was seen to rapidly autoactivate (Colomb, 
Figarella et al. 1979).
Trypsin activity was analysed over an acidic pH range of 3.0-2.0 and 
cationic trypsin activity was found to be unaffected whilst anionic trypsin 
activity receded with increasing acidity. At a constant pH 8 and the 
absence of calcium both trypsin activities were observed to rapidly degrade 
(Colomb, Guy et al. 1978) suggesting trypsin-mediated degradation or 
autolysis (Sahin-Toth 2000). High levels of calcium stabilised cationic 
trypsin activity, but anionic trypsin was only 40% active at 2 hours 
(Colomb, Guy et al. 1978).
More recently, recombinant expression of human trypsinogen has allowed 
renewed study of the catalytic properties of cationic and anionic trypsin. 
Most of the work originated in the laboratories of Miklos Sahin-Toth on
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recombinant trypsinogen expressed in Escherichia Coli as denatured 
inclusion bodies (Sahin-Toth 2000; Sahin-Toth and Toth 2000). The 
proteins were renatured by an in vitro refolding procedure and then 
purified to homogeneity by affinity chromatography using immobilised 
ecotin, a broad specificity protease inhibitor (Lengyel, Pal et ah 1998). 
Zymogens were activated by bovine enterokinase (Sahin-Toth 2000; 
Sahin-Toth and Toth 2000) and cationic trypsin produced by recombinant 
techniques demonstrated similar catalytic activity to that isolated from 
pancreatic juice (Szilagyi, Kenesi et al. 2001). The recombinant proteins 
did have structural differences, compared to native proteins, primarily 
arising from post-translational modifications (Kiraly, Guan et al. 2006). 
Aminopeptidases present in the cytoplasm of E.Coli were observed to him 
the N terminus of the recombinant trypsinogen (Sahin-Toth 2000; Kiraly, 
Guan et al. 2006). In human acinar cells trypsinogen was originally 
described as undergoing post-translational phosphorylation on Tyr 154 
(Gaboriaud, Serre et al. 1996), however, recently it was shown to be 
sulphation (Sahin-Toth, Kukor et al. 2006), but neither modification is 
present in recombinant trypsinogen from E.Coli.
Using these techniques, cationic and anionic hypsinogen reaction kinetics 
have been assessed. Catalytic properties of cationic and anionic trypsin 
were reported to be similar (Kukor, Toth et al. 2003). Autoactivation of 
anionic hypsinogen at pH 8 was only observed in significant amounts
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when the calcium concentration was 0.5mM or higher, whereas cationic 
trypsinogen was seen to autoactivate even in the absence of calcium and 
the effect potentiated with the addition of as little as lOpM of calcium 
(Kukor, Toth et al. 2003). The lack of autoactivation of anionic 
trypsinogen at low calcium concentrations appeared to be a consequence of 
rapid zymogen degradation into small peptides, whilst the addition of 
calcium allowed some stabilisation of the zymogen and thus an opportunity 
to autoactivate to trypsin (Kukor, Toth et al. 2003).
At pH 5 autoactivation of anionic trypsinogen was slower over the whole 
range of calcium concentrations with only 30% of total potential trypsin 
activity seen. This appeared to be due to stabilisation of the zymogen by 
acidic conditions (Kukor, Toth et al. 2003). In contrast, cationic 
trypsinogen autoactivated more rapidly at pH 5 in the absence of calcium 
than at pH 8 (Sahin-Toth 2001) with calcium-dependant stimulation seen 
up to ImM concentration.
In contrast to earlier studies, high calcium concentmtions (s2mM) 
appeared to have an inhibitory effect on autoactivation of cationic 
trypsinogen (Kukor, Toth et al. 2003).
In summary, cationic and anionic trypsinogen readily autoactivated but 
cationic trypsinogen was able to autoactivate in the absence of calcium and
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more prominently than anionic trypsinogen in acidic conditions (Kukor, 
Toth et al. 2003).
Comparison of the rate of autolysis demonstrated a 11-fold difference 
between the rapid degradation of anionic trypsin, with respect to cationic 
trypsin, at pH 8 and in the absence of calcium (Kukor, Toth et al. 2003). 
Addition of calcium reduced the rate of autolysis for both proteins, whilst 
interestingly, addition of sodium chloride had the effect of stabilising 
cationic trypsin (Kukor, Toth et al. 2003). Autolysis was thought to occur 
by cleavage of the Argl22-Vall23 bond followed by rapid proteolysis at 
multiple cleavage sites (Kukor, Toth et al. 2002). This was shown to be 
surprisingly incorrect when it was demonstrated that trypsin-mediated 
cleavage of the Argl22-Vall23 bond did not lead to complete degradation 
but instead resulted in an equilibrium between cleaved and uncleaved 
cationic trypsinogen due to a trypsin catalysed resynthesis of this bond 
(Kukor, Toth et al. 2002). This reaction was calcium sensitive, with the 
equilibrium favouring cleavage in the absence of calcium, at pH 8, and the 
rate of cleavage reduced 20-fold by addition of 5mM calcium.
An unidentified serine protease, named enzyme Y, had been attributed with 
trypsinogen degrading properties when a contaminant was found to 
degrade all trypsinogen isoforms (Rinderknecht, Adham et al. 1988). This 
property of enzyme Y was inhibited by millimolar concentrations of 
calcium suggesting it may have a protective role in the event of
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intrapancreatic trypsin activation (Rinderknecht, Adham et al. 1988). A 
candidate for this elusive enzyme Y was not identified for almost 20 years, 
when it was serendipitously identified as being the same as serum calcium 
decreasing factor (caldecrin), now commonly known as chymotiypsin C 
(CTRC) (Nemoda and Sahin-Toth 2006). Chymotiypsin C was found to 
degrade all three human trypsinogens in a calcium-dependant manner 
(Szmola and Sahin-Toth 2007) whilst at higher calcium concentrations 
(>lmM) chymotiypsin C removed the N-terminal tripeptide from cationic 
tiypsinogen resulting in a 3-fold increase in autoactivation (Nemoda and 
Sahin-Toth 2006).
1.2.5 Protective Mechanisms Within the Acinar Cell 
A number of protective mechanisms exist to protect the acinar cell from 
premature enzyme activation. The enzymes are produced as inactive 
zymogens that can only be activated in the duodenum by the action of 
enterokinase cleaving tiypsinogen to trypsin, which then activates the other 
proenzymes (Neurath and Walsh 1976; Rinderknecht 1986). The 
zymogens are packaged into membrane boimd vesicles and are not allowed 
to be free within the cytoplasm (Sutton, Griddle et al. 2003), and the cell 
also contains a serine protease inhibitor, Kazal type 1 (SPINK1) which can 
inhibit 20% of potential trypsin activity (Witt, Luck et al. 2000; Nathan, 
Romac et al. 2005). Chymotiypsin C is thought to be a second line of 
defence within the acinar cell given its ability to degrade all three tiypsin
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isoforms at low calcium concentrations (Szmola and Sahin-Toth 2007). 
Trypsin can deactivate itself through a process of autolysis, given the 
correct conditions (Sahin-Toth 2001). Calcium concentrations and pH are 
tightly regulated within the organelles of the acinar cell (Sherwood, Prior et 
al. 2007) If these mechanisms are defective or overwhelmed then 
inappropriate intra-acinar activation of trypsinogen can lead to cellular 
injury and acute pancreatitis.
1.3 Acute Pancreatitis 
1.3.1 Epidemiology
Acute pancreatitis is a common clinical condition presenting with 
abdominal pain of varying severity, usually localised to the epigastrium. 
Nausea and vomiting are associated symptoms and diagnosis is confirmed 
by raised plasma concentrations of pancreatic enzymes. The incidence is 
150 to 450 cases per million population, and appears to be rising in the UK 
(Corfield, Cooper et al. 1985; McKay, Evans et al. 1999; Toh, Phillips et 
al. 2000). The incidence may be higher in other European countries (Yadav 
and Lowenfels 2006). The mean or median age of onset in most studies 
was the sixth decade of life, with incidence increasing with age (Yadav and 
Lowenfels 2006). Though the overall sex distribution varied between 
studies, gallstone induced acute pancreatitis was more common in female 
patients whilst alcoholic acute pancreatitis was more common in males 
(Yadav and Lowenfels 2006). In most cases the disease follows a mild
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course with a mortality of less than 1%. However, 20% of patients will 
follow a severe course, and 10 - 30% of those with severe acute 
pancreatitis die (Uhl, Warshaw et al. 2002). An improved understanding of 
the natural history of the disease, with early identification of complication, 
advances in intensive care and avoidance of major surgery have resulted in 
an overall fall in mortality rate from 25-30% to 6-10% (Neoptolemos, 
Raraty et al. 1998).
1.3.2 Aetiology
Acute pancreatitis occurs secondary to biliary disease in half the cases and 
20 - 25% as a result of excessive alcohol consumption (Johnson, Chamley 
et al. 2005). Other causes include metabolic disturbance (i.e. 
hypercalcaemia, hypertriglyceridaemia), drugs (i.e. glucocorticoids, 
azothioprine, thiazides, and oestrogens), duct obstniction (i.e. secondary to 
tumour or pancreatic divisum), iatrogenic (i.e. endoscopic retrograde 
cholangiopancreatography), genetic (i.e hereditary pancreatitis) and trauma 
(Kingsnorth and O'Reilly 2006). However, 20% of cases in adults remain 
idiopathic (Yadav and Lowenfels 2006), though many may be due to 
microlithiases (Lee, Nicholls et al. 1992) or genetic predisposition 
(Whitcomb 2004).
1.3.3 Pathogenesis
Despite the variety of aetiological factors that may potentially initiate acute 
pancreatitis, the clinical course is indistinguishable and appears
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independent of the original stimulus. It has been postulated that acute 
pancreatitis is an autodigestive process occuning as a result of premature 
activation of the zymogens within the pancreas resulting in cellular injury 
(Steer and Meldolesi 1988; Leach, Modlin et al. 1991; Mithofer, 
Fernandez-del Castillo et al. 1998). The acinar cell injury leads to a local 
inflammatory reaction, with the release of pro- and anti-inflammatory 
mediators that may determine progression to a systemic inflammatory 
response syndrome (SIRS) (Davies and Hagen 1997; Brady, Christmas et 
al. 1999; Raraty, Connor et al. 2004). It is this systemic response that, if 
sufficiently severe, can lead to multiple organ dysfunction syndrome 
(MODS) that is ultimately responsible for the early mortality seen within 
the first week of illness (Neoptolemos, Raraty et al. 1998; Wilson, Manji et 
al. 1998; McKay, Evans et al. 1999). There is still considerable debate as to 
the exact mechanism of premature zymogen activation within the acinar 
cells and the sequence leading to MODS (Halangk and Lerch 2005). 
However, inappropriate activation of intra-acinar trypsinogen is considered 
to be a central early event in the pathogenesis of acute pancreatitis, and 
therefore the regulation of inactive trypsinogen within the acinar cell is of 
utmost importance.
1.3.4 Trypsinogen Autoactivation
Trypsinogen is considered a critical player in the early events of acute 
pancreatitis, as its premature conversion to trypsin can initiate an enzyme
23
cascade leading to cellular injury (Neoptolemos, Kemppainen et al. 2000; 
Whitcomb 2001). Human cationic trypsinogen is unique in its ability to 
autoactivate (Figarella, Miszczuk-Jamska et al. 1988) and this property 
makes it a prime candidate for causing pancreatitis (as discussed above). 
Further evidence from studies of hereditary pancreatitis (HP) tends to 
support this theory of autoactivation. Patients with point mutations in the 
cationic trypsinogen gene have a clinical history of early onset recurrent 
acute pancreatitis (Whitcomb, Gorry et al. 1996; Gorry, Gabbaizedeh et al. 
1997). In vitro studies have shown that the two common mutations 
increase the ability of trypsinogen to autoactivate (Sahin-Toth 2001), thus 
suggesting this as a key initiating event. However, doubt remains with 
regards to premature intrapancreatic trypsinogen autoactivation as the 
initial event in acute pancreatitis (Halangk, Kruger et al. 2002), with the 
role of cathepsin B (Halangk, Lerch et al. 2000) or other lysosomal 
enzymes being proposed as the culprits.
1.3.5 Co-localisation
It has also been proposed that Cathepsin B, a lysosomal hydrolase, is 
responsible for premature trypsinogen activation. This theory known as 
‘cO“localisation, proposes that mis-sorting of cathepsin B into the secretory 
pathway is the critical event (Saluja, Saito et al. 1985; Saluja, Hashimoto et 
al. 1987), and is based on obseivations that trypsin and cathepsin B are 
both present within cytoplasmic vacuoles during the early stages of acute
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experimental pancreatitis (Watanabe, Baccino et al. 1984) and that 
cathepsin B can activate trypsinogen in vitro (Figarella, Miszczuk-Jamska 
et al. 1988). Alternatively, co-localisation has been suggested as a 
protective feature (Gorelick and Matovcik 1995). A problem with the co­
localisation hypothesis is that cathepsin B has been shown to be a normal 
passenger in the secretory pathway indicating that co-localisation occurs 
under normal circumstances (Kukor, Mayerle et al. 2002). In vivo studies 
utilising lysosomal inhibitors failed to prevent the onset of experimental 
acute pancreatitis (Lerch, Halangk et al. 2000) and a knockout mouse 
model of cathepsin B null (ctsb_/ ) animals demonstrated a significantly 
reduced trypsin activity after secretagogue induced pancreatitis, however, 
total TAP levels were only reduced by 50% and the level of pancreatitis 
and systemic inflammatory response were not drastically altered (Halangk, 
Lerch et al. 2000).
1.3.6 Calcium Signalling in Acute Pancreatitis 
The calcium ion is an intracellular messenger that is responsible for normal 
zymogen secretion from the apex of the acinar cell (Sutton, Griddle et al. 
2003). Calcium concentration within the cytoplasm of the acinar cell is low 
compared to the extracellular fluid and intracellular stores (i.e the 
endoplasmic reticulum) (Mogami, Tepikin et al. 1998; Petersen, 
Gerasimenko et al. 1998) and these concentration gradients are maintained 
by active transport of calcium driven by ATPase pumps (Bayerdorffer,
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Streb et al. 1984) to maintain tight control of calcium levels in differing 
parts of the cell. Regional increase in calcium concentration can act as a 
secondary messenger to control events, including exocytosis of zymogen 
granules into the duct lumen (Griddle, McLaughlin et al. 2007). Under 
physiological conditions, CCK or Ach generate oscillatory calcium signals 
confined to the apical pole of the acinar cell with spread to the basolateral 
surface limited by calcium uptake into the intervening mitochondria 
(Mukheijee, Griddle et al. 2008). Supramaximal stimulation of the acinar 
cell with CCK or its analogue caerulein in rodents results in a different 
pattern of calcium signalling, a sustained global rise in cytosolic calcium 
levels as opposed to oscillatory rises seen with physiological doses, 
initiating intracellular zymogen activation, cytoskeletal disruption, loss of 
secretory polarity, vacuolisation and other features characteristic of acute 
experimental pancreatitis (Raraty, Ward et al. 2000). Many causes of acute 
pancreatitis have been shown to elicit these pathologically sustained global 
elevations of cytosolic calcium (Griddle, Gerasimenko et al. 2007).
1.4 Chronic Pancreatitis
Chronic pancreatitis is a persistent inflammatory condition characterised 
by permanent damage to the stincture and function of the pancreas gland, 
leading to exocrine and endocrine insufficiency usually associated with 
repeated attacks of severe abdominal pain (Tmninger, Ammann et al. 
2001). The incidence is approximately 3-10 per 100,000 population per
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year (Pezzilli 2009). It is more common in males compared to females with 
a ratio of 4:l(Etemad and Whitcomb 2001). hi the industrialised world, 
alcohol is the major aetiological factor, accounting for 70-80% of all cases 
(Truninger, Ammann et al. 2001) with the remainder having no obvious 
cause and being described as idiopathic chronic pancreatitis. Smoking has 
recently been implicated as an independent risk factor for developing 
chronic pancreatitis (Yadav, Hawes et al. 2009).
Advances in genetic testing led to the identification of mutations in the 
cystic fibrosis transmembrane conductance regulator (CFTR) (Colin, 
Friedman et al. 1998; Sharer, Schwarz et al. 1998), SPINK1 (Witt, Luck et 
al. 2000), cationic trypsinogen (Whitcomb, Gorry et al. 1996) and 
Chymotrypsin C (Rosendahl, Witt et al. 2008) genes in patients with 
idiopathic chronic pancreatitis. A mutation of the anionic trypsinogen 
gene, resulting in substitution of glycine to arginine at codon 191 (G191R), 
was found to be over-expressed in the control population (3.4%) compared 
to patients with chronic pancreatitis (1.3%) (Witt, Sahin-Toth et al. 2006). 
The G191R mutation introduces a new tiyptic cleavage site, and 
biochemical analysis demonstrated a complete loss of trypsin activity, 
suggesting a protective role against chronic pancreatitis (Witt, Sahin-Toth 
et al. 2006). Mutations in CFTR and SPINK1 have been described as 
‘disease modifiers’, either lowering the threshold for initiating pancreatitis 
or exacerbating the severity of the disease (Pfiitzer, Barmada et al. 2000).
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No significant association exists between alcoholic chronic pancreatitis and 
genes encoding for the detoxifying enzymes glutathione S-transferases 
(GSTM1, GSTT1, GSTP1), the cytochrome P450 (CYP2E1, CYP1A1) 
enzymes (Burim, Canalle et al. 2004), and with polymorphisms in genes 
encoding for TGF-bl, interleukin-10, interferon-y, alcohol dehydrogenase 
3 or CYP2E1 (Schneider, Barmada et al. 2004).
Chronic pancreatitis has been associated with an increased risk of 
developing pancreatic cancer (Howes, Lerch et al. 2004; Raimondi, 
Lowenfels et al. 2010), though the pathway for such a process remains to 
be elucidated. The risk of developing pancreatic adenocarcinoma in 
patients with chronic pancreatitis has been estimated to be in the order of 
5% at 20 years from disease onset (Lowenfels, Maisomieuve et al. 1993; 
Goldacre, Wotton et al. 2008). The clearest evidence for such a link has 
come from studies of patients with hereditary pancreatitis as a result of 
mutations in the PRSS1 gene (Lowenfels, Maisonneuve et al. 1997).
1.4.1 SPINK1
The most frequently fomid mutation, asparagine to serine substitution at 
codon 34 (N34S) (Witt, Luck et al. 2000), described in SPINK1 is 
associated with idiopathic chronic pancreatitis in over 20% patients (Witt, 
Luck et al. 2000) and with alcoholic chronic pancreatitis in 6% (Witt, Luck 
et al. 2001). However, this mutation was found in up to 50% of patients 
from Southern India diagnosed with tropical pancreatitis, a condition
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previously thought to be caused by malnutrition (Bhatia, Choudhuri et al. 
2002; Chandak, Idris et al. 2002). The N34S mutation does not segregate 
with the disease to suggest an autosomal dominant or recessive pattern of 
inheritance, and given that it is relatively common in the general European 
population (1-2%), the pathogenesis appears to be more complex (Etemad 
and Whitcomb 2001).
A rare allele, c.27delC, where a frameshift produces a stop codon and the 
entire SPINK 1 gene is deleted, was found in a family with hereditary 
chronic pancreatitis with a penetrance of 75% (Le Marechal, Chen et al. 
2004). However, in another family, the penetrance was a much lower 29% 
(Le Marechal, Chen et al. 2004). Mutations in the signal peptide, which 
result in impaired secretion of SPINK 1, have also been shown to be 
associated with hereditary chronic pancreatitis (Kiraly, Boulling et al. 
2007). These families provide some evidence for haploinsufficiency as a 
pathogenic mechanism for chronic pancreatitis (Le Marechal, Chen et al. 
2004; Kiraly, Boulling et al. 2007).
1.4.2 CFTR
Cystic fibrosis (CF) is a common autosomal recessive disorder caused by 
mutations in the cystic fibrosis transmembrane conductance regulator 
which encodes a cAMP activated chloride channel in epithelial cell 
membranes (Riordan, Rommens et al. 1989). The relationship between 
CFTR mutations and the mechanism causing chronic pancreatitis remains
29
poorly understood (Chen and Ferec 2009). This is compounded by a high 
number of mutations that have been described in the CFTR gene (Cohn, 
Friedman et al. 1998) . Interestingly, it appears as though it is the less 
severe CF-causing mutations that maintain a higher percentage of 
pancreatic sufficiency, which are associated with an increased risk of 
chronic pancreatitis (Cohn, Neoptolemos et al. 2005). A German study 
highlighted the importance of CFTR mutation in sporadic CP by analysing 
67 patients with idiopathic chronic pancreatitis with 60 matched controls 
and found that abnormal CFTR alleles were twice as common in patients 
with idiopathic chronic pancreatitis (Weiss, Simon et al. 2005).
1.4.3 Chymotrypsin C
Chymotrypsin C is considered a second line of defence against prematurely 
activated intrapancreatic trypsin (Szmola and Sahin-Toth 2007) and two 
studies investigating idiopathic chronic pancreatitis demonstrated a 
significantly higher incidence of loss of function mutations in patients. 
(Masson, Chen et al. 2008; Rosendahl, Witt et al. 2008). Biochemical 
analysis of some of the missense mutations indicated that they caused 
impaired activity and/or reduced secretion, thus indicating that CTRC is a 
pancreatitis susceptibility gene (Rosendahl, Witt et al. 2008).
1.5 Hereditary Pancreatitis
Hereditary pancreatitis was first described by Comfort et al in 1952 when
working at the Mayo clinic (Comfort and Steinberg 1952). They described
30
a family with four definite and two suspected cases of relapsing chronic 
pancreatitis in childhood/adolescence (Comfort and Steinberg 1952). The 
observed pattern of inheritance appeared to follow an autosomal dominant 
mode but with an incomplete penetrance (Comfort and Steinberg 1952). 
This observation has since been confirmed by other groups in Europe and 
North America (Gross and Comfort 1957; Gross 1958; Gross, Ulrich et al. 
1962; Gerber 1963; Sibert 1978; Le Bodic, Schnee et al. 1996; 
Sossenheimer, Aston et al. 1997; Amann, Gates et al. 2001; Keim, Bauer et 
al. 2001). Indeed, the incomplete penetrance has been noted by various 
groups with a figure of 80% penetrance being widely accepted (Howes, 
Lerch et al. 2004). However, as affected individuals are more likely to be 
tested for the mutation than unaffected individuals and families with few 
affected members are less likely to be recruited, estimates of penetrance 
may be overestimated (Howes, Lerch et al. 2004). A French study, which 
has described a national exhaustive series of hereditaiy pancreatitis, found 
that the penetrance of the PRSS1 mutations was 93% by including patients 
with only morphological pancreas alterations (Reborns, Boutron-Ruault et 
al. 2009).
Hereditaiy pancreatitis accounts for approximately 1% of all cases of 
pancreatitis (Whitcomb 2004). It is characterized by the onset of recurrent 
attacks of acute pancreatitis in childhood and frequent progression to 
chronic pancreatitis (Moir, Konzen et al. 1992; Konzen, Perrault et al.
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1993; Perrault 1994) The classic clinical and demographic characteristics 
include recurrent episodes of pancreatitis during childhood, equal gender 
distribution, the frequent presence of pancreatic duct stones, a positive 
family history, and the absence of other known causes of pancreatitis 
(Kattwinkel, Lapey et al. 1973; Sato and Saito 1974; Konzen, Perrault et 
al. 1993). The EUROPAC definition of hereditary pancreatitis is two or 
more first-degree relatives, or three or more second-degree relatives, in two 
or more generations with recurrent acute pancreatitis and/or chronic 
pancreatitis in the absence of other precipitating or causative factors such 
as gallstones, tropical pancreatitis or excess ethanol consumption (Howes, 
Lerch et al. 2004). Cases where these criteria were not met, but there was 
more than one affected family member, were classified as familial chronic 
pancreatitis (Howes, Lerch et al. 2004). Other groups have used slightly 
different definitions when categorising patients as suffering from 
hereditary pancreatitis (Teich, Mossner et al. 1998).
The aetiology of hereditary pancreatitis had remained obscure for almost 
50 years until the application of modern molecular genetic techniques. By 
employing linkage analysis using satellite markers, three groups 
established segregation between the disease phenotype and the long aim of 
chromosome 7 (Le Bodic, Bignon et al. 1996; Pandya, Blanton et al. 1996; 
Whitcomb, Preston et al. 1996). Once the hereditary pancreatitis gene was 
mapped to 7q35, positional cloning using a candidate gene approach was
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employed, whereby genes aheady known to be in that region were 
sequenced (Whitcomb, Gorry et al. 1996). Soon afterwards Whitcomb et al 
identified a mutation in the third exon of the cationic trypsinogen gene on 
chromosome 7q35 which segregated with the disease in five families 
(Whitcomb, Gorry et al. 1996).
1.5.1 Mutations in the cationic trypsinogen gene 
Since identification of PRSS1 as a disease gene, a number of different 
mutations have been identified. The two most frequently occurring 
mutations in HP are R122H (approximately 70%) and N29I 
(approximately 20%) (Sahin-Toth 2006) (Fig 1.4). They have been 
identified in families with hereditary pancreatitis from Europe (Ferec, 
Raguenes et al. 1999; Teich, Mossner et al. 1999; Witt, Luck et al. 1999; 
Howes, Lerch et al. 2004), Japan (Nishimori, Kamakura et al. 1999), the 
UK (Bell, Bennett et al. 1998; Creighton, Lyall et al. 1999), the USA 
(Whitcomb, Gorry et al. 1996; Gorry, Gabbaizedeh et al. 1997) and 
Australia (McGaughran, Kimble et al. 2004). However, these mutations in 
PRSS1 were not found in two hereditary pancreatitis families from Brazil 
(Bernardino, Guarita et al. 2003) and to date no hereditary pancreatitis 
families have been reported from Africa.
The R122H mutation was easily identified as it created a novel recognition 
site for the restriction endonuclease Afllll. However, it was demonstrated 
that a neutral polymorphism within this enzyme recognition site may
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produce a false negative result (Howes, Greenhalf et al. 2001). An 
alternative mutation specific polymerase chain reaction approach was 
therefore developed for detection of the mutation even in the presence of 
the polymorphism (Howes, Greenhalf et al. 2001).
1.5.2 R122H
The R122H mutation remains the most frequent genetic alteration 
associated with hereditary pancreatitis (Sahin-Toth 2006). After its 
discoveiy in 1996, Whitcomb proposed that it disrupted the self-destruct 
mechanism that allows autolysis of prematurely activated intrapancreatic 
trypsin (Whitcomb, Gorry et al. 1996) (Fig 1.4). Loss of this ‘fail-safe’ 
mechanism in the R122H mutant (referred to as ‘supertrypsin’) would 
result in increased intrapancreatic trypsin activity, which could activate 
other proenzymes, leading to the onset of acute pancreatitis (Whitcomb 
2001).
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Fig 1.4 Cationic Trypsin Mutations
A schematic ribbon diagram showing cationic trypsin and the positions 
of the R122H and N29I mutations with respect to the autolysis loop and 
the calcium binding pocket. SPINK 1 is shown causing inhibition by 
binding to the activation (AC) site of trypsin. With permission from 
(Whitcomb, Gorry et al. 1996)
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The R122H mutation is a single guanine (G) to adenine (A) transition 
mutation in the third exon of PRSS1 that results in an arginine (CGC) to 
histidine (CAC) missense substitution at amino acid residue 122 
(Whitcomb, Gorry et al. 1996). Originally the mutation was referred to as 
R117H based on the chymotrypsinogen numbering system but later revised 
in accordance with the nomenclature working group (Teich, Hoffmeister et 
al. 2000).
1.5.3 N29I
A second mutation in PRSS1 was discovered a year later in two affected 
families without the R122H mutation (Gorry, Gabbaizedeh et al. 1997). A 
single adenine (A) to thymine (T) transversion mutation was identified in 
exon 2 that results in a change from asparagine (AAC) to isoleucine (ATC) 
substitution at amino acid 29 (Gorry, Gabbaizedeh et al. 1997). The 
mutation was originally known as N21I according to the 
chymotrypsinogen numbering system but later revised to N29I (Teich, 
Hoffineister et al. 2000).
1.5.4 A16V
The third most frequent mutation, where there is a cytosine (C) to thymine 
(T) missense mutation, has been identified in exon 2 that leads to an 
alanine (GCC) to valine (GTC) substitution at codon 16 (A16V)(Witt, 
Luck et al. 1999). This mutation affects the first amino acid of the 
trypsinogen molecule and thus directly the cleavage site for the signal
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peptide. The original hypothesis of the mechanism by which pancreatitis is 
initiated by this mutation focused on a defect in secretion (Witt, Luck et al. 
1999), but recently chymotrypsin C was shown to activate the A16V 
mutant four times faster than wild type cationic trypsinogen (Nemoda and 
Sahin-Toth 2006).
The A16V mutation was identified during a study to determine the 
spectrum and frequency of mutations in the PRSS1 gene in 44 
children/adolescents with chronic pancreatitis (Witt, Luck et al. 1999). 
Thirty of these individuals were found to have idiopathic pancreatitis and 
fourteen to have hereditary pancreatitis. R122H was identified in one 
individual. A16V was found in three individuals with presumed idiopathic 
pancreatitis and in one said to have hereditary pancreatitis (Witt, Luck et 
al. 1999). The A16V mutation was also identified in seven first-degree 
relatives of these patients but only one had clinically apparent pancreatitis, 
suggesting low penetrance of this mutation (Witt, Luck et al. 1999).
1.5.5 Variants
In addition to these three principle mutations, there are multiple variants of 
the PRSS1 gene and these include: -28delTCC (a three base pair deletion at 
position base pairs upstream from the start codon)(Ferec, Raguenes et al.
1999) , D19A (Chen, Kukor et al. 2003), D22G (Teich, Ockenga et al.
2000) , K23R (Ferec, Raguenes et al. 1999), N29T (Pfutzer, Myers et al. 
2002), P36R (Chen, Piepoli Bis et al. 2001), Y37X (Chen, Le Marechal et
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al. 2003), V39A (Arduino, Salacone et al. 2005), E79K (Chen, Piepoli Bis 
et al. 2001), G83E (Chen, Piepoli Bis et al. 2001), K92N (Chen, Piepoli 
Bis et al. 2001), D100H (Tautermann, Ruebsamen et al. 2001), L104P 
(Teich, Bauer et al. 2002), R116C (Le Marechal, Bretagne et al. 2001; 
Teich, Bauer et al. 2002), R122C (Le Marechal, Bretagne et al. 2001), 
V123M (Chen, Piepoli Bis et al. 2001), T137M, C139S (Keiles and 
Kammesheidt 2006), C139F (Teich, Bauer et al. 2002), and G208A (Keiles 
and Kammesheidt 2006). All these variants are rare and in some cases the 
link with hereditary pancreatitis is only suggestive. Two neutral 
polymorphisms (D162D and N246N (Teich, Mossner et al. 1998)) have 
also been described. An updated list of PRSS1 & SPINK 1 mutations is 
available at http:/Av\vw.uni-leipzig.de/pancreasmutat»on/.
However, many families have been described with clinically defined 
hereditary pancreatitis where there is no PRSS1 mutation (Howes, Lerch et 
al. 2004; Rebours, Boutron-Ruault et al. 2009). This indicates that there 
may be at least one more disease gene, which remains to be identified.
1.5.6 Mechanisms of mutation induced pancreatitis 
The discovery of multiple mutations in the cationic trypsinogen gene raised 
the intriguing question as to how they were all associated with a ‘gain of 
function’ rather than the usual finding of mutations leading to ‘loss of 
function’. Whitcomb et al, with the first report of a mutation in cationic 
trypsinogen, proposed a mechanism via which the R122H mutation could
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increase the propensity of developing acute pancreatitis (Whitcomb, Gorry 
et al. 1996). As further mutations were identified several hypotheses were 
proposed to explain the role of each mutation and how they related to a 
central pathogenic pathway causing pancreatitis. The five common theories 
of trypsinogen mutations in causing hereditaiy pancreatitis were (i) 
increased trypsin stability, (ii) increased trypsinogen autoactivation, (iii) 
increased susceptibility to cathepsin B mediated trypsinogen activation,
(iv) loss of trypsin function, (v) chronic SPINK1 depletion.
Whitcomb proposed that the Argl22-Vall23 autolytic peptide bond was an 
important intraacinar failsafe mechanism and the R122H mutation would 
result in a ‘supertrypsiif, that was resistant to autolytic degradation within 
the cell, eventually leading to pancreatitis (Whitcomb, Gony et al. 
1996).The importance of Argl22 for the autolysis of trypsin was 
confirmed by biochemical analysis (Sahin-Toth, Graf et al. 1999; Sahin- 
Toth and Toth 2000) but detailed experiments demonstrated that autolysis 
of cationic trypsin proceeded veiy slowly in vitro (Kukor, Toth et al. 
2003). Also, the R122H mutation not only increased the stability of trypsin 
but also of the zymogen (Sahin-Toth, Graf et al. 1999) and increased 
autoactivation (Sahin-Toth and Toth 2000).
The debate has been further complicated by chymotrypsin C and its ability 
to degrade all three human trypsins (Szmola and Sahin-Toth 2007). In 
condition of low calcium concentration, chymotrypsin C selectively
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cleaves the Leu81-Glu82 peptide bond within the calcium-binding loop 
(Szmola and Sahin-Toth 2007). This is followed by autolytic cleavage by a 
second trypsin molecule cleaving the Argl22-Vall23 peptide bond and 
subsequently rapid degradation of the protein (Szmola and Sahin-Toth 
2007). Millimolar calcium concentrations inhibit chymotrypsin C and 
protect against trypsin degradation and promote autoactivation by cleavage 
of the Phel8-Aspl9 peptide bond (Nemoda and Sahin-Toth 2006). The 
R122H mutation, in this context, protects trypsin from undergoing 
degradation and may contribute to its pathomechanism for causing 
pancreatitis (Szmola and Sahin-Toth 2007).
This raised the possibility that increased trypsin stability was not 
responsible for hereditary pancreatitis. Work to characterise the other 
PRSS1 mutations fomid that they did not affect autolysis, thus suggesting 
that trypsin stability was not a common pathomechanism in hereditary 
pancreatitis.
The mechanism accounting for how N29I causes pancreatitis is uncertain, 
although in light of the assumed mechanism of action of R122H and the 
clinical similarities between R122H and N29I phenotypes, it was originally 
suggested that the mechanism must involve increased trypsin activity 
(Gorry, Gabbaizedeh et al. 1997) by reducing the availability of the 
autolysis loop and thus making the trypsin molecule resistant to 
degradation. Whitcomb et al predicted that the N29I mutation may induce
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early trypsin activation (Whitcomb 2001), or conformational changes 
based on the crystallographic structure of trypsin (Whitcomb 1999) that 
could explain a reduced accessibility to the calcium binding pocket. An 
alternative model was proposed that suggested the N29I mutation alters the 
native structure of cationic trypsinogen to a sheet structure (Nishimori, 
Kamakura et al. 1999). It was implied that this conformational alteration 
might impair* trypsin activation (Nishimori, Kamakura et al. 1999).
Biochemical approaches to investigate the mechanism concluded that the 
N29I mutation increased autoactivation under acidic conditions (Sahin- 
Toth and Toth 2000; Szilagyi, Kenesi et al. 2001), with no alteration in 
trypsin or zymogen stability. As increased autoactivation was seen with 
R122H, N29I and N29T mutation and N29I had not shown evidence of 
increased stability of trypsin, enhanced autoactivation became the leading 
hypothesis for mutant cationic trypsinogen associated pancreatitis. Finding 
of enhanced autoactivation in mutations D19A, D22G, K23R, affecting the 
trypsinogen activation peptide, strengthened the hypothesis (Teich, 
Ockenga et al. 2000; Nemoda and Sahin-Toth 2005). These findings are 
important as these mutations do not affect trypsin structure or function and 
can only exert their effect by altering the properties of cationic trypsinogen. 
This is the most widely accepted mechanism at tire time of writing (Sahin- 
Toth 2006).
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Another hypothesis suggested that pancreatitis-associated mutations may 
be more susceptible to activation by cathepsin B (Szilagyi, Kenesi et al. 
2001), with some evidence demonstrating that the N29I mutant is activated 
faster by cathepsin B (Szilagyi, Kenesi et al. 2001). However, this finding 
was not confirmed by a later study, which found that there was no 
difference in activation by cathepsin B of the R122H, N29I or N29T 
mutants compared to wild type trypsinogen (Kukor, Mayerle et al. 2002). 
Work assessing the role of cathepsin B in the context of D22G and K23R 
mutants demonstrated that trypsinogen activation was decreased (Teich, 
Bodeker et al. 2002).
Some investigators found the large number of ‘gain of function’ mutations 
associated with hereditary pancreatitis to be unusual and speculated 
whether trypsin somehow had a protective role in pancreatitis. This could 
be demonstrated if the mutations caused a Toss of function’. The discoveiy 
of R122C seemed to agree with this hypothesis (Le Marechal, Chen et al. 
2001; Simon, Weiss et al. 2002). The loss of function resulted from 
misfolding of trypsin due to the presence of an unpaired cysteine, however, 
when the active trypsinogen fraction was analysed the R122C mutation had 
a similar profile to the R122H mutation (Simon, Weiss et al. 2002). A 
second mutation E79K was also shown to have decreased autoactivation 
however it appeared to transactivate anionic trypsinogen and thus 
postulated to increase anionic trypsin levels in acinar cell causing
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pancreatitis (Teich, Le Marechal et al. 2004). Though this theory is 
interesting it does not agree with the rest of the biochemical evidence in 
support of enhanced autoactivation.
The chronic SPINK1 depletion hypothesis is an extension of the enhanced 
autoactivation theoiy. It stipulates that the normal inhibition of prematurely 
activated trypsin, as it transits through the secretory pathway, by SPINK1 
is overwhelmed by mutations that enhance autoactivation of cationic 
trypsinogen. Saturation of this protective pathway leads to free activated 
trypsin able to exert a pathological effect on the acinar cell leading to 
pancreatitis. Evidence in support of this theory comes from identification 
of rare severe SPINK1 mutations that cause loss of expression of the 
diseased allele and appear to be associated with hereditary pancreatitis (Le 
Marechal, Chen et al. 2004).
1.5.7 Presentation of hereditary pancreatitis
The prevalence of hereditary pancreatitis has been estimated to be 
0.3/100000 inhabitants in a French national series (Rebours, Boutron- 
Ruault et al. 2009). The initial presentation of patients with hereditary 
pancreatitis is clinically identical to sporadic cases of pancreatitis, with 
acute episodes mimicking gallstone, alcoholic or idiopathic acute and 
chronic episodes similar to any other cause of chronic pancreatitis 
(Chamley 2003). Childhood presentations of HP are similar to idiopathic 
juvenile chronic pancreatitis (Chamley 2003).
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The EUROPAC group found that their cohort of patients (n = 418 affected) 
presented with symptoms of pancreatitis at an early age, with a median 
onset of symptoms at 12 years with over 70% of individuals developing 
symptomatic pancreatitis by the age of 20 years (Howes, Lerch et al. 
2004). Lowenfels et al looked at a large cohort of individuals with 
hereditary pancreatitis (n - 412 affected) from 16 countries and found the 
mean age of symptom onset to be 14.1 years with an equal sex ratio but 
with a slightly more common paternal inheritance pattern (57%) 
(Lowenfels, Maisonneuve et al. 2000), whilst Reborns et al looked at a 
national cohort (n=200 affected) and concluded in their group a median 
age of symptom onset of 10 years (Rebours, Boutron-Ruault et al. 2009).
Howes et al demonstrated that individuals with R122H mutations 
presented earlier at a median age of 10 years in comparison to those 
individuals with the N29I mutation or compared with individuals with no 
PRSS1 mutation, who had a median age of presentation of 14 years and 
14.5 years respectively (Howes, Lerch et al. 2004). Interestingly, Rebours 
et al and also Keim et al, who studied 101 individuals, failed to 
demonstrate any significant difference in age of symptom onset between 
R122H and N29I mutation earners (Keim, Bauer et al. 2001; Reborns, 
Boutron-Ruault et al. 2009). There appears to be a bimodal distribution for 
the age of onset with a peak under the age of 10 years and another at 
around 20 years (Keim, Bauer et al. 2001).
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Amann et al provides one of the few studies looking at identical twins in 
hereditary pancreatitis (Amann, Gates et al. 2001). They found that the 
median age of symptom onset of hereditary pancreatitis in concordant 
twins was almost identical, with similar ages of onset seen in matched 
siblings and a significantly different age of symptom onset from 
individuals from age, sex, and mutation-matched controls (Amann, Gates 
et al. 2001).
The two most frequent symptoms were pancreatic pain (83%) or a bout of 
acute pancreatitis (69%) (Reborn’s, Boutron-Ruault et al. 2009).
1.5.8 Natural clinical history of hereditary pancreatitis 
The EUROPAC Study group has provided the largest detailed study of 
hereditary pancreatitis to date with 527 individuals recruited from 14 
counties of which 418 individuals from 112 families were affected 
(Howes, Lerch et al. 2004). There were 58 (52%) families of whom 222 
individuals (53%) were characterised by R122H mutations, 24 (21%) 
families hadN29I mutations (94 individuals (22%)) and 21 (19%) families 
had no PRSS1 mutation (72 patients (17%)). They demonst’ated an overall 
median of 1.88 attacks per year, which was unrelated to the type of PRSS1 
gene mutation or gender (Howes, Lerch et al. 2004). Not all of the 
symptomatic episodes of pancreatitis were severe enough to warrant 
hospital admission, with the median number of admissions to hospital for 
complications of pancreatitis being 0.3 (Howes, Lerch et al. 2004; Howes,
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Greenhalf et al. 2005). The number of hospital admissions was unaffected 
by gender, however, individuals with PRSS1 mutations did have a 
tendency for fewer hospital admissions than those with no identified 
causative mutation (Howes, Lerch et al. 2004). Approximately, 85% 
(158/176) of individuals reported that symptomatic episodes lasted no 
more than one week; the remaining 15% had attacks over one week. The 
duration of acute pancreatitis was not influenced by either gender or 
PRSS1 mutation status (Howes, Lerch et al. 2004).
Gony et al reported on two large families with PRSS1 mutations and they 
found that 86% (24/28) of individuals in the R122H family had more than 
five hospital admissions in contrast to the N29I family where there were 
just 47% (7/15)(Gorry, Gabbaizedeh et al. 1997). In a larger study by Keim 
et al the clinical characteristics of 30 families with hereditary pancreatitis 
consisting of six families with the N29I mutation (n = 25) and 21 families 
with the R122H mutation (n - 76) were examined (Keim, Bauer et al. 
2001). In the N29I group, 24% had no symptoms and 40% mild symptoms, 
whilst in the R122H group, 26% had no symptoms and 42% mild 
symptoms, though they concede that their sample size is small (Keim, 
Bauer et al. 2001).
The incidence of exocrine and endocrine failure in hereditary pancreatitis 
was shown to be high in the EUROPAC study, with the development of 
malabsorption in 60% at 70 years of age and a median time to
46
malabsorption of 53 years (Howes, Lerch et al. 2004). The cumulative risk 
of diabetes mellitus was 69% by 70 year's of age and a median time to 
diabetes mellitus of 53 years. Neither exocrine nor endocrine failure was 
influenced by the genetic mutation (Howes, Lerch et al. 2004). Rebours et 
al reported exocrine and endocrine insufficiency in 34% and 26% at a 
median age of 29 and 38 years respectively and irrespective of mutational 
status (Rebours, Boutron-Ruault et al. 2009).
Surgical procedures were reported in 19% of affected individuals with 59% 
of those requiring pancreatic resection (Howes, Lerch et al. 2004). The 
time to resection was significantly reduced in women, who had a higher 
cumulative risk of resection in comparison to men (Howes, Lerch et al. 
2004). The time to resection was also significantly reduced with the N29I 
mutation with an associated increased cumulative risk of resection of 35% 
compared to R122H (13%) and mutation negative patients (13%) (Howes, 
Lerch et al. 2004). The resection rate was similar in the report by Reborn's 
et al though they did not find a difference associated with mutational status 
(Rebours, Boutron-Ruault et al. 2009).
1.6 Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common
causes of cancer death in the Western world (Parkin, Bray et al. 2005;
Jemal, Siegel et al. 2009) with an overall 5-year survival rate of below 5%
(Li, Xie et al. 2004). The incidence of PDAC approaches that of mortality
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(Jemal, Siegel et al. 2009). Although only around 10% of patients are 
eligible for resection, prognosis is improved in patients who undergo 
resection followed by adjuvant chemotherapy with 5-year survival rates of 
up to 20-29% (Neoptolemos, Stocken et al. 2004). Certain conditions 
predispose patients to the development of pancreatic ductal 
adenocarcinoma, including increasing age, smoking (Coughlin, Calle et al. 
2000), new onset diabetes mellitus (Chari, Leibson et al. 2005), chronic 
pancreatitis (Howes and Neoptolemos 2002), hereditary pancreatitis 
(Reborn’s, Boutron-Ruault et al. 2008) and an inherited predisposition for 
pancreatic cancer (Vitone, Greenhalf et al. 2006).
PDAC is believed to arise from the ductal epithelium of the pancreas 
(Kozuka, Nagasawa et al. 1982), although some studies suggest a possible 
origin from transdifferentiated acinar cells (Longnecker, Shinozuka et al. 
1980). Pathological studies of PDAC point towards a multistep progression 
similar to the ‘adenoma-carcinoma’ sequence seen in colorectal cancer 
(Hmban, Adsay et al. 2001). The earliest change is one of squamous 
metaplasia, with the next lesion being described as ‘pancreatic 
intraepithelial neoplasia’ or ‘PanIN’ (Hmban, Adsay et al. 2001). This is 
subdivided into PanIN-1, PanIN-2 and PanIN-3 depending on the degree of 
architectural atypia present (Hmban, Adsay et al. 2001) (Fig 1.5). The 
malignant potential of these lesions is unknown and there is suggestion that 
early lesions may resolve back to normal tissue (Hernandez-Munoz,
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Skoudy et al. 2008). Studies have attempted to provide a temporal 
description of the genetic changes associated with the progression of these 
lesions, implicating the role of K-Ras, p53, pl6 and SMAD4, amongst 
others, in the development of pancreatic adenocarcinoma (Hraban and 
Adsay 2009) (Fig 1.5).
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Fig 1.5 Progression model for Pancreatic adenocarcinoma 
It is hypothesized that histologically normal duct cells can progress 
through to a severely atypical duct lesion and carcinoma in situ. (Artwork 
reproduced with permission from publication by Wilentz R.E et al. 2000)
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1.6.1 K-Ras
K-Ras mutations have been observed in 70 - 100% of pancreatic cancers, 
the highest incidence of any human malignancy (Almoguera, Shibata et al. 
1988). It is a G-protein involved with signal transduction and a member of 
the GTPase superfamily (Shields, Pruitt et al. 2000), located on 
chromosome 12 and encoding a 21 KDa membrane bound protein. In 
response to mitogenic stimuli, wild type K-Ras binds GXP and thus 
activates downstream signal cascades including the Raf kinases (Shields, 
Pruitt et al. 2000). After signalling the GXP is hydrolysed to GDP, turning 
off the signal cascade (Malumbres and Barbacid 2003). Xhe commonly 
occurring mutations alter the proteins ability to hydrolyse GXP, effectively 
resulting in the K-Ras protein being persistently active and stimulating its 
downstream targets as though under constant mitogenic stimulus 
(Malumbres and Barbacid 2003). Interestingly, K-Ras mutations are 
present in both invasive and the earlier non-invasive cells but also in 
patients with chronic pancreatitis (Fumya, Kawa et al. 1997) and even seen 
in patients with no pancreatic disease at all (Luttges, Schlehe et al. 1999).
1.6.2 p53
Mutations in p53 are the most common mutations in human cancer, and 
they are seen in PDAC tissue in 27 — 76% of cases (Barton, Staddon et al. 
1991; Rozenblum, Schutte et al. 1997). Xhe p53 tumour suppressor gene is 
located on the short arm of chromosome 17, and encodes a transcription
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factor that np-regulates genes involved in cell cycle arrest and apoptosis 
(Levine 1997), It is activated in response to DNA damaging stress. Mutant 
p53 is unable to initiate cell cycle arrest and thus to prevent tumour cell 
division, resulting in Luther accumulation of mutations in the cell (Levine, 
Hu et al. 2006). Most studies have not shown mutant p53 to be present in 
patients with chronic pancreatitis (Casey, Yamanaka et al. 1993; Apple, 
Hecht et al. 1999), and it is generally believed that p53 mutation occurs 
later than the K-Ras mutation (Hruban and Adsay 2009).
1.6.3 p16INK4A
The pl6INK4A gene is a tumour suppressor gene found on the short arm of 
chromosome 9, which inhibits the cyclin dependant kinase 4 / cyclin D1 
mediated phosphorylation of the retinoblastoma protein thus inducing Gi 
cell arrest (Sharpless 2005). The incidence of p!6INK4A mutation in PDAC 
is around 85% (Caldas, Halm et al. 1994) and microdissection of 
preneoplastic lesions has shown pl6INK4A mutations were always found 
with mutant K-Ras, whereas normal pancreatic duct cells never had any 
pl6INK4A mutations (Moskaluk, Hruban et al. 1997). Thus, it is assumed 
that the acquisition of pl6INK4A occurs later than K-Ras but earlier than p53 
in PDAC (Hernandez-Munoz, Skoudy et al. 2008).
1.6.4 SMAD4 (DPC4)
SMAD4 is homozygously deleted in around 30% of PDAC and in cases of 
loss of heterzygosity of one SMAD4 allele, there is a 20% rate of mutation
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in the other allele (Schutte, Hraban et al. 1996). This is the highest 
incidence in any human cancer and reflects the importance of this gene in 
PD AC (Schutte, Hruban et al. 1996). SMAD4 (or Deleted in Pancreatic 
Cancer, DPC4) is involved in signal transduction induced by the 
transforming growth factor-p (TGF-p) pathway. TGF-P is a potent 
inhibitor of epithelial cell growth and survival (Hahn, Schutte et al. 1996).
1.6.5 Hereditary pancreatitis and pancreatic cancer risk 
Lowenfels et al on behalf of the International Hereditary Pancreatitis Study 
Group estimated that the cumulative lifetime risk (to the age of 70 years) of 
pancreatic adenocarcinoma to be approaching 40% in patients with 
hereditary pancreatitis. The standardised incidence ratio (SIR), which is 
the ratio of observed pancreatic cancer cases in the cohort to the expected 
pancreatic cancers in the background population, adjusted for age, sex, 
and country, was 53 (Lowenfels, Maisonneuve et al. 1997). This was 
supported by the EUROPAC study which reported a cumulative lifetime 
risk of 44% to the age of 70 years and a SIR of 67 (Howes, Lerch et al. 
2004) whilst Rebours et al reported a higher cumulative lifetime risk of 
54% to the age of 75 and a SIR of 87 (Reborns, Boutron-Ruault et al. 
2008). Lowenfels et al also reported that paternal transmission of 
hereditary pancreatitis was associated with a much greater lifetime risk of 
developing pancreatic cancer (Lowenfels, Maisonneuve et al. 1997) but the 
EUROPAC study group and the French study showed that there was no
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significant difference between paternal and maternal transmission (Howes, 
Lerch et al. 2004; Reborn's, Boutron-Ruault et al. 2008). Cigarette 
smoking is implicated as a risk factor related to a significantly earlier 
diagnosis of cancer (Lowenfels, Maisonnenve et al. 2001; Howes, Lerch et 
al. 2004; Reborn's, Boutron-Ruault et al. 2008), with diabetes mellitus 
having a lesser effect (Reborn's, Boutron-Ruault et al. 2008)
1.7 Transgenic Technology 
1.7.1 Historical Perspective
The first successful experiment to manipulate the mouse embiyo was 
preformed at the University of California in 1966 by Teh Ping Lin, who 
reported that it was possible to puncture the pronuclei of the egg, inject 
macromolecules such as bovine gamma globulin and transplant them into 
recipient female mice, with the production of viable mice at term (Lin 
1966). The first microinjection of recombinant DNA was reported by 
Gordon et al m 1980 describing the somatic integration of a cloned gene 
consisting of fragments of the herpes simplex and SV40 vims DNA 
(Gordon, Scangos et al. 1980). It was not long before other groups were 
able to confirm these findings by successfully integrating ‘transgenes’ into 
the mouse genome (Brinster, Chen et al. 1981; Costantini and Lacy 1981; 
Wagner, Stewart et al. 1981; Wagner, Hoppe et al. 1981). These 
experiments also demonstrated that the integration of the transgenes 
appeared to take place in a random fashion, such that it was impossible to
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predict the site or number of copies that would integrate into the genome. 
However, this unpredictability did not completely hinder the prospects for 
gene expression (Brinster, Chen et al. 1981; Wagner, Stewart et al. 1981; 
Wagner, Hoppe et al. 1981) or the ability to pass on the transgene to 
offspring (Brinster, Chen et al. 1981; Gordon and Ruddle 1981). Although 
transgenesis provided a powerful tool, the inability to manipulate 
endogenous genes in a predetennined or precise manner, limited its 
potential in genetic manipulation of the mammalian genome (Matthaei 
2007).
Embryonic stem cells (ES cells) are pluripotent cells derived from the inner 
cell mass of blastocysts (Evans and Kaufman 1981). ES cells were injected 
into a recipient mouse blastocyst, where they were shown to contribute to 
all of the tissues of the adult mouse including the germ line (Bradley, 
Evans et al. 1984). The offspring were chimeras, as a proportion of cells 
were of ES cell decent and the others derived from the recipient embryo. 
The next step of using ES cells to introduce foreign DNA into the mouse 
genome was achieved when integrated retroviral DNA was identified in 
founders and transmitted to the offspring (Robertson, Bradley et al. 1986). 
The introduction of a mutant endogenous gene was reported 
simultaneously by two groups (Hooper, Hardy et al. 1987; Kuehn, Bradley 
et al. 1987), both of whom were working with hypoxanthine 
phosphoribosyltransferase (HPRT) gene which is defective in Lesch-
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Nyhan syndrome, leading to an error in pnrine metabolism (Torres and 
Puig 2007). These were the first models of human disease generated by the 
manipulation of ES cells, and paved the way for gene targeted exchange of 
an endogenous allele by a mutated copy via homologous recombination 
(Hooper, Hardy et al. 1987; Kuehn, Bradley et al. 1987).
It was not long before many laboratories started to publish reports of the 
first ‘knockout’ mice (Koller, Hagemann et al. 1989; Thompson, Clarke et 
al. 1989; Thomas and Capecchi 1990), and there have been many further 
reports of targeted manipulation of the mouse genome, whereby an 
endogenous gene has been mutated to destroy its function (knock-out) or 
switched to a disease associated allele (knock-in) (Matthaei 2007).
1.7.2 Site Specific DNA Recombinase
Recently, the ability to switch a specific gene on or off has been made 
possible by the development of conditional genetic manipulation using site 
specific recombination. Two members of the integrase family of site- 
specific recombinases are, Cre from bacteriophage PI (Sauer and 
Henderson 1989) and Flp from Saccharomyces cerevisiae (O'Gorman, Fox 
et al. 1991)
Cre catalyses recombination between two 34bp recognition sites called 
loxP (locus of crossover PI). The 34bp sequence consists of an 8bp core, 
which determines directionality, and is flanked by 13bp of palindromic
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sequence (Nagy 2000). A gene flanked by loxP sites is referred to as a 
floxed gene. The Cre/lox system has been developed for use in the mouse 
(Lakso, Sauer et al. 1992) and usually requires a mouse strain containing a 
targeted gene flanked by two loxP sites to be crossed with a mouse 
expressing Cre recombmase. Depending on the position and orientation of 
the loxP sites, the DNA sequence can be excised, inverted or translocated 
(see Fig 1.6). When the loxP sites are flanking the target sequence in the 
same direction, Cre excises the intervening DNA segment, with just a 
single loxP site remaining. If the loxP sites are inserted in opposite 
orientation with respect to each other, then the DNA segment is inverted, 
with both loxP sites remaining. To achieve translocation, the loxP sites are 
located on differing strands of DNA orientated in the same direction, Cre 
recombinase then results in the translocation of these segments (Nagy 
2000). This simple system is an extremely powerful tool allowing, with the 
addition of the appropriate promoters, a wide variety of genetic 
manipulations of the mouse genome, in a tissue or cellular specific fashion 
(Nagy 2000).
The Flp (flippase) recombinase is a very similar system also recognising a 
34bp sequence (Flp recombinase target - FRT) (O'Gorman, Fox et al. 
1991). The DNA sequence flanked by two FRT sites is referred to as 
‘flrted’. However, Flp is not as potent a recombinase as Cre at a body 
temperature of 37°C and has thus been modified to produce an enhanced
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Flp (Flpe) which functions more efficiently at body temperature 
(Buchholz, Angrand et al. 1998).
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Fig 1.6 Site-specific DNA recombination
Schematic diagram showing the action of the Cre recombinase on 
paired LoxP sites with (a) excision of the DNA or gene when the LoxP 
sites are ‘in cis’ and orientated the same way or (b) inversion of the 
DNA or gene when the LoxP sites are ‘in trans’ and orientated in 
opposite directions.
1.7.3 The Tet-Off and Tet-On Systems
A popular tool in transgenic science is the binary transcription 
transactivation systems, Tet-Off & Tet-On. In the Tet-Off system gene 
expression is turned off in the presence of doxycycline or tetracycline, 
whilst in the Tet-On system gene expression is turned on in the presence of 
doxycycline only (Gossen and Bujard 1992).
The system is based on two components, the first a tetracycline dependant 
regulatory protein first identified in E.Coli, the Tet repressor protein 
(TetR)(Gossen, Freundlieb et al. 1995) that is fused to the VP 16 activation 
domain of the Heipes simplex vims, generating a transcription activator 
known as tetracycline controlled transactivator (tTA) (Gossen, Freundlieb 
et al. 1995). This is the critical component of the original Tet-Off system, 
whilst the Tet-On system was created by introducing a four amino acid 
change in TetR resulting in a protein rtTA (reverse tTA) (Baron, Gossen et 
al. 1997).
The second component is the tetracycline response element (TRE) that 
controls expression of the gene of interest. In the presence of Doxycycline, 
rtTA bind to TRE and induces gene expression (see Fig 1.7), whilst in 
contrast, tTA is only able to bind TRE in the absence of doxycycline. For 
the purpose of mammalian work the Tet-On system was optimised and 
only responsive to doxycycline (Kistner, Gossen et al. 1996). The 
regulatory protein is referred to as optitTA.
60
rtTAA
rtTA
ft / \ ""ft
Doxycyclin*
Fig 1.7 Tet-On System
Schematic diagram of the Tet-On system. The transcription of the 
rtTA protein is under control of a given promoter. The rtTA protein, in 
the presence of doxycycline, binds to TRE and activates transcription 
of the gene of interest.
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1.7.4 Pancreas Specific Promoters
A promoter is a DNA sequence, which is recognised directly or indirectly, 
and bound by a DNA dependent RNA polymerase during the initiation of 
RNA transcription (Margaritis and Holstege 2008). The promoter lies 
upstream with respect to the gene of interest, and when developed into a 
construct for integration into the mouse genome, can confer tissue 
specificity and thus determine the site of transcription. The promoter may 
allow a gene to be widely expressed in a variety of tissues i.e. 
metallothionein (MT-I), actin, collagen and viral promoters (Palmiter and 
Brinster 1986), whilst other promoters under the influence of tissue 
specific transcription factors allow gene expression to be tissue specific i.e 
albumin promoter for the liver (Postic, Shiota et al. 1999), myogenin for 
skeletal muscle (Grieshammer, Lewandoski et al. 1998), lymphocyte- 
specific tyrosine kinase promoter for T cells (Gu, Marth et al. 1994) etc.
At the time of writing, no promoter has been identified that targets gene 
expression specifically to the ductal cells of the pancreas (Bardeesy and 
DePinho 2002; Hezel, Kimmelman et al. 2006). This obviously has 
implications for developing mouse models of ductal disease, in particular 
pancreatic adenocarcinoma. Fortunately, through an increasing 
understanding of pancreatic organogenesis (Kim and Hebrok 2001), other 
promoters have been identified that enable the development of mouse 
models of pancreatic cancer and pancreatitis (Hezel, Kimmelman et al.
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2006). Early attempts to understand pancreatic adenocarcinoma utilised the 
rat elastase promoter (Omitz, Hammer et al. 1987; Omitz, Hammer et al. 
1987; Quaife, Pinkert et al. 1987) that allows gene expression in the acinar 
compartment of the pancreas (Omitz, Hammer et al. 1987). 
Metallothionein and Misti promoters also target the acinar cells though not 
as efficiently as the elastase promoter (Hezel, Kimmelman et al. 2006). 
The Pdxl and Ptfl-p48 promoters allow expression in the common 
progenitors of all pancreatic cell types with relatively little expression 
outside the pancreas (Hingorani, Petricoin et al. 2003), and have been 
successfully employed to develop mouse models of pancreatic 
adenocarcinoma (Hingorani, Petricoin et al. 2003; Hingorani, Wang et al. 
2005).
1.8 Transgenic models of pancreatitis
Genetically modified mice are a valuable tool to evaluate the in vivo 
consequences of specific genes, and their proteins, by allowing generation 
of gain of function (i.e. overexpression of a specific protein) or loss of 
function (i.e. deletion of gene) models (Matthaei 2007). These models have 
been extensively utilised to study the mediators of acute pancreatitis and 
how they cause pancreatic injury and multiple organ dysfunction syndrome 
(Pastor and Frossard 2001). Most models have focused their attention on 
the action of cytokines and chemokines and their role in the local insult and 
propagation of the systemic inflammatory response (Brady, Christmas et
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al. 1999). Interleukin 1(3 (IL-1|3) and tumour necrosis factor a (TNF-a) are 
proinflammatory mediators shown to increase in acute pancreatitis (Brady, 
Christmas et al. 1999). Studies using IL-1 and TNF-a receptor knockout 
mice demonstrated an attenuated severity of pancreatitis and improved 
survival (Norman, Fink et al. 1996; Denham, Yang et al. 1997) whilst mice 
deficient for the IL-1-converting enzyme, and therefore unable to secrete 
IL-1, had a reduced severity of acute pancreatitis, reduced lung injury and 
an increase in survival from 24%-80% (Norman, Yang et al. 1997). 
However, there is likely to be some redundancy in the immune response as 
highlighted by the study comparing acute pancreatitis induced by a choline 
deficient ethionine supplemented diet in either IL-1 receptor null mice or 
TNF-a receptor negative mice that found a similar reduction in the severity 
and mortality of acute pancreatitis but compound knock-out mice deficient 
in both receptors did not have an additive response (Denham, Yang et al. 
1997). The above studies also reported that IL-6, a cytokine found to 
increase in proportion to the severity of the pancreatic injmy, was 
significantly reduced in the knock-out mice (Norman, Fink et al. 1996; 
Denham, Yang et al. 1997). An IL-6 knock-out mouse model showed that 
caemlein induced pancreatitis resulted in more severe injury and a higher 
mortality rate compared to wild type animals (Cuzzocrea, Mazzon et al. 
2002). However, plasma levels of IL-1 and TNF-a were increased, raising 
the possibility that deletion of IL-6 had resulted in a compensatory up- 
regulation of these cytokine (Cuzzocrea, Mazzon et al. 2002).
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NF-kB (nuclear factor kappa light chain enhancer of activated B cells) 
proteins are transcription factors, which in response to a stimulus such as 
stress, cytokines, bacterial or viral antigens, allows rapid gene expression 
of proinflammatory mediators (Gilmore 2006). NF-kB is present as an 
inactive complex in the cytosol of cells bound to IkB (inhibitor of kappa B) 
and is activated by an IkB kinase (IKK) complex (Gilmore 2006). The 
IKK complex is composed of 2 catalytic subunits (IKK1 & IKK2) and a 
scaffold and regulatory component called NF-kB essential modulator 
(NEMO/IKKy). Both IKK1 &IKK2 can phosphorylate IkB proteins, 
releasing NF-kB to enter the nucleus and induce transcription of its target 
genes including TNF-a, IL-1, IL-6 and ICAM1 (Gilmore 2006). To 
investigate the role of the NF-kB pathway in acute pancreatitis Baumann et 
al. developed transgenic mice expressing iff A under the control of a rat 
elastase promoter to mediate acinar cell expression of IKK2 alleles 
(Baumann, Wagner et al. 2007). They reported that dominant negative 
IKK2 expression ameliorated caerulein-induced pancreatitis though there 
was no effect on trypsin activation (Baumann, Wagner et al. 2007). 
Expression of constitutively active IKK2 was sufficient to induce a 
phenotype of acute pancreatitis with evidence of oedema, mononuclear cell 
infiltration, tissue necrosis and fibrosis, again without evidence of trypsin 
activation (Baumann, Wagner et al. 2007).
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Though these, and other models, assessing the role of cytokine in acute 
pancreatitis continue to increase our rmderstanding of the disease, they are 
not thought to be responsible for the earliest events leading to the onset of 
the disease (Halangk and Lerch 2005). The current dogma in acute 
pancreatitis is based on inappropriate intracellular activation of pancreatic 
zymogens leading to autodigestion (Whitcomb 2001). Cationic trypsinogen 
is considered to be a key early player that is prematurely activated to 
cationic trypsin, which then activates other proteases leading to cellular 
injury (Whitcomb 2001). This hypothesis was strengthened by the finding 
of mutations of cationic trypsinogen in patients with hereditary pancreatitis 
(Whitcomb, Gorry et al. 1996). To investigate the proposal that co­
localisation of cathepsin B is responsible for the premature activation of 
trypsinogen Halangk et al. reported a knockout mouse model of cathepsin 
B deficient animals with significantly reduced trypsin activity after 
secretagogue induced pancreatitis, however, total TAP levels were only 
reduced by 50% and the level of pancreatitis and systemic inflammatory 
response were not drastically altered (Halangk, Lerch et al. 2000). This 
suggested that there must be at least one other mechanism of trypsinogen 
activation (Halangk, Kruger et al. 2002).
The effects of trypsin inhibition were tested in a model in which rat 
pancreatic secretory trypsin inhibitor I, driven by the rat elastase I 
promoter, was over-expressed by 190% in mice acinar cells (Nathan,
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Romac et al. 2005). Caerulin-induced pancreatitis was significantly 
ameliorated in the transgenic animals with no difference in TAP levels but 
trypsin activity was reduced (Nathan, Romac et al. 2005). A SpinkJ^ 
model, in which the mouse homolog of SPINK1 was knocked out, resulted 
in autophagic loss of acinar cells and death by 14.5 days after birth 
(Ohmuraya, Hirota et al. 2005). Trypsin activity was detected in SpinkS 
deficient animals but not in wild-type controls (Ohmuraya, Hirota et al. 
2006). These studies concur with previous work suggesting that trypsin 
activity is tightly regulated in the acinar cells and that SPINK 1 is 
protective.
The SpinkS'1' mouse model failed to address the issue that loss of function 
mutations in SPINK1 result in chronic pancreatitis (Ohmuraya, Hirota et 
al. 2005). This was also tine of a study examining CFTR deficient mice 
that found only mild histological abnormalities consistent with early 
human cystic fibrosis but no overt signs of chronic pancreatitis (Durie, 
Kent et al. 2004). Other models have described various changes similar to 
human chronic pancreatitis, though they are not based on genetic alteration 
that have been described in humans, and include overexpression of keratin 
8 (Casanova, Bravo et al. 1999), defective ciliary function (Cano, Sekine et 
al. 2006), inactivating transforming growth factor-[3 (TGF-(3) signalling 
(Bottinger, Jakubczak et al. 1997), overexpression of IL-1[3 (Marrache, Tu
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et al. 2008), deficient for protein kinase PERK (Harding, Zeng et al. 2001), 
and E2F1/E2F2 double mutant mice (Iglesias, Murga et al. 2004).
Hereditary pancreatitis has clinical features of acute pancreatitis leading to 
chronic pancreatitis and a significantly increased risk of pancreatic 
adenocarcinoma, and thus a faithful transgenic mouse model may allow 
interrogation of the pathway leading to these diseases as well as exploring 
the in vivo role of cationic trypsinogen (Ulrich, Kopras et al. 2000). Selig et 
al. attempted to generate a model of hereditary pancreatitis by expressing 
the human cationic trypsinogen with the R122H mutation targeted to the 
acinar cells of the pancreas by the rat elastase promoter (Selig, Sack et al. 
2006). This model failed to develop any spontaneous signs of either acute 
or chronic pancreatitis within 18 month, but did show a slightly more 
severe caerulein induced pancreatitis (Selig, Sack et al. 2006). The 
conclusion was that the transgene expression had been insufficient to 
develop a phenotype (Selig, Sack et al. 2006). Archer et al. developed a 
mouse model in which they introduced an equivalent of human PRSS1 
R122H mutation into mouse trypsinogen 4 and driving the expression in 
acinar cells with a rat elastase promoter (Archer, Jura et al. 2006). The 
transgenic animals began to display a phenotype by 7 weeks of age, with 
evidence of acinar cell vacuolisation and evidence of cell necrosis. By 12 
weeks of age there were signs of interacinar inflammatory infiltrates and 
collagen deposition consistent with fibrosis was seen in 24% of animal at
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4-7 months of age increasing to 40% at 1 year (Archer, Jura et al. 2006). 
Morphological changes at 1 year included the development of tubular 
complexes and increased acinar cell proliferation (Archer, Jura et al. 2006). 
However, the results of the paper were limited by the lack of rigorous 
controls. The authors did not report a control group that had transgenic 
expression of wt-trypsinogen 4, which would allow comparison to assess 
whether the pathological response was due to trypsinogen over-expression 
or related to the mutation. There were no transgenic mice generated to 
ascertain whether a neutral mutation could affect a pathological response. 
The transgenic construct had a C-terminal FLAG epitope tag and tandem 
Ires-GFP element to facilitate assessment of transgene expression, 
however, no mechanism was developed to exclude these affecting the 
tertiary structure of mouse trypsinogen 4 (Archer, Jura et al. 2006). The 
transgene expression was confirmed in the acinar cells by 
immunohistochemistry, but its subcellular location was not investigated in 
detail to confirm whether transgenic trypsinogen 4 entered the secretory 
pathway and was appropriately secreted by the acinar cells (Archer, Jura et 
al. 2006). These shortcomings limit the conclusions that can be drawn 
regarding the R122H mutation in the model and raises doubts about any 
parallels with the human disease.
Two models have attempted to demonstrate the link between chronic 
pancreatitis and pancreatic adenocarcinoma (Guerra, Schuhmacher et al.
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2007; Marrache, Tu et al. 2008). Marrache et al. described a IL-1|3 
overexpressing mouse with features of chronic pancreatitis crossed with a 
p53Ri72H mutant mouse, and found only one mouse developed pancreatic 
adenocarcinoma which may have simply been due to the p53 mutation 
(Marrache, Tu et al. 2008). Guerra et al. in an elegant model generated 
mice based on a Cre/lox and Tet-On system to conditionally express 
mutant K-rasG12V in the acinar cells of the pancreas (Guerra, Schuhmacher 
et al. 2007). They found that adult acinar cells were resistant to mutant K- 
ras mediated transformation and showed no evidence of acinar to ductal 
metaplasia or PanIN lesions (Guerra, Schuhmacher et al. 2007). However, 
in transgenic animals with caemlein-induced chronic pancreatitis PanIN 
lesion were seen with a third of the cohort developing invasive pancreatic 
cancer (Guerra, Schuhmacher et al. 2007). The pathway involved in this 
progression from inflammation to cancer remains to be elucidated (Guerra, 
Schuhmacher et al. 2007).
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1.9 Aims of the Study
The aim of the study was to develop a transgenic mouse model of 
hereditary pancreatitis by expressing human PRSS1 in the acinar cells of 
the mouse pancreas, which would allow interrogation of the in vivo effects 
of human cationic trypsinogen expression and its role into the pathways 
leading to acute and chronic pancreatitis and pancreatic adenocarcinoma. 
The transgenic mice were designed to express either wild type PRSS1 or 
one of the two most frequent mutations described in patients with 
hereditary pancreatitis; PRSS1 R122H or PRSS1 N29I. The generation of 
transgenic mice expressing human wtPRSSl would act as a control group 
along with a matched cohort of non-transgenic animals. These animals 
would then be analysed to assess whether they develop a phenotype similar 
to hereditary pancreatitis in humans.
The model should only express the gene of interest (i.e. wtPRSSl, PRSS1 
R122H, or PRSS1 N29I) in the pancreatic acinar cells of the mouse, and 
the protein must be transported and excreted along the secretory pathway. 
The protein should be identifiable amongst the native mouse 
trypsins/trypsinogens. The transgene should not cause inadvertent 
developmental or functional sequelae outside the pancreas.
To achieve these aims two separate strategies were developed. The first 
‘inducible’ model would be based on the Tet-On system and allow spatial
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and temporal control of the transgene. This model will require the 
development of two separate constructs. The first construct, based on the 
pBI-G bidirectional vector, will carry the gene of interest i.e. wtPRSSl or 
one of the two mutants (tenned pBI-G wtPRSSIHA, pBI-G PRSS1HA 
R122H, or pBI-G PRSS1HA N29I) driven by a minimal CMV promoter 
that also contains a TRE. The second construct, which expresses the 
regulator protein OptrtTA, would be driven by an upstream rat elastase 1 
promoter (See Fig 1.8). Cross breeding of mice transgenic for these 
constructs would provide a compoimd mouse strain that could be induced 
to express the gene of interest in the acinar cells of the pancreas upon 
feeding with doxycycline (See fig 1.8). The second <;non-inducible, model 
would utilise a construct where the rat elastase promoter drives the gene of 
interest in the acinar cells of the mouse pancreas in an autonomous fashion. 
This strategy was to be a backup in the event of difficulties with the 
inducible model. Both models would have a Haemaglutinin (HA) tag at 
the C-terminus of the protein of interest to aid identification.
A table outlining the constructs described above is shown in figure 1.9.
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Optimised rtTA
Strain 1 ^ A
Fig 1.8 Compound transgenic mice
Schematic diagram showing the two panels of mice. Strain 1 carries 
the regulatory protein, OptrtTA, and strain 2 carries the gene of 
interest and a reporter driven by a bidirectional promoter. Cross 
breeding the two strains creates the compound mouse, which will 
express the gene of interest on feeding with doxycycline. (*The gene of 
interest shown is wtPRSSIHA but may also be PRSS1HA R122H or 
PRSS1HA N29I).
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Constructs
Non-
inducible
model
pBEG wtPRSSIHA
pBEG PRSS1HAR122H
pBEG PRSS1HAN29I
Inducible
model
pBI-G wtPRSSIHA
pBI-G PRSS1HAR122H
pBI-G PRSS1HAN29I
pBEG optrtTA
Fig 1.9 Constructs for non-inducible & inducible models 
Table showing the constructs required to generate transgenic founder 
animals to develop a non-inducible and inducible mouse model of 
hereditary pancreatitis
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Therefore the objectives of this study are:
1. To develop a set of constructs required to generate the two different 
models.
2. To generate potential transgenic founders for each strain by 
microinjection of the constructs into mouse embiyos.
3. To identify transgenic animals and expand each strain. Cross breed the 
two panels required for the inducible model creating a compound strain for 
wtPRSSIHA, PRSS1HA R122H, and PRSS1HA N29I.
4. To analyse the transgenic mice to assess whether they exhibit a 
phenotype similar to hereditary pancreatitis.
As a secondary objective to the study, which would be undertaken 
concurrently with development of the transgenic animals, the wtPRSSl and 
the two mutants would be subcloned into a pCEP expression vector. These 
constructs would be used to transiently transfect commercially available 
mammalian cell lines and used to assess the reaction kinetics of cationic 
trypsinogen compared to the mutant proenzymes. In this way we hoped to 
ensure that the proteins were successfully transcribed, and most 
imperatively, functionally intact and capable of enzymatic activity in vitro.
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Chapter 2
2 MATERIALS AND METHODS 
2.1 Materials And Reagents
Unless otherwise stated all general chemicals and reagents used were 
obtained from either Sigma-Aldrich Company Ltd (Poole, Dorset, UK) or 
VWR International (Leicestershire, UK) and were of the highest grade
available.
Chemical / Reagent / Material Supplier
Acrylamide (Aciylogel 40%) VWR
Ampillicin Sigma
Antaractic Phosphatase New England Biolabs Ltd
APS VWR
(I-mercaptoethanol Sigma
Biomax Transcreen & Cassette VWR
Blotting Grade Blocker Non Fat Dry Milk Bio-Rad Laboratories Ltd
Bio-Rad Protein Assay Reagent Bio-Rad Laboratories Ltd
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BSA (powder) Sigma
Cell scrapers Coming Ltd
Chloroform VWR
Deoxynucleotide Solution Mix (dNTPs) New England Biolabs Ltd
Dextran Sulphate GE Healthcare
DMEM Sigma
DMSO VWR
DNA ligase/buffer Ambion/Applied Biosystems
DNA Polymerase I Klenow Fragment New England Biolabs Ltd
EDTA Sigma
EndoFree® Plasmid Purification Kit Qiagen Ltd
Enterokinase Light Chain New England Biolabs Ltd
Ethanol VWR
Ethidium Bromide Sigma
FBS Sigma
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Formaldhyde VWR
Fuji Medical X-ray Film Fisher Scientific
Geneclean® Turbo Kit Q.BIO Gene
GeneSieve LE Agarose Flowgen Bioscience
Glycerol Sigma
Hybond & Hybond XL Membranes GE Healthcare
lodination Grade Human Trypsin EMD Biosciences
Isopropanol VWR
Ikb DNA ladder Invitrogen
L-glutamine Sigma
Luria Bertani Broth Powder Sigma
Megaprime DNA labelling system GE Healthcare
Methanol Sigma
Mini Protean III Electrophoresis System Bio-Rad Laboratories Ltd
Mini Trans-Blot System Bio-Rad Laboratories Ltd
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One Shot TOPIO is.co/z Invitrogen
Orange G VWR
pBI-G Clontech Inc
PBS Sigma
pCEP4 Invitrogen
pCR2.1 Invitrogen
32P dCTP GE Healthcare
Penicillin Sigma
Phenol VWR
Ponceau S Sigma
Potassium Chloride Sigma
Potassium Ferricynide Sigma
Potassium Ferrocynide Sigma
Prestained Protein Marker New England Biolabs Ltd
Proteinase K Sigma
19
QIAprep Spin miniprep Kit Qiagen Ltd
QIAquick Gel Extraction kit Qiagen Ltd
Restricton Endonucleases New England Biolabs Ltd
RPMI1640 Sigma
rTth DNA polymerase XL Ambion/Applied Biosystems
Sheared Salmon Sperm DNA Eppendorf Ltd
Seakem GTG Agarose Cambrex
Sephradex G 50 GE Healthcare
SOC medium Invitrogen
Streptomycin Sigma
Submerged Gel Electrophoresis Units Web Scientific
T4 DNA ligase New England Biolabs Ltd
T4 ligase/buffer Ambion/Applied Biosystems
Taq DNA polymerase New England Biolabs Ltd
TEMED VWR
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Tissue culture flasks / dishes Nunc
Total pancreatic RNA
Triton X-100
Trypsin-EDTA
Tween®20
Virkon
Western Lightning Chemiluminescence 
Reagent
Ambion/Applied Biosystems
Sigma
Sigma
GE Healthcare
MRC
Perkin Elmer Life Sciences
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2.2 General Solutions
All solutions and buffers not supplied by the manufacturer were prepared 
in reverse osmosis (RO) treated water of 18MQ.
Blocking Solution
5% Bio-Rad Blotting Grade Blocker in PBS Tween
Calcium Chloride
500mM CaCh Stock solution
Denaturing Solution for Southern Blot 
1.5M NaCl, 0.5M NaOH 
Depurination Solution for Southern Blot
0.2N HC1
Freezing Medium
90% FBS, 10% dimethyl sulphoxide
LB Agar
2.5% w/v LB powder, 1.2% w/v agar, lOOpg/ml ampicillin
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Lysis Buffer
50mM Tris-HCl (pH 8), lOOmM EDTA, 0.5% SDS
Neutralisation Solution for Southern Blot
1M Tris-HCl (pH7.4), 1.5M NaCl
PBS Tween
0.065M Na2HP04, 0.015M NaH2P04, 0.075M NaCl, 0.1% Tween® 20 
(Polyoxyethylene sorbitan monolaurate)
Phenol: Chloroform:Isoamyl alcohol (PCI)
25:24:1 v/v
10X Ponceau S
2% Ponceau S (3-hydroxy-4-[2-sulpho-4-(sulpho-phenylazo)phenylazo]- 
2,7-naphthalene disulphonic acid), 30% trichloroacetic acid, 30% 
sulphosalicylic acid
Pre-hybridisation Solution for Southern Blot
1M NaCl, 10% Dextran Sulphate, 1% SDS
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Proteinase K
lOmg/ml Proteinase K in RO H2O 
Protein Gel Electrophoresis Buffer 
25mM Tris, 250mM glycine, 0.1% SDS 
Protein Loading Buffer (4X)
0.25M Tris-HCl (pH 6.8), 8% SDS, 40% glycerol, 0.04% bromophenol 
blue, 1% J3-mercaptoethanol
Protein Transfer Buffer
25mM Tris, 192raM Glycine, 20% methanol
12% Resolving gel (10ml)
4.3ml H20, 3ml 40% acrylamide 2.5ml 1.5M Tris-HCl (pH 8.8), 0.1ml 
10% SDS, 0.1ml 10% ammonium persulphate (APS), 8j.il TEMED
10% Resolving gel (10ml)
As for 12% gel above but with 2.5ml 40% acrylamide and 4.8ml H2O
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SLIP Buffer
50mM HEPES (pH7.5), 10% Glycerol, 0.1% Triton X-100, 150mM NaCl, 
0.5 mg/ml BSA
20X SSC
3M NaCl, 0.3M sodium citrate pH 7
Stacking gel (10ml)
7.225ml H2O, 1.275ml 40% acrylamide, 1.25ml 1M Tris (pH 6.8), 0.1ml 
10% SDS, 0.1ml 10% APS, lOpl TEMED
SOX TAE
2M Tris base, 2M glacial acetic acid, 50mM EDTA
IX TE
lOmM Tris-HCl (pH8.0), ImM EDTA
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2.3 Antibodies
Mouse monoclonal antibodies against human cationic trypsin 
(13401,13402,13403,13404) were purchased from Source Bioscience 
Autogen. Anti-haemaglutinin (anti-HA) (12CA5) antibody used to detect 
HA-tagged protein was purchased from Roche Molecular Biochemicals. 
The anti-actin antibody (C-2), used as a protein loading control, and the 
anti-|3-galactosidase antibody, to assess transfection, were purchased from 
Santa Cruz Biotechnology. Secondary antibodies, anti-mouse IgG 
Horseradish Peroxidase linked whole antibody (from sheep) and anti-rabbit 
Ig Horseradish Peroxidase linked whole antibody (from donkey), was 
purchased from GE Healthcare.
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2.4 Primers
All primers were purchased from Eurofins MWG Operon (Germany). 
OptrtTA_5’ screen
5’ AGT AAG GTG ATT AAC AGC GCA CTG 3’
OptrtTA_3 ’
5’ TAG TCG TCA ATT CCA AGG GCA TCG 3’
5’ BamHIPRSSl
5’ GAG AGG ATC CCA CCA TGA ATC AAG CTC TCC TCA 3’
3’ BamHIPRSSl
5’ GAG AGG ATC CTT TAG CTA TTG GCA GCT ATG GT 3’
3’ HABamHIPRSS 1
5’ GAG AGG ATC CTC AAA GAG CGT AAT CTG GAA CAT CGT 
ATG GGT AGC TAT TGG CAG CTA TGG TGT TC 3’
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2.5 Plasmids
The plasmids utilised in this project are pCR2.1, pCEP4, and pBI-G, which 
are commercially available.
pCR2.1(Invitrogen) is an intermediate vector frequently used in cloning 
because it allows the direct ligation of PCR products into the vector 
without the use of restriction enzymes. The linearised vector has a single 3’ 
deoxythymidine (T) residue which enables PCR products with a single 
deoxyadenosine (A) residue to ligate efficiently. This vector also contains 
ampicillin and kanamycin resistance genes allowing for positive selection 
in prokaryotic and eukaryotic cells respectively.
pCEP4 (Invitrogen) is a mammalian expression vector that utilises a 
cytomegalovirus (CMV) promoter/enhancer for transcription of 
recombinant genes inserted into the multiple cloning site. This vector also 
contains ampicillin and hygromycin B resistance genes allowing for 
positive selection in prokaryotic and eukaryotic cells respectively.
pBI-G (Clontech Inc) is an expression vector that utilises a bidirectional 
Tet-responsive promoter to drive the expression of a gene of interest and (j- 
galactosidase simultaneously. The promoter contains the Tetracycline 
response element (TRE), which is responsive to the tTA and rtTA 
regulatory proteins of the Tet-On and Tet-Off systems respectively. The 
TRE is positioned between two minimal CMV promoters, which lack the
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enhancer element, and therefore only allow transcription upon binding of 
the regulatory protein. Binding to the TRE by the regulatory protein 
enables simultaneous bidirectional transcription of a gene of interest and f3- 
galactosidase. The vector contains the ampicillin resistance gene.
pBEG plasmid was a kind gift from Martin E. Fernandez Zapico, MD, 
from the Mayo Clinic, Minnesota, USA. It is based on the pBluescriptll 
SK+ vector backbone with the rat elastase promoter cloned into the 
HindllMBamHi site and human growth hormone sequence cloned into the 
BamMVNotl site. This results in a unique BatriHl restriction enzyme sites 
between these two sequences suitable for further cloning. The vector 
contains the ampicillin resistance gene (Fig 2.1).
pOptrtTA plasmid was a kind gift from Maria Valencik, Phi), from the 
University of Utah, USA. It is also based on the pBluescriptll SK+ vector 
backbone with the optimised rtTA (optrtTA) sequence cloned into the 
E'coRI site. The vector also contains the ampicillin resistance gene (Fig 
2.2).
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F1 ori
LacZ alpha
M13-fwd
693 Hindlll
Elastase
1218 BamHI
ColEI origin '
5603 bp
LacO
Human growth hormoneM 13-rev
3383 Notl
Fig 2.1 pBEG Expression Vector
Schematic diagram of the expression vector pBEG (kind gift from Dr 
Fernandez Zapico). Cloned into a pBluescript backbone is the rat 
elastase promoter and the human growth hormone polyA sequence. 
Unique restriction enzymes sites for HindiW, BamWl and Notl are 
shown.
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AmpR
Fig 2.2 pOptrtTA Expression Vector
Schematic diagram of the expression vector pOptrtTA (kind gift from 
Dr Maria Valencik). Cloned into a pBluescript backbone is the 
OprtTA sequence and the human growth hormone polyA sequence. 
Unique restriction enzymes sites for HindiW, and E’coRI are shown.
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2.6 Cell Culture
2.6.1 Cell Lines
Most of the cell lines used were from the cell collection held at the 
Division of Surgery & Oncology, University of Liverpool. Three 
commonly used cell lines were HI299, a human non-small cell lung 
carcinoma derived from a metastatic lymph node site; MCF7, a human 
breast adenocarcinoma cell line derived from a pleural effusion, and HEK 
293T, a transformed human embryonic kidney cell line. These cell lines are 
also available commercially. The AR42J, a rat pancreatic acinar cell line, 
was a kind gift from Dr F.X Real (Unitat de Biologica Cellular i molecular, 
Institut Municipal d’ivestigacion Medica, Barcelona, Spain).
2.6.2 Growth Conditions
All cells were cultured as a monolayer using standard tissue culture 
techniques. Cells were grown at 37°C in a 95% air, 5% CO2 humidified 
cell incubator. HI299 cells were maintained in RPMI 1640 medium 
supplemented with 10% foetal bovine serum (FBS) whilst MCF7, HEK 
293T were maintained in DMEM supplemented with 10% FBS and 2mM 
L-glutamine, and AR42J cell lines were maintained in DMEM 
supplemented with 20% FBS and 2mM L-glutamine.
HI 299, HEK 293T and MCF7 cell lines were split when they became 
approximately 100% confluent whilst the AR42J cells were split when they
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became ~70% confluent and patches of cells started forming domes. The 
medium was removed and the cells (except HEK 293T) were washed in 
warm PBS followed by incubation with 0.25% Trypsin-EDTA solution at 
37°C for 2-4 minutes. Cells were observed under the microscope to ensure 
the cell layer had dispersed and then the appropriate growth medium 
added. The H1299, HEK 293T and MCF7 cells were split 1:10 twice a 
week, whilst the AR42J cells were split 1:5 twice a week.
2.6.3 Cell Seeding for Experimental Use
Cells were split from the routine growing flasks and seeded into 
appropriate tissue culture dishes at least 24 hours prior to use, at a 
confluence dependant on experimental conditions. For the purposes of 
transfection, cells were seeded with the aim of achieving 60-70% 
confluence after 24 horns.
2.6.4 Cryostorage of Cell Stocks
All cell lines were expanded and multiple aliquots frozen for storage. 
Confluent T175 flasks were harvested and the cells pelleted at 300xg for 4 
minutes at room temperature. The pellets were re-suspended in freezing 
medium (90% v/v FBS, 10% v/v DMSO). The aliquots were frozen at - 
80°C overnight and then transferred to liquid nitrogen for long-term 
storage.
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2.7 Transfection of Cell Lines
2.7.1 Transfection of H1299, MCF7 & HEK 293T
The day prior to transfection, cells were seeded in the appropriate culture 
medium to achieve a 60-80% confluence after 24hrs incubation at 37°C 
(5% CO2). Transfections were performed using GeneJuice as
recommended by manufacturer’s instructions. Briefly, for a 100mm dish, 
100pi serum free medium was mixed thoroughly with GeneJuice (3 pi for 
every Ipg of DNA) and incubated at room temperature for 5 minutes. 
Typically, 10pg of plasmid DNA was mixed with 2.5pg of a reporter ((3- 
Galactosidase) plasmid DNA and then added to the GeneJuice/semm free 
medium solution and incubated at room temperature for 15 minutes. The 
GeneJuice /DNA mixture was added drop-wise to the cells in growth 
medium to cover the whole surface, and incubated for 24 hours at 37°C 
(5% CO2). The cells were harvested by washing with PBS (except the 
HEK 293T cell line) and then mobilized, using a cell scraper, into 10ml of 
PBS. The cells were transferred into 15ml tubes and centrifuged at 300xg 
for 5 minutes. The resulting supernatant was removed and the cell pellets 
were stored at -80°C.
2.7.2 (3 Galactosidase in Situ Assay
Transfection efficiency was assessed by detection of the expression of 
exogenous |3-galactosidase using an in situ assay. Cells were washed with 
PBS then fixed with 0.5% v/v gluteraldehyde in PBS and incubated at
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room temperature for 15 minutes. Cells were washed again with PBS and 
then incubated with 3mM potassium ferrocynide, 3mM potassium 
ferricynide, ImM magnesium chloride, and 0.5mg/ml X-gal (5-bromo-4- 
chloro-3-indolyl-[3-D-galactopyranoside) in PBS for 6 horn's at 37°C. 
Successfully transfected cells stained blue.
2.8 Westem Blot Analysis
2.8.1 Preparation of Whole Cell Lysates
Medium was completed removed and the cells were washed with PBS and 
then mobilised using a cell scraper into 10ml of PBS. The cells were 
transferred into 15ml tubes and centrifuged at 300xg for 5 minutes. The 
resulting supernatant was removed and the cell pellet was either stored at 
-80°C or underwent protein extraction.
2.8.2 Determination of Protein Concentration
The cell pellets were lysed using SLIP buffer and then centrifuged at 
16,000xg at 4°C for 10 minutes. The supernatant was removed and the 
protein concentration was determined using tire Bradford method 
(Bradford 1976). Protein standards were prepared by serial dilutions of 
20mg/ml of BSA in SLIP buffer. 2pi of each standard were added to IX 
Bio-Rad protein assay reagent to a final volume of 1ml and the absorbance 
(A) measured with an Eppendorf Biophotometer using a wavelength of
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595nm to generate a standard curve. Samples were then assayed in a 
similar fashion to determine the protein concentration.
2.8.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Cell lysates were adjusted to 2.5p,g protein per pi using 2X and IX protein 
sample buffer and denatured by heating to 100°C for 5min then centrifuged 
at 16,000xg at 4°C for 5 minutes.
0.75mm gels were cast using the Bio-Rad Mini Protean III Electrophoresis 
system with an upper 5% stacking gel and a lower 10-12% resolving gel 
depending on the size of the protein of interest. The gels were submerged 
in protein gel electrophoresis buffer and typically 50pg (final volume of 
20pi) of protein was loaded per well alongside 15 pi of pre-stained protein 
marker. The samples were subjected to electrophoresis at 200V.
2.8.4 Transfer of Proteins
Hybond ECL nitrocellulose membrane was cut to size and pre-soaked in 
SQ water for 10 minutes before being soaked (with Whatman paper and 
sponges) in transfer buffer at room temperature with gentle agitation. After 
completion of electrophoresis, the resolving gel was set up for transfer of 
proteins to the nitrocellulose membrane using the Bio-Rad Mini Trans-Blot 
system. Transfer was carried out at 100V for 60 minutes in transfer buffer 
with an ice block in situ to avoid over heating of the system.
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2.8.5 Protein Staining
The transfer apparatus was disassembled and the membrane was stained 
with Ponceau S for 5 minutes to assess transfer and even loading. The 
membrane was cut if necessaiy and then completely destained in several 
washes of PBS Tween.
2.8.6 Immunoblotting & Chemiluminescence
Non specific protein binding sites on the membrane were blocked using 
5% Bio-Rad Blotting Grade Blocker Non Fat Diy Milk in PBS Tween for 
a minimum of 1 hour at room temperature with gentle agitation or 
overnight at 4°C. The membranes were then incubated with a primary 
antibody diluted in PBS Tween/milk buffer (each at 3pg/ml except anti- 
tiypsin antibodies which were diluted 1:200) for Ihr at room temperature 
with gentle agitation. The primary antibody solution was removed and the 
membrane washed with 3 changes of PBS Tween for 15 minutes each. 
Next the membrane was incubated with Horseradish peroxidase conjugated 
secondary antibody, raised against the primary antibody species source, 
diluted in PBS Tween/milk buffer for 1 hr at room temperature with gentle 
agitation. The anti-mouse antibody was diluted to a concentration of 
1:2500 and the anti-rabbit antibody to a concentration of 1:5000. The 
secondary antibody solution was removed and the membrane washed with 
3 changes of PBS Tween for 15 minutes each.
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Detection of the bound antibody complex was preformed using enhanced 
chemiluminescence. Equal amounts of enhanced luminal reagent and 
oxidizing reagent were mixed and used to completely cover the surface of 
the membrane for 1 minute at room temperature. Excess ECL was 
removed and the membrane was wrapped in cling film. The membrane was 
exposed to Fuji medical x-ray film in a dark room and the film developed 
by placing it in Kodak developer for 2 minutes and then Kodak fixer for 2 
minutes before washing with tap water.
2.9 Trypsin Assay 
2.9.1 Assay of cell lysates
Cells were seeded and grown as described above. If required, transient 
transfection of a cell line was achieved using Genejuice as per 
manufacturer’s instructions and outlined above. After incubation for 24 
hours at 37°C (5% COi), the cells were harvested by washing with PBS 
and then mobilized using a cell scraper into 10ml of PBS. The cells were 
transferred into 15ml tubes and centrifuged at 300xg for 5 minutes. The 
resulting supernatant was removed and the cell pellets were placed at - 
80°C for 20 minutes. The pellets were lysed in SLIP buffer without 
addition of any protease inhibitors and the protein concentration assessed 
using the Bradford method as described above.
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The trypsin assay was performed for cellular lysates using the synthetic 
chromogenic substrate BZiPAR (Rhodamine 110, bis-(N-CBZ-L- 
isoleucyl-L-prolyl-L-arginine amide), dihydrochloride) at 5pM. The 
reaction kinetics were followed at excitation wavelength of 498nm and 
emission wavelength of 520nm in 0.1M Tris-HCl (pH 8.0), ImM CaCb, 
2ng/ml of human enterokinase and 150jxg/ml of protein lysate at 37°C 
using a Hitachi F2000 Spectrophotometer. Readings were taken every 10 
minutes unless stated otheiwise.
During optimization of the assay, untransfected cell lines routinely 
available in the laboratory were analysed as described above but with the 
addition of 20ng/ml of high-grade recombinant human trypsin.
2.9.2 Assay of Supernatant
HEK 293T cells were grown, seeded and transfected as described above. 
24 hours after transfection, the growth media was removed and replaced by 
OptiMEM and incubated at 37°C (5% CO2), for a further 24 hours. The 
OptiMEM was removed and used for the assay in place of the 0.1M Tris- 
HCl (pH 8.0) with the other reagents and procedures as described above 
unless stated otherwise. The pH of the OptiMEM was adjusted using a 
weak acid or alkali as required. The cells were harvested, as described 
above, for Western blot analysis. Supernatant used for Western blot 
analysis was harvested prior to addition of any reagents for the trypsin
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assay and adjusted using 4X sample buffer. The remainder of the 
procedure was similar to Western blot analysis as described above.
2.10 Recombinant DNA Techniques
2.10.1 Transformation of E.Co//with plasmid DNA
Aliquots of Top 10 E.coli cells were thawed and lOOng of plasmid DNA, 
or 5pi of ligation reaction, added and placed on ice for 30 minutes. Cells 
were heat shocked at 42°C for 30 seconds and replaced on ice for 2 
minutes. 400pl of SOC (salt optimised and carbon) medium was added to 
each aliquot and the cells were then incubated at 37°C for 1 hour with 
agitation. The cells were grown on LB agar (2.5% & 1.2% w/v) plates 
containing appropriate antibiotics and incubated overnight at 37°C. If 
blue/white selection was required then LB agar plates coated with 32pi of 
5% X-Gal and 8pl of 1M IPTG were used. Colonies were picked based on 
blue/white selection bias, white colonies indicating that the lac Z gene is 
disrupted by the successful presence of the insert.
2.10.2 Small Scale Plasmid Purification
This was performed using the QIAprep Spin Miniprep Kit according to the 
manufacturer’s instructions. Single colonies were picked from selective 
plates and inoculated into 5ml of LB medium containing appropriate 
antibiotics and grown to saturation overnight at 37°C with agitation. 
Bacterial cells were harvested by centrifuging at 16000 x g at room
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temperature for 5 minutes. The supernatant was removed and plasmid 
DNA was purified from the bacterial pellet. The procedure utilised alkaline 
lysis of bacterial cells followed by binding of DNA onto silica in the 
presence of high salt and then elution using a low salt solution. Briefly, the 
pellet was completely suspended in 250j.il of suspension buffer (Buffer PI) 
containing RNase A. The pellet was then lysed in 250j.il of sodium 
hydroxide/SDS (Buffer P2). The lysates was neutralised and adjusted to a 
high salt binding conditions by adding 350^1 of neutralising buffer (Buffer 
N3). The high salt allows precipitation of denatured protein, chromosomal 
DNA, cellular debris and SDS, whilst plasmid DNA remained in solution. 
The lysate was centrifuged at 16000 x g for 10 minutes. The supernatant 
was transferred to a QIAprep spin column and centrifuged for 1 minute. 
The flow through was discarded and 0.5ml of wash buffer (Buffer PB) 
applied to the QIAprep spin column and centrifuged for 1 minute to 
remove endonucleases. The flow through was discarded and 0.75ml of a 
second wash buffer (Buffer PE) applied to the QIAprep spin column and 
centrifuged for 1 minute to remove salts. The flow through was discarded 
and column centrifuged for a minute to ensure removal of residual wash 
buffer. The DNA was eluted by adding 50j.il of SQ water or elution buffer 
(Buffer EB lOmM Tris, pH8.5).
2.10.3 Large Scale Plasmid Purification
This was performed using the Quigen Plasmid Purification Kit according
to the manufacturer’s instructions. Single colonies were picked from
101
selective plates and inoculated into 500ml of LB medium containing 
appropriate antibiotics and grown to saturation overnight at 37°C with 
agitation. The plasmid DNA was purified using either the Qiagen Plasmid 
Midi kit or EndoFree Plasmid Mega Kit respectively depending on 
quantity of DNA required. The procedure utilised alkaline lysis of bacterial 
cells followed by binding of plasmid DNA to QIAGEN anion-exchange 
resin under low salt and pH conditions. The DNA is eluted in a high salt 
buffer and then concentrated and desalted by isopropanol precipitation. 
Briefly, bacterial cells were harvested by centrifuging at 6000 x g for 15 
minutes at 4°C and the supernatant removed. The pellet was completely 
suspended in 4ml of suspension buffer (Buffer PI) containing RNase A. 
The pellet was then lysed in 4ml of sodium hydroxide/SDS buffer (Buffer 
P2) for 5 minutes. The lysate was neutralised and adjusted to a high salt 
binding conditions by adding 4ml of chilled acidic potassium acetate 
neutralising buffer (Buffer P3) and incubated on ice for 15 minutes. The 
high salt allows precipitation of denatured protein, chromosomal DNA, 
cellular debris and SDS, whilst plasmid DNA remained in solution. The 
lysate was centrifuged at 20000 x g for 30 minutes at 4°C and the 
supernatant removed and centrifugation repeated for a further 15 minutes 
at 4°C, and again, the supernatant containing plasmid DNA removed. 
Applying 4ml of a buffer containing sodium chloride, isopropanol and 
Triton X-100 (Buffer QBT), equilibrated a QIAGEN-tip 100. The
supernatant was applied to the QIAGEN-tip and allowed to enter the resin
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by gravity. The QIAGEN-tip was then washed with 2x 10ml of a medium 
salt buffer (Buffer QC) to remove all remaining contaminants. The plasmid 
DNA was eluted using 5ml of a high salt buffer (Buffer QF) and 
precipitated by adding 3.5ml of isopropanol and immediately centrifuged 
at >15000 x g for 30 minutes at 4°C. The supernatant was removed and the 
DNA pellet washed with 2ml of 70% ethanol to remove residual salt, and 
centrifuged at >15000 x g for 10 minutes. The ethanol is removed and the 
pellets air dried for 10 minutes and dissolved in TE buffer (lOmM Tris, 
pH8; ImMEDTA).
The procedure was slightly different when Endofree QIAGEN Megaprep 
Kit was used in that the volume for buffers P1-P3 is 50ml. In addition, 
after adding buffer P3 the lysate was not incubated on ice, but poured onto 
a QIAfilter Mega-Giga cartridge and incubated at room temperature. The 
vacuum was used to enable all of the supernatant to pass through 
completely. The cartridge was washed with 50ml of wash buffer 
containing potassium acetate (Buffer FWB2), and 12.5ml of specific 
endotoxin removal buffer (Buffer ER) was added to the filtered lysate, 
mixed by inverting and incubated on ice for 30 minutes. The QIAGEN-tip 
2500 was equilibrated with 35 ml of buffer QBT and the filtered lysate was 
allowed to enter the resin by gravity. The QIAGEN-tip was then washed 
with 200ml of a medium salt buffer (Buffer QC) to remove all remaining 
contaminants. The plasmid DNA was eluted using 35ml of a high salt 
buffer (Buffer QN) and precipitated by adding 24.5ml of isopropanol and
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immediately centrifuged at >15000 x g for 30 minutes at 4°C. The 
supernatant was removed and the DNA pellet washed with 7ml of 
endotoxin free 70% ethanol to remove residual salt, and centrifuged at 
>15000 x g for 10 minutes. The ethanol was removed and the pellets air 
dried for 10 minutes and dissolved in endotoxin free TE buffer (lOmM 
Tris, pH8; ImM EDTA). To determine the yield, DNA concentration was 
determined by UV spectrophotometry at 260nm and 280nm. Typical 
A260/280 values were 1.8 +/- 0.05.
2.10.4 Bacterial Glycerol Stocks
Glycerol stocks were made by adding 500pl of bacterial cell culture to 
500j.il of 50% filter sterilised glycerol and stored at -80°C.
2.10.5 Agarose Gel Electrophoresis
This technique was used for the examination of DNA from restriction
enzyme digests and DNA purification. Gels were cast by dissolving
agarose into IX TAE buffer and adding 0.5|.ig/ml of ethidium bromide,
then allowed to set. The mini, midi & maxi submerged horizontal gel
electrophoresis imits were used to cast gels of 50, 100 & 150mls final
volume respectively. Samples were prepared by adding Orange G (10% of
final volume) and loaded onto the gel. The gel was subjected to an
electrical field to achieve migration of the DNA towards the positive
electrode, and the electrophoresis assessed against a Ikb ladder by UV
illumination and photography of the gel. High-grade (GTG) agarose was
104
used for applications requiring DNA purification, whilst standard agarose 
was used for all other applications.
2.10.6 DNA Purification from Agarose Gel
DNA was extracted and purified from selected bands run on an agarose gel 
using die Q.BIOgene Geneclean Turbo Kit as per manufacturer’s 
instructions. DNA binds to silica in high concentrations of chaotropic salt 
and elutes when the salt concentration is low. Briefly, the gel slice was 
placed in a 1.5ml microcentrifuge tube with lOOpl GENECLEAN* Turbo 
salt solution per O.lg of gel. This was incubated at 55°C for 5 minutes to 
melt the gel. The tube was inverted to allow mixing and the DNA/salt 
solution transferred to a GENECLEAN* Turbo cartridge. This was 
centrifuged at <14000 x g for about 5 second to allow all the liquid to pass 
through the filter. The liquid was discarded. 500pl of GENECLEAN* 
Turbo Wash solution was added to the fdter and again centrifuged at 
<14000 x g for 5 seconds. The liquid was discarded and the wash repeated. 
The GENECLEAN* Turbo cartridge was centrifuged at <14000 x g for 4 
minutes to ensure all the wash solution had been expelled. The 
GENECLEAN* Turbo cartridge was inserted into a new catch tube and 
20pi of GENECLEAN* Turbo elution solution added directly onto the 
GLASSMILK* -embedded membrane, which was incubated for 5 minutes 
at room temperature. The DNA was eluted by centrifugation at <14000 x g 
for 1 minute into the catch tube. The concentmtion of the product was
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calculated by running 10% v/v on a 0.7% w/v agarose gel and comparing 
the resultant band intensity with the 1636bp band that contains 10% of the 
mass applied to the gel.
2.10.7 DNA Restriction Digests
DNA was digested using restriction endonucleases according to 
manufacturer’s instructions. Reactions were set up with 10 units of 
restriction enzyme for eveiy Ipg of DNA with IX recommended buffer 
and IX BSA (if required) at 37°C for 2 hours, unless stated otherwise. In 
the case of double digests, an equal number of units of each types of 
enzyme were used ensuring that the total volume of the enzyme mixture 
did not exceed 10% of the total reaction volume and an appropriate buffer 
was used to allow optimal function of both enzymes.
2.10.8 Dephosphorylation of Vector DNA
After linearization of a vector, prior to cloning, the 5’ ends are 
dephosphorylated to prevent recircularization by self ligation. Reactions 
were set up with 5 units of Antarctic Phosphatase for eveiy Ipg of DNA 
with IX Antarctic Phosphatase Buffer at 37°C for 15 minutes. The reaction 
was heat inactivated at 65 °C for 5 minutes.
2.10.9 DNA Ligation Reaction
The vector and insert DNA were extracted from a 1% agarose gel and 
purified using the Q.BIOgene Geneclean Turbo Kit. The concentration of
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the vector and insert DNA were calculated by running 10% v/v on a 0.7% 
w/v agarose gel and comparing band intensity against the 1636bp band. 
Ligation reactions were set up such that there was an insert to vector ratio 
of 7:1, with IX recommended ligase buffer and 5U T4 DNA ligase in a 
final volume of lOpl. The reaction was incubated overnight at 12°C.
2.10.10 Polymerase Chain Reaction
For a typical 50 pi reaction, Ipg of DNA template was added to a mixture 
containing O.lpg of 3’ primer and 0.1 pg of 5* primer along with IX 
recommended buffer, BOOpM dNTPs, 1.5mM Mg(OAc)2 and 2units rTth 
polymerase. The PCR reaction was set up for cycles comprising 30 
seconds at 94°C to allow denaturation followed by an appropriate 
annealing temperature for 30 seconds and finally elongation at 70°C for 90 
seconds. The hot start technique was used to reduce nonspecific 
amplification during the initial stages of the PCR. The product of the PCR 
reaction was run on a 1% w/v GTG agarose gel.
2.11 Pro-nuclear Micro injection
Microinjection of the transgenes into mice embryos was performed by Dr 
N Vlatkovic (Head of Transgenic Unit). Briefly, female mice were 
superovulated by intraperitoneal injection of hormones, and then mated 
with stud males overnight. The females that had mated successfully, as 
judged by the presence of a plug, were sacrificed and fertilised embiyos at
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a single cell stage isolated and cultured. The transgene DNA, diluted to 1- 
2ng/ml in microinjection quality TE buffer, was injected into one of the 
two visible pronuclei. The microinjected embryos were incubated 
overnight and those that divided into two cell stage embryos were 
transferred into the oviduct of a pseudopregnant female.
2.12 Isolation of Genomic DNA From Mouse Tails 
Genomic murine DNA was isolated using the phenol-chloroform based 
method. Typically, 6-10mm of a mouse tail was clipped and placed into 
individually labelled 1.8ml screw cap tube corresponding to the unique 
mouse identifying number. Each tail was later cut into 2-3mm pieces and 
incubated with 0.75ml of lysis buffer and 37.5pl proteinase K overnight at 
55°C in order disrupt the cells and remove proteins. The next morning, 
0.75ml of phenol was added to each tube and mixed for 1 hr on a rocking 
platform at room temperature. The solution was further mixed for 5 
minutes by hand then centrifuged at 16,000xg at room temperature for 5 
minutes to help separate the organic and aqueous layers. The upper, DNA 
containing, aqueous layer was transferred into a fresh tube containing 
0.75ml of phenol:chloroform:isoamyl alcohol (PCI) and mixed by hand for 
5 minutes then centrifuged at 16000xg at room temperature for 5 minutes. 
Again, the upper aqueous layer was transferred into a fresh tube and the 
DNA precipitated by adding 75pi of 3M sodium acetate (pH6) and 0.75ml 
of 100% ethanol then centrifuging at 16000xg at room temperature for 10
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minutes. The 100% ethanol was removed and the DNA pellet washed with 
1ml of 70% ethanol and centrifuged at 16000xg at room temperature for 5 
minutes. The 70% ethanol was removed and the DNA pellet allowed to air 
dry for 5-10 minutes. The pellet was dissolved in lOOpl of TE containing 
lOpg/ml of DNAse free RNAse. DNA concentration was calculated by 
measuring absorbance (A) using an Eppendorf Biophotometer at a 
wavelength of 260nm (A260 of 1 ~ 50pg of DNA/ml) and the purity of each 
sample detennined by the ratio 260nm/280nm5 with an ideal value of 1.8.
2.13 Southern Blot Analysis
A particular DNA sequence or gene can be detected in a complex mixture 
of genomic DNA by Southern blotting (Southern 1975). Briefly, DNA 
fragments are electrophoresed on an agarose gel then the DNA is 
denatured, to separate double stranded DNA (dsDNA) into single stranded 
DNA (ssDNA), and transferred onto a membrane. The fragment of interest 
was identified by hybridisation with a radioactive or enzyme linked 
complementary ssDNA (Southern 1975).
2.13.1 Restriction Enzyme Digestion of Genomic Murine DNA 
Typically, 10pg of murine genomic DNA was digested using a restriction 
enzyme chosen for its ability as a single site cutter within the integrated 
transgene. The restriction endonuclease Stu I was used for digestion when 
screening animals for the presence of the PRSS1 transgene (wild or mutant
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from the pB-IG or pBEG vector). The endonuclease EcoN I was initially 
selected when screening animals for the presence of the OptrtTA 
transgene, however, the strategy was later revised and Stu I also preferred 
for this transgene. Digests were set up in a final volume of 30pi containing 
lOpg of genomic DNA, IX recommended restriction enzyme buffer and 
10U of Stu I per pg of DNA or 15U of EcoN I per pg of DNA. The digests 
were incubated at 37°C overnight.
Samples were run on a 0.7% w/v agarose gel and the electrophoresis 
assessed by UV illumination and photography of the gel.
2.13.2 Single Copy Calculation
Controls equivalent to known number of copies of the transgene, typically 
0.1, 1, 10 and 20, that would allow assessment of copy number of the 
transgene in the positive animals as well as sensitivity of the probe used in 
Southern Blotting, were also run on the agarose gel in addition to the 
samples. The transgene integrates into the pronuclear genome completely 
randomly, as a single unit or multiple tandem copies, usually in a head to 
tail fashion as a concatamer. There is a simple formula to calculate the 
equivalent of a single copy of a trasgene:
Mass of transgene DNA N bp transgene DNA 
N pg genomic DNA 3 x 109 bp genomic DNA
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If, for instance, a transgene is 3.6kb and lOjig of mouse genomic DNA is 
used then the mass of the transgene is (3600bp x lOpg DNA)/3 x 109 bp of 
mouse genomic DNA. This gives a mass of ~12pg.
2.13.3 Capillary Transfer of DNA To Membrane 
After completion of electrophoresis, the gel was placed in a glass dish and 
wash using denaturing solution (1.5M NaCl, 0.5M NaOH), for 3 x 15 
minutes each at room temperature with gentle agitation. The gel was 
depurinated in 0.2N HC1 for 5 minutes at room temperature then washed in 
RO H2O. The gel was washed in neutralisation solution (1M Tris-HCl 
pH7.4, 1.5M NaCl) for 3 x 15 minutes at room temperature with gentle 
agitation. Finally the gel and Hybond XL nitrocellulose membrane (pre­
soaked in RO H2O) were rinsed in 10X SSC transfer buffer for 30 minutes.
10X SSC transfer buffer was placed in a glass dish with a glass platform 
positioned at its centre (see Figure 2.3). Two 3MM Whatman paper wicks 
(pre-soaked in 10X SSC) were placed onto the plate, ensuring the ends 
were submerged into the transfer buffer, and the gel placed inverted on top 
so that its underside is now uppermost. The top of the gel was covered with 
nitrocellulose membrane, cut exactly to the size of the gel, followed by 
3MM Whatman paper. Paper towels were stacked, cut slightly smaller than 
the gel, over the 3MM Whatman paper to a height of 8cm and then a glass 
plate was balanced on top and weighed down with a ~500g weight.
Ill
Weight(~500 g)
Glass plate
Nitrocellulose
membrane
Pyrex
glass
dish
10XSSC
A pile of blue tissue paper 
cut to the size of the gel
2sheets of 3MM cut 
to the size of the gel
Gel (up-side down)
“wick" made of 2 sheets of 
Whatmann 3MM paper (cut 
to the width of the gel)
Gel tray 
(up-side down)
Fig 2.3 Transfer of DNA onto a membrane
Schematic diagram demonstrating a set up to allow trasfer of DNA 
from the agarose gel onto a nitrocellulose membrane .
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The entire transfer setup was wrapped in cling-film, allowing transfer to 
occur* overnight (Fig 2.3).
Following transfer, the membrane was air-dried, and then the DNA was 
fixed by cross-linking using UV irradiation at a wavelength of 254nm and 
0.12J cm2. The membrane was then soaked in 1M NaCl for a minimum of 
30 minutes at room temperature with gentle agitation. Following this the 
membrane was placed in a hybridisation bottle with 20 ml of pre­
hybridisation solution (1M NaCl, 10% Dextran Sulphate, 1% SDS) and 
incubated for 3-4 hours or overnight at 65°C with gentle agitation.
2.13.4 Probe Preparation
50ng of the appropriate DNA probe was labelled using the Amersham 
MegaPrime DNA Labelling System and 50p,Ci [a-32P] dCTPs according to 
manufactures instructions. Briefly 50ng of DNA probe was incubated with 
5 pi of random primers and heated to 100°C for 5 minutes then slowly 
cooled to room temperature. 10pi of labelling buffer (containing unlabelled 
nucleotides), 2pl Klenow enzyme and 5pl of [cx-32P] dCTPs were added to 
a final volume of 50pl and incubated at 37°C for 45 minutes. Chilling on 
ice for 5 minutes stopped the reaction.
2.13.5 Probe Purification
The probe was purified by passing through a Sephredex G-50 column. 
Briefly, a glass pipette was plugged with a piece of siliconised glass wool
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at the bottom and packed with Sephradex G-50 equilibrated in RO H2O. 
20|iil of Dextran Blue (Img/ml) and 20pl of Orange G (Img/ml) were 
added to the labelled probe, which was then applied onto the column. 
Column was washed with RO H2O and fractions collected. High molecular 
weight fraction containing the desired labelled probe was eluted with 
Dextran Blue.
2.13.6 Scintallation Count And Hybridisation
2p,l of eluted probe was placed in a scintillation counter with a program for 
32P and a reading taken to calculate the volume of probe required to 
achieve lOcpm/ml of hybridisation solution.
The probe (at a calculated volume) was denatured by boiling for 10 
minutes with Salmon Sperm DNA (lOOqg/ml final concentration in 
prehybridisation solution) and then chilled on ice for 5 minutes before 
mixing with 20mls of prehybridisation solution and hybridised at 65° 
overnight.
The following day the membrane was removed from the hybridisation 
bottle and washed in two changes of 2X SSC for 20 minutes at room 
temperature with gentle agitation. Two stringent washes were perfonned in 
2X SSC, 0.1% SDS at 65°C for 20 minutes each with gentle agitation, 
followed by two washes in 0.1 X SSC for 20 minutes at room temperature 
with gentle agitation. The membrane was finally moimted on 3MM
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Whatman paper, wrapped in cling film and exposed to Kodak Biomax MS 
film which was placed between a Biomax TranScreen-HE intensifying 
screen and incubated at -80°C for 2-48 horns.
2.13.7 Film Development
The film cassette was removed from the -80°C freezer and allowed to 
reach room temperature. The film was removed in a dark room and placed 
in Kodak developer for 2 minutes and then into Kodak fixer for 2 minutes 
before washing in tap water.
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Chapter 3
3 GENERATION OF EXPRESSION PLASMIDS
3.1 Introduction
The aim of this work was to generate genetically modified mice that stably 
express the wild-type human cationic trypsinogen gene, or one of the two 
common mutated alleles, in the acinar cells of the pancreas. To achieve this 
aim, we first set out to establish a set of expression plasmids canying the 
genes of interest that would be utilised in generating the transgenes for 
microinjection.
The work to generate the cDNA of wtPRSSl and then introduce the point 
mutation, R122H or N29I, was performed by my predecessor Catherine 
Merriman. Briefly, the cDNA of PRSS1 was synthesised from human 
pancreatic RNA by reverse transcription. The PRSS1 cDNA was amplified 
by PCR using specific primers S’PRSSl and 3’PRSS1, and the product 
was cloned into the intermediate vector, pCR2.1 and transformed into XL1 
Blue cells. Clones were picked and plasmid DNA purified and sent for 
sequencing. Once the sequence had been successfully confirmed further 
clones were generated using specific primers to infroduce a Haemaglutinin 
(HA) tag, which would allow antibody mediated detection of the protein, to 
the 3’ end of the sequence and Noil or BamHl restriction enzymes sites at 
both 3’ and 5’ ends to enable sub-cloning into the expression vectors
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pCEP, pBI-G and pBEG. The mutations, R122H and N29I, were 
introduced by PCR mutagenesis and the products were ligated into the 
intermediate vector pCR2.1. The wild-type PRSS1 and the two mutants 
were all generated with and without a HA tag. The sequence of each 
construct was confirmed.
3.2 Results
3.2.1 Generation of pCR2.1 PRSS1HAN29I 
The PRSS1HA N29I mutant was cloned into the pCR2.1 intermediate 
vector. The PRSS1HA N29I construct was generated using pBI-G PRSS1 
N29I as a template for PCR and the primers 5’BamHIPRSSl, 3’ 
HABamHIPRSSl (as described in section 2.10.10) in order to create 
BamRl restriction sites necessary for subsequent cloning into the pBEG 
vector (see sections 3.2.3. and 3.2.4.). The sample was then subjected to 
agarose gel electrophoresis, the BOObp band containing PRSS1HA N29I 
excised and the DNA extracted. pCR2.1 and PRSS1HA N29I were then 
ligated to produce pCR2.1 PRSS1HA N29I (see section 2.10.9 and figure 
3.1). The ligation products were transformed into One Shot® ToplO E.Coli 
competent cells (see section 2.10.1). Colonies were picked based on 
blue/white selection bias, white colonies indicating that the lac Z gene is 
disrupted by the successful presence of the insert. The plasmid was then 
commercially sequenced to confirm the fidelity of the insert.
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pUC ori
Ba/nHI
PRSS1 N29I'
AmpR —
FI ori
KanR
Fig 3.1 pCR2.1 PRSS1HA N29I Intermediate Vector
A schematic map of the intermediate vector pCR2.1 with the insert 
PRSS1HA N29I ligated to generate the plasmid pCR2.1 PRSS1HA 
N29I. (*shown is the N29I mutant but the vector may also represent 
pCR2.1 wtPRSSIHA orpCR2.1 PRSS1HA R122H)
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3.2.2 Generation of pCR2.1 PRSS1 N29l
The PRSS1 N29I mutant without the HA tag was cloned into the pCR2.1 
intermediate vector. These imtagged constructs would not feature in the 
initial efforts to generate transgenic animals, but as the potential biological 
or biochemical effect of the HA tag could not be anticipated in our animal, 
these constructs could provide great utility in the future. The PRSS1 N29I 
construct was generated using pBI-G PRSS1 N29I as a template for PCR 
and the primers S’BamHIPRSSl, 3’ BamHIPRSSl (as described in section 
2.10.10). The sample was then subjected to agarose gel electrophoresis and 
the 800bp band containing PRSS1 N29I excised and the DNA extracted. 
pCR2.1 and PRSS1 N29I were then ligated to produce pCR2.1 PRSS1 
N29I (see section 2.10.9 and figure 3.2). The ligation products were 
transformed into One Shot® Top 10 E.Coli competent cells (see section 
2.10.1). Colonies were picked based on blue/white selection bias. The 
plasmid was then commercially sequenced to confirm the fidelity of the 
insert.
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BamH\
pUC ori
PRSS1 N29I
BamH\pCR2-1 PRSS1N29I 
4693bp
AmpR —
FI ori
KanR
Fig 3.2 pCR2.1 PRSS1 N29I Intermediate Vector
A schematic map of the intermediate vector pCR2.1 with the insert 
PRSS1 N29I ligated to generate the plasmid pCR2.1 PRSS1 N29I. 
(♦shown is the N29I mutant but the vector may also represent pCR2.1 
wtPRSSl orpCR2.1 PRSS1 R122H)
120
3.2.3 Generation of pBEG PRSS1 HA mutants 
Plasmids were generated with the genes of interest downstream of the rat 
elastase I promotor, thus allowing expression to occur only in the acinar 
cells of the mouse pancreas.
The PRSS1HA R122H and PRSS1HA N29I sequences were excised from 
the intermediate vectors pCR2.1 PRSS1HA R122H and pCR2.1 
PRSS1HA N29I respectively using the restriction endonuclease BamWi 
(see section 2.10.7). Similarly, pBEG was linearised by digestion with 
BamRl and dephosphorylated with Antarctic phosphatase to minimise self­
ligation (see section 2.10.8). The samples were subjected to agarose gel 
electrophoresis, die bands containing pBEG and PRSS1HA R122H or 
PRSS1HA N29I extracted (as described in section 2.10.6). pBEG was then 
ligated with either PRSS1HA R122H or PRSS1HA N29I to produce pBEG 
PRSS1HA R122H and pBEG PRSS1HA N29I (see section 2.10.9 and 
figure 3.3). A restriction digest using EcoRI, which yielded fragments of 
2,8kb and 3.5kb, confirmed the correct orientation.
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FI ori
LacZ alpha
M13-fwd
Elastase
Col El origin
PRSS1HAR122H*pBEG PRSS1HAR122H 
6389 bp
Ml 3-rev
luman growth hormone
Fig 3.3 pBEG PRSS1HA R122H Vector
A schematic map of the expression vector pBEG with the insert 
PRSS1HA R122H ligated to generate the plasmid pBEG PRSS1HA 
R122H. (*shown is the R122H mutant but the vector may also 
represent pBEG wtPRSSIHA or pBEG PRSS1HA N29I)
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3.2.4 Generation of pBEG PRSS1 mutants
The pBEG PRSS1 R122H and pBEG PRSS1 N29I constructs (without the 
HA tag) were generated and verified (see figure 3.4) in a similar manner to 
the pBEG PRSS1HA constructs (described in section 3.2.3).
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F1 ori
LacZ alpha
M13-fwd
Elastase
ColEI origin
__PRSS1 R122HpBEG PRSS1 R122H 
6389 bp
Ml 3-rev
luman growth hormone
Fig 3.4 pBEG PRSS1 R122H Vector
A schematic map of the expression vector pBEG with the insert PRSS1 
R122H ligated to generate the plasmid pBEG PRSS1 R122H. (’•‘shown 
is the R122H mutant but the vector may also represent pBEG wtPRSSl 
or pBEG PRSS1N29I)
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3.2.5 Generation of pBEG OptrtTA
The plasmid, pOptrtTA, containing the optimised itTA (OptrtTA) 
sequence was a kind gift from Dr M. Valencik, PhD. In order to ensure that 
expression of the OptrtTA inducer would take place specifically in tire 
acinar cells of the mouse pancreas, the gene needs to be driven by a well- 
defined upstream rat elastase I promotor (see section 1.7.4). In a compound 
mouse, OptrtTA would bind to the Tet responsive element (TRE) in the 
presence of doxycycline leading to transcription and expression of our 
gene of interest.
To achieve this, the OptrtTA fragment was liberated from the pOprtTA 
vector by restriction digest with Hindill and AcoRI restriction enzymes, 
blunted (see section 2.10.6) and cloned into the expression vector pBEG 
that has been digested with the restriction enzyme BaniHI and treated with 
Antarctic Phosphatase to minimise self ligation (see section 2.10.8).
The samples were subjected to agarose gel electrophoresis and the bands 
containing pBEG and OptrtTA were extracted and ligated (see figure 3.5). 
A restriction digest using Sad, which yielded fragments of 4.3kb, 1.6kb 
and 0.8kb, confirmed the correct orientation. The plasmid was then 
commercially sequenced to confirm the fidelity of the insert.
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FI ori
LacZ alpha
M13-fwd
Elastase
ColE1 origin
pBEG OptrtTA 
6628 bp OptrtTA
LacO, 
M 13-rev*
Human growth hormone
Fig 3.5 pBEG OptrtTA Vector
A schematic map of the expression vector pBEG with the insert 
OptrtTA ligated to generate the plasmid pBEG OptrtTA.
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3.2.6 Generation of pCEP PRSS1
The plasmids described above could not be used for generic expression 
studies in mammalian cells in culture, since the rat elastase I promotor 
would be activated only in the pancreatic acinar cells. Attempts to 
transiently transfect AR4-2J cells, which are derived from rat acinar cells, 
or 266-6 cells, derived from mouse acinar cells, with any plasmid were 
unsuccessful due to very poor transfection efficiency. Therefore, to test the 
expression of the wtPRSSl and mutants (with and without the HA tag), the 
genes of interest were subcloned into the pCEP vector where they would 
be under the control of a CMV promotor. This allowed transient 
transfection of human cell lines in culture, i.e H1299 or MCF7.
A set of plasmids with the wtPRSSl or the mutant genes (with and without 
the HA tag) in a pCEP backbone had already been generated in our 
laboratory. However, the pCEP PRSS1 vector did not express due to 
omission of the ATG codon and this was therefore recloned.
The wtPRSSl was excised from the intermediate vectors pCR2.1 PRSS1 
using the resfriction endonuclease Notl (see section 2.10.7), and subcloned 
into the pCEP vector that was linearised by digestion with Notl and 
dephosphorylated with Antarctic phosphatase to minimise self ligation (see 
section 2.10.8). The samples were subjected to agarose gel electrophoresis, 
the bands containing pCEP and wtPRSSl extracted (as described in section 
2.10.6). pCEP was then ligated with wtPRSSl to produce pCEP wtPRSSl
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(see figure 3.6). A restriction digest using iscoRI and BamHL, which 
yielded fragments of 5.3kb and 2.3kb and 0.7kb, confirmed the correct 
orientation.
Protein expression of the pCEP-based vectors was demonstrated by 
Western blotting following transient transfection of H1299 cells (as 
described in section 2.7 and 2.8). This also confirmed that the HA tagged 
proteins could be detected by the monoclonal a-HA antibody and that both 
the tagged and untagged proteins could be detected using a monoclonal a- 
PRSS1 antibody (see figure 3.6).
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Pcmv
12 3 4 5 6 7
----- 33
4—« a-PRSS1 1. HI299 ♦ pCEP
—25 2. HI299 ♦ pCEP wtPRSSl
------------— - _ — - ---------- - - 4. HI 299 ♦ pCEP PRSS1 R122H
— - ||L-- 1 33 5. H1299 ♦ pCEP PRSS1HAR122H
a-HA 6 H1299 ♦ pCEP PRSS1 N29I
—   ----- 25 7. HI299 ♦ pCEP PRSS1HAN29I
Fig 3.6 pCEP PRSS1 Vector and Western blot
(A) Schematic map of the expression vector pCEP with the insert wtPRSSl (the 
vector may represent wtPRSSl, or the two mutants, with or without the HA tag) 
ligated to generate the plasmid pCEP wtPRSSl. (B) 50g of total protein in each lane 
on a 12% polyacrylamide gel according to Laemmli (1976). Protein was transferred to 
nitrocellulose membrane via electrotransfer and expression of the whole pCEP-based 
library detected (lanes 2-7) using antibodies against the HA tag or an epitope on 
human PRSS1.
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3.2.7 pBI-G plasmid
The pBI-G based plasmids were already available in our laboratory. They 
had been generated using similar techniques as described above. Briefly, 
wtPRSSl and the two mutants had been generated with a C-terminus HA 
tag and Notl sites at both termini. They were cloned into the intermediate 
vector pCR2.1 and then subcloned into the commercially available pBI-G 
plasmid using the Not! site (see figure 3.7).
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Fig 3.7 pBI-G wtPRSSIHA Vector
A schematic map of the expression vector pBI-G wtPRSSIHA (*the 
map may also represent pBI-G PRSS1HA R122H or pBI-G PRSS1HA 
N29I). The Tet responsive element (TRE) with the bi-directional 
promoters transcribing the lacZ and gene of interest (GOI), 
wtPRSSIHA, (*may represent a map for PRSS1HA R122H or 
PRSS1HAN29I) is shown in detail.
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3.3 Summary
A series of vectors were created in order to generate appropriate transgenes 
for the development of genetically modified mice expressing human wild- 
type PRSS1 or one of the two common mutations. This collection of 
plasmids would allow development of an inducible transgenic model and a 
second model with constitutively expressed proteins, specifically within 
the acinar cells of the pancreas. In addition, plasmids were created to allow 
transient transfection of human cell lines, based on the pCEP backbone, 
utilising a CMV promotor to drive expression of the genes of interest. 
Protein expression of all these constructs was demonstrated by Western 
blotting after transfection of the plasmids into HI299 cells.
The completed set of plasmids is shown in figure 3.8 with those shown in 
black text already available in our laboratory whilst those in blue were 
created as part of this project.
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pCR2.1 wtPRSSl wtPRSSIHA
PRSS1 R122H PRSS1HA R122H
PRSS1 N29I PRSS1HA N29I
pCEP wtPRSSl wtPRSSIHA
PRSS1 R122H PRSS1HA R122H
PRSS1 N29I PRSS1HA N29I
pBEG wtPRSSl wtPRSSIHA
PRSS1 R122H PRSS1HA R122H
PRSS1 N291 PRSS1HA N29I
OptrtTA
pBI-G wtPRSSIHA
PRSS1HA R122H
PRSS1HA N29I
Fig 3.8 Table of plasmids
A table showing all the plasmids created to allow the generation of 
genetically modified mice expressing our genes of interest within the 
acinar cells of the mouse pancreas. (Plasmids in black text were created
by Catherine Merriman)
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Chapter 4
4 GENERATION OF MICE WITH INDUCIBLE TRANSGENES
4.1 Introduction
Having created a set of plasmid constructs, the aim was to generate 
genetically modified mice with ‘inducible’ protein expression, based on the 
Tet-On system, allowing spatial and temporal control of the transgene 
expression. The first construct, based on the pBI-G bidirectional vector, 
would carry the gene of interest i.e. wt PRSS1 or one of the two mutants 
and the second construct, which expresses the regulator protein OptrtTA, 
would be driven by an upstream rat elastase 1 promoter. Cross breeding 
these two strains of mice would generate a compound mouse strain that 
could, upon feeding with doxycycline, be induced to transcribe the gene of 
interest in the acinar cells of the pancreas (see figure 4.1),
4.2 Results
4.2.1 Preparation of transgenes
The transgenes for pBI-G wtPRSSIHA, pBTG PRSS1HA R122H and 
pBI-G PRSS1HA N29I were liberated in a similar fashion, by digesting the 
constructs with the restriction enzyme Asel. The samples were subjected to 
agarose gel electrophoresis and the 7.3kb band containing the transgene 
was extracted (as described in section 2.10.6) (see figure 4.2).
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Optimiwd rtTA
Strain 1 A
Fig 4.1 Compound transgenic mice
Schematic diagram showing the two panels of mice. Strain 1 carries 
the regulatory protein, OptrtTA, and strain 2 carries the gene of 
interest and a reporter driven by a bidirectional promoter. Cross 
breeding the two strains creates the compound mouse, which will 
express the gene of interest on feeding with doxycycline. (*The gene of 
interest shown is wtPRSSIHA but may also be PRSS1HA R122H or 
PRSS1HA N29I).
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The pBEG OptitTA construct was digested using the restriction enzymes 
Hindlil and Not! liberating a 3.6kb band containing the ti’ansgene (see 
figure 4.3). The transgenes were used for pronuclear microinjection of 
fertilised mouse eggs (see section 2.11).
4.2.2 Preparation of Probes for Southern Blotting 
In order to identify successful integration of the transgene into the murine 
genome, the litter from microinjected animals was screened using a 
Southern blot technique (see section 2.13). This required a radionucleotide 
labelled probe to allow specific hybridisation with a corresponding 
sequence of the integrated transgene.
The screening of animals microinjected with the transgenes pB-IG 
PRSS1HA wt, pB-IG PRSS1HA R122H or pB-IG PRSS1HA N29I was 
performed using the same probe. The probe was prepared by digesting the 
native pB-IG plasmid using the restriction endonucleases Xbal and EcoRN 
and Notl (see figure 4.2). The samples were subjected to agarose gel 
electrophoresis and the 1203bp band containing the probe was extracted 
and prepared as described in section 2.13.
The screening of the pBEG OprtTA transgene was perfonned using a 
probe prepared by PCR. Using the pBEG OptrtTA construct as a template, 
OptitTA_5’ screen and OptrtTA_3’ screen primers were utilised to 
generate the probe (see section 2.10.10 and figure 4.3). The samples were
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subjected to agarose gel electrophoresis and the 900bp band containing the 
probe was extracted and prepared as described in section 2.13.
4.2.3 Establishing Founder Animals
After microinjection of the mouse embiyos, the newborn pups were 
screened by Southern blot analysis to identify founder animals. The mice 
that were found to be positive carriers of the transgene were backcrossed 
with wild type, non-transgenic mice. This allowed each lineage to be 
expanded, and also, enabled the segregation of the transgene if it had 
integrated into multiple sites of the murine genome. Wild type murine 
DNA was always digested and loaded with the samples to exclude false 
positive identification. Transgene DNA was loaded at known 
concentrations to help estimate the number of copies integrated (see 
section 2.13.2).
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PRSS1-HA* Lac Z
2.6 kb
0.8 kb
TRANSGENE -7.3 kb
[Southern probe
Eco RV
4.7 kb
Fig 4.2 pBI-G wtPRSSIHA transgene
Schematic diagram representing the pBI-G wtPRSSIHA transgene 
(*may also represent PRSS1HA R122H or PRSS1HA N29I). Shown 
are the Asel digestion sites used to liberate the transgene. The Stul site 
is cut when digesting genomic DNA and the Southern probe is 
liberated by digestion with Xbal and EcoRV.
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TRANSGENE -3.6 kb
3.2 kb
Eco Nl
2.9 kb700 bp ->■
0.5 kb 2.1 kb
hGH-polyAOpt rtTA
Southern probe
- 900 bp
Fig 4.3 pBEG OptrtTA transgene
Schematic diagram representing the pBEG OptrtTA transgene. Shown 
are the HindlW and Not\ digestion sites used to liberate the transgene. 
The Stn\ site is cut when digesting genomic DNA and the Southern 
probe is generated by PCR. Also shown is the position of the 
restriction site £coNl, which was initially used for genomic digestion. 
(El, elastase I promotor. hGH, human growth hormone).
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4.2.4 Screening for pBI-G wtPRSSI HA
11 animals were generated from the first round of microinjections but 
Southern screening did not identify a founder animal.
21 animals were generated from the second round of microinjections and 
genomic DNA extracted from ~lcm tailclips of each animal. The DNA 
was digested using the Stul restriction endonuclease and then samples were 
subjected to agarose gel electrophoresis and transferred to a nitrocellulose 
membrane (see section 2.13). The membrane was hybridised with a 
specific radionucleotide labelled probe to identify potential founder 
animals as described in section 4.2.2. A positive founder animal, number 
20 (female), was identified (see figure 4.4). The Southern blot suggested 
that the fransgene had integrated at multiple sites, given that there are more 
than two bands of a different size to the transgene. The intensity of the 
fransgene band was similar to the 1 copy control and certainly less than the 
lOx copy control.
The founder animal was backcrossed onto wild type mice with the aim of 
generating a litter of mice carrying the fransgene. The first generation litter 
of 19 animals was screened by the Southern blot technique and yielded 
three positive animals, 7.1, 8.3, and 9.2, showing a blot pattern similar to 
that of the foimder animal (see figure 4.5).
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Each of these animals were backcrossed onto wild type mice to sufficiently 
expand the transgenic strain and then mated with other positive animals to 
eventually generate both homozygous transgenic mice.
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pBIG wtPRSSIHA Transgene copy control
I---------------- L—------------ \
Fig 4.4 Southern Blot of pBI-G wtPRSSIHA animals
lOpg genomic DNA (animals 9-21) digested using Stul then run on a 
0.7% w/v agarose gel and transferred to nitrocellulose membrane. 
Presence of transgene detected by SOpCi [cx-32P] radiolabelled probe 
demonstrated a positive animal 20. Transgene copy controls allow 
approximation of the number of transgenes integrated into murine 
genome. (M, marker; wt, wild type).
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pBIG wtPRSSIHA backcross Transgene
copy controlr—-- i——t
Fig 4.5 Southern Blot of pBI-G wtPRSSIHA backcross animals
lOpg genomic DNA (animals 5.1-10.1) digested using Stul then run on 
a 0.7% w/v agarose gel and transferred to nitrocellulose membrane. 
Presence of transgene detected by 50pCi [a-32P] radiolabelled probe 
demonstrated positive animals 7.1, 8.3 & 9.2. Transgene copy controls 
allow approximation of the number of transgenes integrated into 
murine genome. (M, marker; wt, wild type).
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4.2.5 Screening for pBI-G PRSS1HA R122H 
18 animals were generated from the first round of microinjections and 
screened by my predecessor, Catherine Merriman. This litter identified two 
possible founders - animal 6 (female) and animal 14 (female)
These potential founder animals were backcrossed with wild type mice 
producing a total litter of 54 animals. These animals were extensively 
screened by me, but failed to show positive animals. The litter was re­
clipped and screened but again no positive animals were identified. The 
original DNA from founder animal 6 was screened and failed to show the 
presence of the transgene.
5 animals were generated from a second round of microinjections and 
genomic DNA extracted from ~lcm tailclips of each animal. The DNA 
was digested using the StuI restriction endonuclease and the samples were 
subjected to agarose gel electrophoresis then transferred to nitrocellulose 
membrane (see section 2.13). The membrane was hybridised with a 
specific radionucleotide labelled probe to identify potential founder 
animals as described in section 4.2.2. Two possible founder animals - 
animal 21 (male) and animal 22 (female) were identified (see fig 4.6). The 
Southern blot suggested that the transgene had integrated at multiple sites 
in animal 22 and the band intensity for both positive animals was less than 
the lOx copy control.
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The founder animals were backcrossed onto wild type mice producing a 
total litter of 33 animals. These animals were analysed by Southern blot 
screening and resulted in identification of a further four positive animals, 
16.1,18.1,18.4, and 23.2 (see figure 4.7A&B).
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Fig 4.6 Southern Blot of pBI-G PRSS1HA R122H animals
lOpg genomic DNA (animals 19-23) digested using Stul then run on a 
0.7% w/v agarose gel and transferred to nitrocellulose membrane. 
Presence of transgene detected by 50pCi [cx-32P] radiolabelled probe 
demonstrated positive animals 21 & 22. Transgene copy controls allow 
approximation of the number of transgenes integrated into murine 
genome. (M, marker; wt, wild type).
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pBIG PRSS1HA R122H backcross
M wt
.1 .2 .3 .1 .2 .3 .1 .2 .3 .4 .1 .2 .3 .4; .2 .3
Transgene 
copy control
I—“4------------- \
0.1.1* 10.
Fig 4.7A Southern Blot of pBI-G PRSS1HA R122H backcross animals
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pBIG PRSS1HA R122H backcross
Transgene
Fig 4.7B Southern Blot of pBI-G PRSS1HA R122H backcross animals
lOpg genomic DNA (animals 14.1-23.3) digested using Stid then run on 
a 0.7% w/v agarose gel and transferred to nitrocellulose membrane. 
Presence of transgene detected by 50pCi [a- "P] radiolabelled probe 
demonstrated positive animals 16.1, 18.1, 18.4 (A) and 23.2 (B). 
Transgene copy controls allow approximation of the number of 
transgenes integrated into murine genome. (M, marker; wt, wild type).
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4.2.6 Screening for pBI-G PRSS1 HA N29I
9 animals were generated from the first round of microinjections and 
genomic DNA extracted from ~lcm tailclips of each animal. The DNA 
was digested using the Stul restriction endonuclease and analysed by 
Southern blotting as described in section 4.2.5. Two possible founders 
animals -animal 2 and animal 9 were identified (see figure 4.8). The 
potential founder animals were backcrossed onto wild type mice. 
Subsequent screening of offspring from founder animal 2 failed to show 
positive animals and the founders were re-clipped and analysed. 
Unfortunately, animal 2 did not demonstrate the presence of the transgene.
Founder animal 9 was back-crossed and generated a litter of 14 animals. 
Screening of these animal by Southern blot identified three positive second 
generation animals; animal 9 (male), animal 11 (female), animal 12 
(female) (see figure 4.9). The positive animals had a similar pattern on the 
Southern blot as the parent animal, however, due to degradation during 
storage of the transgene used as the copy control, the band intensity could 
not be reliably assessed.
Each of these animals was backcrossed onto wild type mice to sufficiently 
expand the transgenic strain and then mated with other positive animals to 
eventually generate homozygous transgenic mice.
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pBIG PRSS1HA N29I
Fig 4.8 Southern Blot of pBI-G PRSS1HA N29I animals
lOpg genomic DNA (animals 1-9) digested using Stul then run on a 
0.7% w/v agarose gel and transferred to nitrocellulose membrane. 
Presence of transgene detected by 50pCi [a-32P] radiolabelled probe 
demonstrated positive animals 2 & 9. Transgene copy controls allow 
approximation of the number of transgenes integrated into murine 
genome. (M, marker; wt, wild type).
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Fig 4.9 Southern Blot of pBI-G PRSS1HA N29I backcross animals
10pg genomic DNA (animals 1-14) digested using Stul then run on a 
0.7% w/v agarose gel and transferred to nitrocellulose membrane. 
Presence of transgene detected by SOpCi [a-32P] radiolabelled probe 
demonstrated positive animals 9, 11 & 12. Transgene copy controls 
allow approximation of the number of transgenes integrated into 
murine genome. (M, marker; wt, wild type).
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4.2.7 Screening for pBEG OprtTA
68 animals were generated over two rounds of microinjections and 
genomic DNA extracted from ~lcm tailclips of each animal. The DNA 
was digested using the AcoNI restriction endonuclease analysed by 
Southern blotting. Screening of these animals did not identify any positive 
founder animals.
Generation of the pBEG OptrtTA animal was imperative for the inducible 
model, as without this animal we would be unable to generate the required 
compound animal that would be able to transcribe our genes of interest in 
an inducible manner. Given the success of generating the pBI-G PRSS1HA 
cohort of animals, and the failure of repeated attempts of identifying a 
positive pBEG OptrtTA animal from a reasonable large potential group, 
the pBEG OptrtTA plasmid was cloned again from scratch and 
commercially sequenced (see section 3.2.5). This revealed that there were 
two EcoNl restriction sites present in the transgene as opposed to the one 
site that the screening stmtegy had been based upon (see figure 4.3). The 
strategy was therefore altered with the restriction endonuclease EcoNl 
being replaced by Still.
12 animals were generated from the third round of microinjections. 
Screening of this litter demonstrated a positive female founder animal 
number 193.1 (see figure 4.10). The band intensity suggested the transgene
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had integrated more than once and less than ten times into the murine 
genome.
The founder animal was backcrossed with a wild type animal in order 
assess integration of the transgene into the germ line and to expand the 
lineage of the transgene.
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pBEG OptrtTA Transgene copy control
1 i
M wt 192 193.1 194 195 196 197 O.lx lx 10* 20x
.1 .2 .3 .1 .2 .3 .1 .2 .1 .1 .2
*>■
4
Fig 4.10 Southern Blot of pBEG OptrtTA animals
lOpg genomic DNA (animals 192.1-197.2) digested using Stul then 
run on a 0.7% w/v agarose gel and transferred to nitrocellulose 
membrane. Presence of transgene detected by 50pCi [a-~l2P] 
radiolabelled probe demonstrated a positive animal 193.1. Transgene 
copy controls allow approximation of the number of transgenes 
integrated into murine genome. (M, marker; wt, wild type).
154
4.3 Summary
The aim of the experiments described above was to generate genetically 
modified mice with ‘inducible’ protein expression, based on the Tet-On 
system. The first construct, based on the pBI-G bidirectional vector, would 
cany the gene of interest i.e. wt PRSS1 or one of the two mutants and the 
second construct, which expresses the inducer protein OptrtTA, would be 
driven by an upstream rat elastase 1 promoter. Cross breeding of these two 
strains of mice would provide a compound mouse strain that could, upon 
feeding with doxycycline, be induced to transcribe the gene of interest in 
the acinar cells of the pancreas.
Analysis of the offspring microinjected with the pBI-G wtPRSSIHA 
transgene identified a positive animal number 20. This animal was then 
backcrossed and gave rise to three positive offspring (animals 7.1, 8.3, & 
9.2). Two founder animals were successfully identified carrying the pBI-G 
PRSS1HA R122H transgene (animals 21 & 22) and the pBI-G PRSS1HA 
N29I transgene (animals 2 & 9). These stmins were also backcrossed with 
wild type non-transgenic animals to generate positive offspring (animals 
16.1, 18.1, 18.4, 23.2 and animals 9, 11, 12 respectively).
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Founder animals Second generation
pBI-G wtPRSSIHA 20 7.1, 8.3, 9.2
pBI-G PRSS1HA R122H 21,22 16.1, 18.1, 18.4, 
23.2
pBI-G PRSS1HA N29I 2,9 9, 11, 12
pBEG OptrtTA 193.1
Fig 4.11 Table of positive founder animals
A table showing the positively identified founder and second 
generation of transgenic animals for the strains pBI-G wtPRSSIHA, 
pBI-G PRSS1HA R122H, pBI-G PRSS1HA N29I and pBEG OptrtTA.
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The animals positively identified canying the transgenes are summarised 
in figure 4.11.
Generation and identification of mice with integration of the essential 
pBEG OptrtTA transgene into their genome was far less successful. 
Despite the creation of a large cohort of potentially positive animals, 
screening failed to identify integration of the transgene into the murine 
genome. This failure was of great concern, as the pBEG OptrtTA transgene 
would be crucial in driving expression of the PRSS1 transgenes in the final 
compound mouse. Due to these difficulties, it was decided that the plasmid 
should be cloned again and then re-sequenced prior to microinjection. The 
sequencing revealed that there were two EboNI site located within the 
transgene and digesting the murine genome with this restriction 
endonuclease would result in a fragment that would not run at the expected 
position, and may in fact be too small to detect, on a Southern blot. New 
animals were created by microinjection of the new pBEG OprtTA 
transgene and the restriction endonuclease Stul was used to digest the 
murine genome. This led to the identification of a positive founder animal 
number 193.1.
All positively identified animals were extensively backcrossed to generate 
a large pool of transgenic animals for each of the individual strains. 
Eventually, compound mice would be generated carrying the pBEG 
OptrtTA transgene and one of the PRSS1 based transgenes. These animals
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would then be analysed to determine whether they develop a phenotype, 
either spontaneously or after a pharmacological challenge, characteristic of 
pancreatitis.
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Chapter 5
5 GENERATION OF MICE WITH CONSTITUTIVELY 
EXPRESSED TRANSGENES
5.1 Introduction
As a consequence of the difficulties encountered in establishing a 
genetically modified mouse carrying the pBEG OptrTA transgene, a 
different strategy of generating genetically modified mice stably 
expressing human cationic trypsinogen was developed. As opposed to the 
inducible model, which required a compound mouse with the PRSS1 and 
OptrtTA transgenes integrated into the murine genome, a ‘non-inducible’ 
model was designed. In this model the human cationic trypsinogen gene or 
one of the two mutants (R122H or N29I) would be directly driven by the 
rat elastase I promoter. This model would therefore allow constitutive 
expression of the transgene, specifically in the acinar cells of the mouse 
pancreas.
5.2 Results
5.2.1 Preparation of transgenes
The transgenes for pBEG wtPRSSIHA, pBEG PRSS1HA R122H and 
pBEG PRSS1HA N29I were liberated in a similar fashion, by digesting the 
appropriate constructs with the restriction endonucleases Hindlll and Notl. 
The samples were subjected to agarose gel electrophoresis and the 3.4kb
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band containing the transgene was extracted (as described in section 
2.10.6) (see figm'e 5.1).
5.2.2 Preparation of Probe for Southern Blotting
In order to identify successful integration of the transgene into the murine 
genome, the litter from microinjected animals was screened using a 
Southern blot technique (see section 2.13). This required a radionucleotide 
labelled probe to allow specific hybridisation with a corresponding 
sequence on the integrated transgene.
The screening of animals microinjected with the transgenes pBEG 
wtPRSSIHA, pBEG PRSS1HA R122H or pBEG PRSS1HA N29I was 
performed using the same probe. The probe was prepared by digesting the 
pBEG wtPRSSIHA plasmid with BamHl and the sample was run on a 
0.7% w/v GTG agarose gel. The 800bp band, representing the probe, was 
extracted and prepared as described in section 2.13.
Alternatively, the probe could be generated by PGR, using the 5’ PRSS1 
and 3’ PRSS1 primers and pBEG wtPRSSIHA plasmid as the template 
DNA (see figure 5.1).
5.2.3 Establishing Founder Animals
After microinjection of the mouse embryos, the newborn pups were 
screened by Southern blot analysis to identify founder animals. The mice 
that were found to be positive carriers of the transgene were then
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backcrossed with wild type, non-transgenic mice. This allowed each 
lineage to be expanded, and also, enabled the segregation of the transgene 
if it had integrated into multiple sites of the murine genome. Wild type 
murine DNA was always digested and loaded with the samples to exclude 
false positive identification. Transgene DNA was loaded at known 
concentrations to help estimate the number of copies integrated (see 
section 2.13).
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TRANSGENE -3.4 kb
2.5 kb 933 bp ->
0.5 kb 0.8 kb
hGH-polyA
' ‘Southern probe
- 800 bp
BamHIBamHI
Fig 5.1 pBEG wtPRSSIHA transgene
Schematic diagram representing the pBEG OptrtTA transgene (*may 
also represent PRSS1HA R122H or PRSS1HA N29I). Shown are the 
HindiW and Noil digestion sites used to liberate the transgene. The Stul 
site is cut when digesting genomic DNA and the Southern probe is 
liberated by digestion with BamHI or PCR. (El, elastase I promotor. 
hGH, human growth hormone).
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5.2.4 Screening for pBEG wtPRSSI HA
14 animals were generated from the first roimd of microinjections and 
genomic DNA extracted from ~lcm tailclips of each animal. The DNA 
was digested using the Stui restriction endonuclease and then samples were 
subjected to agarose gel electrophoresis and transferred to nitrocellulose 
membrane (see section 2.12). The membrane was hybridised with a 
specific radionucleotide labelled probe to identify potential founder 
animals as described in section 5.2.2. A positive founder animal, number 
13 (female), was identified (see figure 5.2). The Southern blot suggested 
that the transgene had integrated at least at one site, whilst the intensity of 
the transgene band was greater than 1 copy control and less than the lOx 
copy control.
The founder animal was backcrossed onto wild type mice with the aim of 
generating a litter of mice carrying the transgene. Each of these positive 
animals was backcrossed onto wild type mice to sufficiently expand the 
transgenic strain and then mated with other positive (heterozygous) 
animals to eventually generate homozygous transgenic mice.
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pBEG wtPRSSIHA Transgene 
copy control
Fig 5.2 Southern Blot of pBEG wtPRSSIHA animals
10pg genomic DNA (animals 1-14) digested using Stul then run on a 
0.7% w/v agarose gel and transferred to nitrocellulose membrane. 
Presence of transgene detected by 50(iiCi [cx-32P] radiolabelled probe 
demonstrated a positive animal 13. Transgene copy controls allow 
approximation of the number of transgenes integrated into murine 
genome. (M, marker; wt, wild type).
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5.2.5 Screening for pBEG PRSS1 HA R122H 
8 animals were generated from the first round of microinjections but 
screening this litter failed to identify any positive animals
26 animals (numbers 38.1-46.3) were generated from a second round of 
microinjections and genomic DNA extracted and screened as described in 
section 5.2.4. A possible founder animal 39.1 (female) was identified (see 
fig 5.3A). The Southern blot suggested that the transgene had integrated at 
least at one site and the band intensity was similar to the lOx copy control.
The founder animal was backcrossed onto wild type mice with the aim of 
generating a litter of mice canying the transgene. Each of these positive 
animals was backcrossed onto wild type mice to sufficiently expand the 
fransgenic strain and then mated with other positive (heterozygous) 
animals to eventually generate homozygous transgenic mice.
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pBEG PRSS1HA R122H Transgene
copy control
Mwt 1 2 3 4 5 O.lx lx 2Ox lOx
2 3 12 12 3
Fig 5.3 A Southern Blot of pBEG PRSS1HA R122H animals
166
pBEG PRSS1HA R122H Transgene
copy control
--------- •--------
M wt 42. O.lx lx lOx 2Ox
Fig 5.3B Southern Blot of pBEG PRSS1HA R122H animals
lOpg genomic DNA (animals 1-5; 38.1-41.4 (A) & (B) animals 42.1 - 
46.3) digested using Stul then run on a 0.7% w/v agarose gel and 
transferred to nitrocellulose membrane. Presence of transgene detected 
by 50pCi [a- ~P] radiolabelled probe demonstrated a positive animal 
39.1 (A). Transgene copy controls allow approximation of the number 
of transgenes integrated into murine genome. (M, marker; wt, wild 
type).
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5.2.6 Screening for pBEG PRSS1 HA N29I
19 animals were generated from the first round of microinjections and 
genomic DNA extracted and screened as described in section 5.2.4.
Three possible fomider animals 10, 14, 19 were identified (see fig 5.4). The 
Southern blot suggested that the transgenes had integrated at least at one 
site. The band intensity of founder animal 19 was similar to the lx copy 
control, the band intensity of founder animal 14 was greater than the lx but 
less than the lOx copy control, whilst the band intensity of founder animal 
10 was greater than lOx and similar to the 20x copy control.
Again, the founder animals were backcrossed onto wild type mice with the 
aim of generating a litter of mice carrying the transgene. Each of these 
positive animals was backcrossed onto wild type mice to sufficiently 
expand the transgenic strain and then mated with other positive 
(heterozygous) animals to eventually generate homozygous transgenic 
mice.
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pBEG PRSS1HA N29I Transgene copy control
Fig 5.4 Southern Blot of pBEG PRSS1HA N29I animals
lOpg genomic DNA (animals 1-19) digested using Stul then run on a 
0.7% w/v agarose gel and transferred to nitrocellulose membrane. 
Presence of transgene detected by 50pCi [a-32P] radiolabelled probe 
demonstrated positive animals 10, 14 & 19. Transgene copy controls 
allow approximation of the number of transgenes integrated into 
murine genome. (M, marker; wt, wild type).
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5.3 Summary
As a consequence of the difficulties encountered in establishing a 
genetically modified mouse carrying the pBEG OptrTA transgene, a 
critical component of the inducible model, a different strategy of 
generating genetically modified mice stably expressing human cationic 
trypsinogen was developed. The aim was to generate genetically modified 
mice in which the rat elastase driven genes of interest were integrated into 
the murine genome. This model would allow constitutive expression of the 
PRSS1 based transgenes within the acinar cells of the mouse pancreas.
Analysis of the offspring from the first round of microinjections with the 
pBEG wtPRSSIHA transgene identified a founder, animal 13, from a litter 
of fourteen animals. Two round of microinjection were completed, 
generating a total litter of 34 animals, prior to the identification of a 
positive founder, animal 39.1, for the pBEG PRSS1HA R122H transgene. 
Microinjection of the pBEG PRSS1HA N29I transgene proved to be most 
successful as the first round generated a litter of 19 mice of which three 
were potential founder animal; animals 10, 14, & 19. These animals are 
summarised in figure 5.5.
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Founder animals
pBEG wtPRSSIHA 13
pBEG PRSS1HA R122H 39.1
pBEG PRSS1HAN29I 10, 14, 19
Fig 5.5 Table of positive founder animals
A table showing the positively identified founder and second 
generation of transgenic animals for the strains pBEG wtPRSSIHA, 
pBEG PRSS1HA R122H, pBEG PRSS1HA N29I.
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The positive animals from each cohort were paired with wild type non- 
transgenic mice to expand the pool of genetically modified animals. The 
positive animals would all be dated at birth and eventually analysed at 
different time points to detennine whether they develop features of 
pancreatitis.
The analysis of the animals for each of the transgenic strain began once 
adequate numbers had been generated in each cohort. The characterisation 
of the phenotype developed in each transgenic strain and the consequences 
of challenging these animals with widely recognised techniques to induce 
acute pancreatitis, were performed after completion of the laboratory work 
undertaken for this MD project, and is therefore outside the scope of this 
thesis.
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Chapter 6
6 ASSAY TO ASSESS TRYPSIN ACTIVITY
6.1 Introduction
Having created expression plasmids with the aim of expressing human 
cationic trypsinogen, or one of the two common mutant alleles, it was 
imperative to ensure that the proteins were expressed and that they retained 
their enzymatic activity. As described in chapter 3, the PRSS1 gene had 
been cloned into a pCEP plasmid with expression driven by a CMV 
promoter. This would allow transient transfection of cultured cell lines to 
determine whether protein expression was detectable. If protein expression 
was confirmed, then cell lysates could be subjected to an in vitro assay to 
assess trypsin activity. The assay would be based on the ability of trypsin 
to cleave a fluorogenic substrate (Rhodamine-110), resulting in peak 
excitation and emission wavelengths of 498nm and 521nm respectively, 
and the fluorescence measured by a spectrophotometer.
6.2 Results
6.2.1 Detection of human cationic trypsinogen 
The genes designed to be expressed in the transgenic mice were all labelled 
with a HA tag in an effort to allow identification as we were unsure 
whether a specific antibody directed against cationic trypsinogen would be 
sufficiently sensitive or specific at detection of the transgenic protein in a
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backdrop of native murine trypsinogens. However, cDNA were developed 
with and without a HA tag and cloned into the pCEP vector to assess 
expression.
Prior to this, we tested a polyclonal and four monoclonal antibodies raised 
against human cationic trypsinogen. As positive controls, serial dilutions of 
recombinant human trypsin, ranging from lOOOng to 3ng, were run on a 
SDS-PAGE gel and transferred to a nitrocellulose membrane then probed 
with each of the antibodies (as described in section 2.8). The polyclonal 
antibody and two of the monoclonal antibodies failed to detect any protein 
at the tested concentrations. The monoclonal antibody anti-PRSSl 13404 
was shown to be the most sensitive, detecting a visible band corresponding 
to as little as 15ng of recombinant human trypsin (see figure 6.1).
HI299 cells were transiently transfected (as described in section 2.7) with 
the pCEP-based plasmids to establish expression of the proteins of interest. 
WB analysis (as described in section 2.8) using the anti-HA antibody and 
the anti-PRSSl (13404) antibody would allow comparison of the relative 
sensitivity of the individual antibodies, whilst simultaneously confirming 
expression in vitro.
As shown in figure 6.2, expression of the proteins is demonstrated using 
both the anti-PRSSl and also the anti-HA antibody. Mock transfection 
using the empty pCEP vector acted as a negative control (seen in the first
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lane figure 6.2). The untagged proteins run lower than their tagged 
counterparts as seen using anti-PRSSl, consistent with the slight difference 
in molecular weight. The anti-HA antibody appears to be slightly more 
sensitive relative to anti-PRSSl. Loading of each lane is similar as shown 
by the actin bands, whilst the (3-gal levels reveal variable transfection 
efficiency.
This data suggests that HI299 can be transiently transfected with the 
pCEP-based plasmids and that the proteins of interest are expressed at 
detectable levels. Detection of as little as 15ng of protein appears to be 
possible using the anti-PRSSl antibody whilst tire anti-HA antibody is 
slightly more sensitive.
6.2.2 Optimisation of the trypsin assay
An assay to assess the enzymatic activity of the tagged forms of human 
cation trypsinogen was developed once detectable expression had been 
shown, in transiently transfected cells in culture, by western blot analysis.
Prior to applying the assay to transfected cell lysates, the principles were 
assessed using a commercially available high-grade recombinant human 
trypsin. 20ng/ml of recombinant trypsin was spiked into 0.1M Tris-HCl 
(pH 8.0), with 5pM BZiPAR (a Rhodamine-110 based substrate allowing 
fluorescence after cleavage by trypsin) with or without the addition of 
ImM CaCf and 2ng/ml of enterokinase (1ml final volume). The assay was
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Fig 6.1 Detection of recombinant human cationic trypsinogen
Serial dilutions of recombinant human trypsin ranging from lOOOng to 
3ng were run on 12% SDS polyacrylamide gel and transferred to 
nitrocellulose membrane and probed with anti-PRSSl (13404) 
antibody. Detection of as little as 15ng of protein was achieved.
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33----
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25----
a- p-gal 
a- Actin
a- PRSS1
a- HA
Fig 6.2 Western blots of human cationic trypsinogen
Transiently transfected HI299 cells with indicated pCEP-based 
plasmids (as shown per lane) were subjected to western bloting 
according to Laemelli (1976), and probed with the relavent antibodies.
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performed (as described in section 2.9) over a time course of 60 minutes, at 
room temperature, with measurements taken every 10 minutes.
Enterokinase by itself was used as a negative control and generated the 
weakest activity with regards to cleavage of the Rhodamine-110 substrate 
(see figure 6.3). Recombinant trypsin activity was augmented by the 
addition or either ImM calcium chloride or 2ng/ml enterokinase. The 
activity of recombinant trypsin was highest with the addition of 2ng/ml 
enterokinase and ImM calcium chloride (see figure 6.3), suggesting that 
there may be some trypsinogen present within the mixture that required 
enterokinase mediated activation. The assay demonstrated that 20ng of 
recombinant trypsin could cleave the fluorogenic substrate at a level 
detectable by the spectrophotometer over the course of an hour.
H1299 cells were transiently transfected with pCEP wtPRSSIHA and 
either mock transfected with the empty pCEP vector or left untransfected 
in order to provide negative controls (see section 2.7). Cells were 
harvested, lysed using SLIP buffer without protease inhibitors, and the 
total protein concentration calculated the Bradford method (see section 
2.7). 50|Lig/ml of protein was loaded onto 12% SDS polyacrlamide gels for 
western blotting (see section 2.8) and probed with anti-HA antibody. 
150pg/ml total protein was spiked into 0.1M Tris-HCl (pH 8.0) for the 
trypsin assay (see section 2.9). 2ng/ml enterokinase, ImM CaCE and 5pM
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Assay to assess activity of recombinant trypsin in 0.1 M Tris pH 8.0
Tima (min)
Enterokinase
-a— Trypsin
—Trypsin + Calcium
a Trypsin + 
Enterokinase 
—Tryp + Enterokinase 
■i-Calcium
Fig 6.3 Assay to assess activity of recombinant human trypsin
20ng/ml of recombinant human trypsin was spiked into 0.1M Tris-HCl 
(pH 8.0) with or without the addition of 2ng/ml enterokinase and ImM 
CaCb. 5pM (final concentration) of the Rhodamine-110 based 
substrate BZiPAR was added to each reaction and the reaction kinetics 
followed over the course of 60 minutes. Enterokinase (2ng/ml) was 
used as a control. The activity of recombinant trypsin was evident, 
especially in the presence of 2ng/ml enterokinase and ImM CaCb. 
(Fluorescence measured in arbitary units).
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BZiPAR were added to give a final volume of 1ml. The reaction kinetics 
were followed over a period of 60 minutes.
The experiment showed little to no difference in fluorescence between the 
negative controls and the pCEP wtPRSSIHA lysates (see figure 6.4). 
Western blotting confirmed detectable levels of wtPRSSIHA. The 
experiment was repeated but with similar results.
This raised the possibility that the tagged wtPRSSIHA protein was either 
not enzymatically functional or that there was inhibition of its activity in 
HI299 cells. The HI299 cells may have a native trypsin inhibitor or 
modify the protein to ameliorate its activity. To test this hypothesis, 
20ng/ml recombinant trypsin was spiked into untransfected HI299 cell 
lysate and AR4-2J (derived from rat pancreas tumour cells) cell lysate. A 
positive control was set up by spiking recombinant trypsin into SLIP buffer 
to ensure this did not alter the enzymatic activity. As before, 2ng/ml 
enterokinase, ImM CaCf and 5pM BZiPAR were added to a final volume 
of 1ml in 0.1 M Tris-HCl (pH 8.0) and the reaction kinetics were assessed 
for 60 minutes (see section 2.9).
Recombinant trypsin in SLIP buffer showed a dramatic ability to cleave the 
substrate BZiPAR, whilst its activity in H1299 cells was almost completely 
ameliorated (see figure 6.5). The activity of recombinant trypsin spiked
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Assay to assess activity of wtPRSSIHA in 0.1 M Tris pH8
H1299
pCEP
PRSS1HA
Time (min)
Fig 6.4 Assay to assess activity of wtPRSSIHA in cellular lysate
Transiently transfected HI299 cells were lysed in SLIP buffer without 
the addition of protease inhibitors. 150pg/ml of total protein was added 
to 0.1 M Tris-HCl (pH 8.0) with 2ng/ml enterokinase and ImM CaCh. 
5pM (final concentration) of the Rhodamine-110 based substrate 
BZiPAR was added to each reaction and the reaction kinetics followed 
over the course of 60 minutes at 37°C. 50pg/ml of total protein was run 
on a 12% SDS polyacrylamide gel, transferred to nitrocellulose 
membrane and probed with anti-HA antibody (insert). No difference in 
activity was seen. (Fluorescence measured in arbitary units).
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Assay to assess activity of recombinant trypsin in cell lysates
—•-H1299 
—AR42JPACO 
-♦-SUP
Fig 6.5 Assay to assess activity of recombinant trypsin in cell lysates
20ng/ml of recombinant human trypsin was spiked into either 
untransfected HI299 or AR4-2J cell lysates with 2ng/ml enterokinase 
and ImM CaCh in 0.1 M Tris-HCl (pH 8.0). 5pM (final concentration) 
of the Rhodamine-110 based substrate BZiPAR was added to each 
reaction and the reaction kinetics followed over the course of 60 
minutes at 37°C. Recombinant trypsin in SLIP buffer was a positive 
control (red line). The activity of recombinant trypsin was evident in 
SLIP buffer but inhibited by both cell lysates. (Fluorescence measured 
in arbitary units).
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into the AR4-2J cell lysate, though severely inhibited, appeared to be less 
affected than in the H1299 cell lysate.
Having identified an inhibitory effect in cell lysates, which could render 
the trypsin assay obsolete, an extensive search was undertaken to find a 
cell line that did not exhibit this property or was least effective. We utilised 
cell lines in regular* use in our laboratory derived from colon cancer, 
pancreatic cancer or renal cancers. Cell lines A498, ACHN, HEK 293T, 
111, 115, 117 and 121 were derived from renal cell carcinomas, SW 480, 
SW 620, HCT+, HT29 and LOVO were derived from colorectal 
adenocarcinomas and MiaPaCa cell line from pancreatic cancer.
Again, 20ng/ml of recombinant trypsin was spiked into each different cell 
lysate with the other conditions as described above and in section 2.9. The 
activity of the recombinant trypsin was reduced in all cell lysates in 
relation to the activity achieved in SLIP buffer (see figure 6.6), The least 
inhibitory effect appeared to occur in tire cell line ACHN and A498 both 
derived from renal cell cancer. In these cell lines the fluorescence at 60 
minutes was just under 50% of the maximum achieved in SLIP buffer, 
suggesting that they may be the best candidates for further assay 
experiments.
However, at this time Sahin-Toth et al published a paper describing a cell 
line, human embryonic kidney 293T (HEK 293T), amenable to transient
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transfection with cationic trypsinogen, which then secreted the protein into 
the culture medium (Sahin-Toth, Kukor et al. 2006). This provided an 
opportunity to develop the trypsin assay to assess enzymatic activity of the 
proteins harvested from the culture medium (see section 2.9). In this way 
we would hope to elimmate the inhibitory effects that were encountered 
whilst using cell lysates.
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Assay to assess activity of recombinant trypsin in different cell lysates
Time (min)
—♦—(Trypsin 
—Sw620 
Sw480
—MiaPaCa 
—H1299 
-•-115 
—HCT+
------- Suit2
------- 117
HT29 
« 111 
—♦—121 
—>*—Lovo 
—ACHN 
—A498
Fig 6.6 Activity of recombinant trypsin in various cell lysates
20ng/ml of recombinant human trypsin was spiked into different cell 
lysates as shown with 2ng/ml enterokinase and ImM CaCh in 0.1 M 
Tris-HCl (pH 8.0). 5pM (final concentration) of the Rhodamine-110 
based substrate BZiPAR was added to each reaction and the reaction 
kinetics followed over the course of 60 minutes at 37°C. Recombinant 
trypsin in SLIP buffer was a positive control (sky blue line; rTypsin). 
The activity of recombinant trypsin was evident in SLIP buffer but 
inhibited to varying degrees in the different cell lysates. Colorectal cell 
lines: SW 480, SW620, HCT+, HT29, LOVO. Renel cell lines: A498, 
ACHN, 111, 115,117, 121. Pancreas cell line MiaPaCa. (Fluorescence 
measured in arbitary units).
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The HEK 293T cells were transiently transfected with pCEP wtPRSSIHA, 
or one of the mutant alleles, and the culture medium changed for a reduced 
serum medium Opti-MEM. Secretion of the proteins into the Opti-MEM 
medium would be subjected to assay. Prior to this it was necessaiy to 
determine whether the assay could be performed with recombinant human 
trypsin in Opti-MEM (see section 2.9.2).
20ng/ml recombinant trypsin with 2ng/ml enterokinase, ImM CaCh and 
5pM BZiPAR were made to a final volume of 1ml in Opti-MEM (see 
section 2.9). The reaction kinetics were followed at 37°C for 60 minutes 
(see section 2.9.2). Negative controls were Opti-MEM without additives 
and Opti-MEM with 2ng/ml enterokinase and ImM CaCk. Minimal 
activity, suggestive of substrate cleavage, was seen with either control (see 
figure 6.7) but was clearly seen with recombinant trypsin. This confirmed 
the suitability of Opti-MEM for use in the assay.
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Assay to assess activity of recombinant trypsin in Opti-MEM
Time (min)
—Opti-MEM 
♦ Enterokinase 
—rtrypsin
Fig 6.7 Assay to assess activity of recombinant trypsin in Opti-MEM
20ng/ml of recombinant human trypsin was spiked into Opti-MEM, a 
reduced serum culture medium, with 2ng/ml enterokinase ImM CaCE, 
and 5pM BZiPAR (final concentrations) and the reaction kinetics 
followed over the course of 60 minutes at 37°C. Opti-MEM without 
additives (grey line) and Opti-MEM with 2ng/ml enterokinase and 
ImM CaCE (blue line) were negative controls. The activity of 
recombinant trypsin in Opti-MEM (red line) was evident whilst almost 
no activity was seen in either control. (Fluorescence measured in 
arbitary units).
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6.2.3 Results of trypsin assay
HEK 293T cells were transiently transfected with pCEP wtPRSSIHA, 
mock transfected with empty pCEP vector or left untransfected. 12 hours 
after transfection the culture medium was replaced by Opti-MEM. A 
further 12 hours later the Opti-MEM was harvested and 20pi loaded onto a 
12% SDS polyacrylamide gel for western blotting with anti-HA antibody. 
The remainder was used for the trypsin assay supplemented with 2ng/ml 
enterokinase, ImM CaCl2 and 5pM BZiPAR at pH 8. The reaction kinetics 
were followed over 60 minutes at 37°C (see section 2.9.2).
The supernatant harvested from cells transfected with pCEP wtPRSSIHA 
demonstrated a higher level of fluorescence achieved by cleaving the 
BZiPAR substrate in relation to the negative controls (see figure 6.8). This 
indicated that the enzymatic activity did not arise natively from the Opti- 
MEM medium or from transfection with the empty pCEP vector, but was 
likely related to the function of the secreted wtPRSSIHA protein. The 
western blot demonstrated a band con*espending to wtPRSSIHA detected 
in the harvested Opti-MEM medium only.
These results demonstrated that the wtPRSSIHA protein had enzymatic 
activity and was capable of cleaving the substrate BZiPAR (see figure 6.8). 
To ensure that this was also the case with PRSS1HA R122H and 
PRSS1HA N29I, transfection of HEK 293T cells was set up with the
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Assay to assess activity of wtPRSSI HA in Opti-MEM
= 15
Time (min)
—*-293T 
—*-pCEP 
—PRSS1HA
Fig 6.8 Assay to assess activity of wtPRSSI HA in Opti-MEM
Transiently transfected HEK 293T cells supplemented with Opti-MEM 
medium for 12 hours. The medium was harvested and 20pl loaded onto 
a 12% SDS polyacrylamide gel and subject to immunoblotting with 
anti-HA antibody (insert). The remainder of the Opti-MEM medium 
was supplemented with 2ng/ml enterokinase, ImM CaCb, and 5pM 
BZiPAR (final concentrations) and the reaction kinetics followed over 
60 minutes at 37°C. Opti-MEM harvested from untransfected cells 
(grey line) and mock transfected cells (blue line) were negative 
controls. The enzymatic activity of wtPRSSI HA (red line) was higher 
than in the controls. (Fluorescence measured in arbitary units).
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wtPRSSIHA and the two mutant alleles. Untransfected HEK 293T cells
and cells mock transfected with empty pCEP vector would serve as 
negative controls. All experiments were run in triplicates.
The assay confirmed that supernatant harvested from cells transfected with 
pCEP wtPRSSIHA had a significantly higher level of fluorescence by 
cleaving the substrate BZiPAR compared to the negative controls (see 
figure 6.9). However, the highest level of fluorescence was seen in 
supernatant harvested from cells transfected with pCEP PRSS1HA R122H 
whilst the fluorescence of supernatant from pCEP PRSS1HA N29I cells 
was lower in relation to the wild-type protein. The western blot revealed 
similar levels of all three proteins with no obvious asymmetry seen in the 
loading controls. The standard error of the mean was calculated for each 
triplicate with no large discrepancy or overlap (besides the two negative 
controls) seen. This result was seen repeated over multiple replications of 
the experiment.
The difference in fluorescence detected at 60 minutes between 
wtPRSSIHA and the mutants PRSS1HA R122H and PRSS1HA N29I 
indicated differing activity between the three enzymes in cleaving the 
substrate BZiPAR. This finding had not been described previously in the 
literature and raised the possibility that the effect may be due to the HA 
tag. We, therefore, repeated the assay using the untagged constructed to 
transiently fransfect HEK 293T cells. pCEP wt PRSS1, pCEP PRSS1
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Fig 6.9 Assay to assess activity of wtPRSSIHA versus mutant alleles
Transiently transfected HEK 293T cells supplemented with Opti-MEM 
medium for 12 hours. The medium was harvested and 20pl loaded onto 
a 12% SDS polyacrylamide gel and subjected to immunoblotting with 
anti-HA antibody (insert; loading controls seen above). Harvested 
Opti-MEM medium was supplemented with 2ng/ml enterokinase, 
ImM CaCb, and 5pM BZiPAR (final concentrations) and the reaction 
kinetics followed over 60 minutes at 37°C. Opti-MEM harvested from 
pCEP wtPRSSIHA (red line), pCEP PRSS1HA R122H (blue line) and 
pCEP PRSS1HA N29I show greater activity than the negative controls 
(pale lines; Untx, pCEP). Error bars show standard error of the mean
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R122H and pCEP PRSS1 N29I were transiently transfected into HEK 
293T cells and after 12 hours the culture medium was replaced by 
OptiMEM. A further 12 hours later the Opti-MEM was harvested and 20 pi 
loaded onto a 12% SDS polyacrylamide gel for western blotting with anti- 
PRSS1 (13404) antibody. The remainder was used for the trypsin assay 
supplemented with 2ng/ml enterokinase, ImM CaCb and 5pM BZiPAR at 
pH 8 unless otherwise stated. The reaction kinetics were followed over 60 
minutes at 37°C (as described above and in section 2.9.2).
The results from the untagged proteins demonstrated that given similar 
concentrations of protein, as shown by western blotting, there was no 
significant difference between the wtPRSSl and the mutant PRSS1 R122H 
proteins in cleaving BZiPAR, as measured by the level of fluorescence. 
However the initial experiments showed that there was a lower level of 
fluorescence seen with relation to the mutant PRSS1 N29I protein (see 
figures 6.10 & 6.11). Interestingly, the peak fluorescence seen at 60 
minutes with the untagged proteins was significantly higher than seen with 
the tagged proteins. The value was generally more than twice as great for 
the untagged proteins in similar conditions.
The experiments were repeated using the untagged proteins with variation 
in conditions to assess the impact of pH and calcium concentration (see 
figures 6.12-6.15). The supernatant was supplemented with either ImM
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Assay to assess activity of wtPRSSI vs mutants in HEK 293T supernatant 
at 37deg C, ImM CaCI2, 2ng enterokinase, pH 8
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Fig 6.10 Assay to assess activity of wtPRSSI versus mutant alleles
Transiently transfected HEK 293T cells supplemented with Opti-MEM 
medium for 12 hours. The medium was harvested and 20j.il loaded onto 
a 12% SDS polyacrylamide gel and subjected to immunoblotting with 
anti-PRSSl antibody (insert; loading controls seen above). Harvested 
Opti-MEM medium was supplemented with 2ng/ml enterokinase, 
ImM CaCb, and 5j.iM BZiPAR (final concentrations) and the reaction 
kinetics followed over 60 minutes at 37°C. Opti-MEM harvested from 
pCEP wtPRSSI (red line), pCEP PRSS1 R122H (blue line) and pCEP 
PRSS1 N29I show greater activity than the negative controls (pale 
lines; Untx, pCEP). Error bars show standard error of the mean (n=3).
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at 37deg C, ImM CaCI2, 2ng enterokinase, pH 8
1800 
1600 
1400 
| 1200 
jj 1000 
J 800
u.
600
400
200
0
0 10 20 30 40 50 60
Time (min)
Unix 
—pCEP 
—PRSS1 
—R122H 
—N29I
Fig 6.11 Assay to assess activity of wtPRSSl versus mutant alleles
Transiently transfected HEK 293T cells supplemented with Opti-MEM 
medium for 12 hours. The medium was harvested and 20pi loaded onto 
a 12% SDS polyacrylamide gel and subjected to immunoblotting with 
anti-PRSSl antibody (insert; loading controls seen above). Harvested 
Opti-MEM medium was supplemented with 2ng/ml enterokinase, 
ImM CaCb, and SpM BZiPAR (final concentrations) and the reaction 
kinetics followed over 60 minutes at 37°C. Opti-MEM harvested from 
pCEP wtPRSSl (red line), pCEP PRSS1 R122H (blue line) and pCEP 
PRSS1 N29I show greater activity than the negative controls (pale 
lines; Untx, pCEP). Error bars show standard error of the mean (n=3).
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CaCl2 or 5mM EDTA and the pH of the OptiMEM was adjusted to either 
pH 8 or pH 5. The other conditions were maintained as described above.
No real difference was seen in terms of fluorescence between supernatant 
supplemented with ImM CaCh or 5mM EDTA, however, the level of 
fluorescence detected in samples with pH 5 was significantly reduced 
compared to similar experiments conducted at pH 8 (see figures 6.12-6.15). 
This suggested that under acidic condition (pH 5) the ability of the 
enzymes to cleave the substmte BZiPAR was significantly reduced. The 
PRSS1 N29I mutant had a lower level of fluorescence compared to 
wtPRSSl and PRSS1 R122H, and this was particularly demonstrated in 
experiments conducted at pH 5 (see figures 6.14 & 6.15). Both wtPRSSl 
and PRSS1 R122H had similar levels of fluorescence detected in the 
experiments, whether conducted at pH 5 or pH 8 and with ImM CaCf or 
5mM EDTA (see figures 6.12-6.15).
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Assay to assess activity of wtPRSSI vs mutants in HEK 293T supernatant 
at 37deg C, 1mM CaCI2, 2ng enterokinase, pH 8
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Fig 6.12 Assay to assess activity of wtPRSSI at pH 8, ImM CaCh
Transiently transfected HEK 293T cells supplemented with Opti-MEM 
medium for 12 hours. The medium was harvested and 20pl loaded onto 
a 12% SDS polyacrylamide gel and subjected to immunoblotting with 
anti-PRSSl antibody (insert; loading controls seen above). Harvested 
Opti-MEM medium was supplemented with 2ng/ml enterokinase, 
ImM CaCb, and SpM BZiPAR (final concentrations) and the reaction 
kinetics followed over 60 minutes at 37°C. Opti-MEM harvested from 
pCEP wtPRSSI (red line), pCEP PRSS1 R122H (blue line) and pCEP 
PRSS1 N29I show greater activity than the negative controls (pale 
lines; Untx, pCEP). Error bars show standard error of the mean (n=3).
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Assay to assess activity of wtPRSSI vs mutants in HEK 293T supernatant 
at 37deg C, 5mM EDTA, 2ng enterokinase, pH 8
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Fig 6.13 Assay to assess activity of wtPRSSI at pH 8, 5mM EDTA
Transiently transfected HEK 293T cells supplemented with Opti-MEM 
medium for 12 hours. The medium was harvested and 20pl loaded onto 
a 12% SDS polyacrylamide gel and subjected to immunoblotting with 
anti-PRSSl antibody (insert; loading controls seen above). Harvested 
Opti-MEM medium was supplemented with 2ng/ml enterokinase, 
5mM EDTA, and SpM BZiPAR (final concentrations) and the reaction 
kinetics followed over 60 minutes at 37°C. Opti-MEM harvested from 
pCEP wtPRSSI (red line), pCEP PRSS1 R122H (blue line) and pCEP 
PRSS1 N29I show greater activity than the negative controls (pale 
lines; Untx, pCEP). Error bars show standard error of the mean (n=3).
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Fig 6.14 Assay to assess activity of wtPRSSI at pH 5, ImM CaCh
Transiently transfected HEK 293T cells supplemented with Opti-MEM 
medium for 12 hours. The medium was harvested and 20pl loaded onto 
a 12% SDS polyacrylamide gel and subjected to immunoblotting with 
anti-PRSSl antibody (insert; loading controls seen above). Harvested 
Opti-MEM medium was supplemented with 2ng/ml enterokinase, 
ImM CaCh, and 5pM BZiPAR (final concentrations) and the reaction 
kinetics followed over 60 minutes at 37°C. Opti-MEM harvested from 
pCEP wtPRSSI (red line), pCEP PRSS1 R122H (blue line) and pCEP 
PRSS1 N29I show greater activity than the negative controls (pale 
lines; Untx, pCEP). Error bars show standard error of the mean (n=3).
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Fig 6.15 Assay to assess activity of wtPRSSI at pH 5, 5mM EDTA
Transiently transfected HEK 293T cells supplemented with Opti-MEM 
medium for 12 hours. The medium was harvested and 20f.il loaded onto 
a 12% SDS polyacrylamide gel and subjected to immunoblotting with 
anti-PRSSl antibody (insert; loading controls seen above). Harvested 
Opti-MEM medium was supplemented with 2ng/ml enterokinase, 
5mM EDTA, and 5pM BZiPAR (final concentrations) and the reaction 
kinetics followed over 60 minutes at 37°C. Opti-MEM harvested from 
pCEP wtPRSSI (red line), pCEP PRSS1 R122H (blue line) and pCEP 
PRSS1 N29I show greater activity than the negative controls (pale 
lines; Untx, pCEP). Error bars show standard error of the mean (n=3).
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6.3 Summary
Having generated plasmids designed to express either the wt human 
cationic trypsinogen or the R122H or N29I mutant forms it was necessary 
to assess in vitro expression and examine the that enzymatic function of 
each construct, with and without the HA tag. Due to the potential difficulty 
of identifying the transgenic protein from native murine trypsinogens a HA 
tag had been introduced on the C-teuninus.
The pCEP-based expression vectors were used to transiently transfect 
HI299 cells and expression was assessed by western blot analysis. The 
anti-HA antibody and an anti-PRSSl (13404) antibody were found to be 
the most sensitive at detecting, and therefore demonstrating, the in vitro 
expression of the proteins. The bands representing the HA tagged proteins 
were foimd to run higher than those for the untagged proteins, consistent 
with the higher molecular weight.
Attempts to assay the enzymatic activity of the proteins were initially
unsuccessful. Transfected H1299 cells were lysed and loaded into 0.1M
Tris-HCl with enterokinase and calcium chloride to activate the
trypsinogen proteins. The fluorogenic substrate BZiPAR was used to
assess the enzymatic activity of the trypsin. Despite numerous attempts, no
activity was seen when compared to the negative controls. It was
speculated that an inhibitor within the cell lysate might be affecting the
assay and experiments using recombinant human trypsin found evidence of
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this in HI299 cells as well as a variety of other cell lines in regular use in 
our laboratory.
At this stage personal communication with Miklos Sahin-Toth about a 
forthcoming publication revealed that his team had transiently transfected 
human embryonic kidney 293T cell with human cationic tiypsinogen and 
found the protein secreted into the culture medium (Sahin-Toth, Kukor et 
al. 2006). By removing the culture medium it was possible to harvest the 
proteins.
We used this technique to transiently transfect HEK 293T cells with our 
pCEP-based constructs and harvested the supernatant for the assay. The 
assay demonstrated cleavage of the BZiPAR substrate by the wtPRSSIHA 
protein, but interestingly, when comparing the activity of this protein to the 
two mutant alleles, we found that PRSS1HA R122H appeared to be more 
efficient at cleaving BZiPAR whilst PRSS1HA N29I had a reduced 
efficiency. There was no indication on the western blots to suggest that 
there was a significant difference in the relative quantities of each protein. 
No previous reports assessing the properties of cationic tiypsinogen and 
the two mutant alleles had found any difference in their activity (Sahin- 
Toth 2001; Szilagyi, Kenesi et al. 2001), leading us to speculate whether 
the HA-tag, placed on the protein tail to aid identification, was having an 
influence on the enzymatic activity of one or more of the proteins.
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Using the pCEP-based construct not canying the HA-tag, we repeated the 
experiments. The assay showed that wtPRSSl and PRSS1 R122H had 
similar levels of fluorescence indicating a similar ability to cleave the 
BZiPAR substrate whilst PRSS1 N29I appeared to be not as efficient. 
Interestingly, all the untagged proteins achieved a higher level of 
fluorescence at 60 minutes then seen with the HA-tagged proteins. This 
suggested that the HA-tag may influence the enzymatic activity of each of 
the proteins, though they retained a reduced ability to cleave the BZiPAR 
substrate.
A significant difference in the level of fluorescence was seen with respect 
to each protein when the experiments were conducted at pH 5 or pH 8. The 
acidic conditions reduced the level of fluorescence of the wtPRSSl and the 
PRSS1 R122H proteins almost 20-fold at 60 minutes, whilst fluorescence 
of the PRSS1 N29I protem was reduced almost 100-fold.
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Chapter 7
7 SUMMARY AND DISCUSSION
7.1 Introduction
Hereditary pancreatitis is an autosomal dominant disease, characterised by 
recurrent episodes of acute pancreatitis usually beginning during 
adolescents and progressing to chronic pancreatitis. It was first described in 
1952 by Comfort and Steinberg (Comfort and Steinberg 1952) but it was 
not until 1996 that the disease-causing gene was mapped to chromosome 
7q35, implicating mutations of the cationic trypsinogen gene (Whitcomb, 
Gony et al. 1996). The disease is clinically characterised by episodes of 
acute pancreatitis begin in adolescence, and often progressing to chronic 
pancreatitis, with patients having a significantly increased risk of 
developing pancreatic adenocarcinoma (Howes, Lerch et al. 2004; 
Rebours, Boutron-Ruault et al. 2008).
The two most common mutations of cationic trypsinogen, R122H and 
N29I, have been well characterised in patients with hereditaiy pancreatitis. 
However, the pathophysiology of these mutations and the general 
pathways leading to pancreatitis and adenocarcinoma remain poorly 
understood. In this respect hereditary pancreatitis is imique as it allows 
interrogation of all three common pathologies of the exocrine pancreas.
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The ultimate aim of this work was to generate a genetically modified 
mouse model that stably expressed either wild type or mutant human 
cationic trypsinogen, in the acinar cells of the pancreas. The transgene 
would be integrated into the murine genome in a random fashion and have 
constitutive expression based on an upstream rat elastase promoter or 
require doxycycline induction as part of a Tet-On compound inducible 
mouse system. These models would enable us to assess whether the 
presence of human cationic trypsinogen, in its wild type or mutated form, 
in the mouse pancreas results in a pathological phenotype, and if so, 
whether it is consistent with the clinical spectrum seen in patients with 
hereditaiy pancreatitis.
7.2 Generation of mice with inducible transgene expression 
The primary aim was to generate genetically modified mice with inducible 
expression of the transgenes, based on the Tet-On system, specifically 
within the acinar cells of the pancreas. This transgenic model allows 
precise spatial and temporal control over the expression of the genes of 
interest. In order to achieve this aim two constructs were generated; the 
first inducible construct, based on the pBI-G bidirectional vector, carries 
the gene of interest i.e. wt PRSS1 or one of the two mutants and the second 
construct, which expresses the inducer/regulator protein OptrtTA, driven 
by an upstream rat elastase 1 promoter to ensure tissue specificity. Cross 
breeding these two strains of mice would produce a compound mouse that
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would express OptrtTA specifically within the acinar cell by virtue of the 
rat elastase promoter. Upon feeding the compound mouse with 
doxycycline, a conformational change would take place, resulting in 
binding of the OptrtTA to the Tet-responsive element (TRE) and ignition 
of transcription of the gene of interest in the acinar cells of the pancreas.
Founder animals were identified for all the PRS SI-based transgenes. These 
animals were back-crossed to generate larger numbers of stable 
heterozygous animals and ultimately homozygous animals for each 
transgene.
Generation of mice with integration of the pBEG OptrtTA transgene into 
the genome was far less successful. Despite the creation of a relatively 
large number of potentially positive animals, screening failed to identify 
integration of the transgene into the murine genome. This failure was of 
great concern, as the pBEG OptrtTA transgene would be ciucial in driving 
expression of the PRS SI transgenes in the final compound mouse. Without 
this transgenic strain it would be impossible to induce the expression of the 
PRSS1-based transgenes. Due to these difficulties, the plasmid was 
redesigned and cloned again prior to microinjection. The sequencing 
revealed that there were two EcoNl site located within the transgene and 
digesting the murine genome with this restriction endonuclease resulted in 
a fragment that would not run at the expected position, and may in fact be 
too small to detect, on a Southern blot. New animals were created by
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microinjection of the new pBEG OprtTA transgene and the restriction 
endonuclease Stul was used to digest the murine genome. This strategy led 
to the identification of a positive founder animal. During the course of this 
work, a group described a similar transgenic animal that they had 
generated expressing the rtTA protein under the control of a rat elastase 
promoter (Baumann, Wagner et al. 2007). If our own pBEG OptrtTA 
transgenic mouse did not express the rtTA protein or was unsuitable for the 
intended experimental work, we would endeavour to import this transgenic 
animal.
7.3 Generation of mice with constitutive transgene expression 
As a consequence of the difficulties encountered in establishing a mouse 
carrying the pBEG OptrTA transgene, a critical component of the 
inducible model, a different strategy of generating genetically modified 
mice stably expressing human cationic trypsinogen was developed. The 
genetically modified mice in which the rat elastase promoter driven genes 
of interest were integrated into the murine genome would allow 
constitutive expression of the PRSS1 based transgenes within the acinar 
cells of the mouse pancreas. Though this model would not allow temporal 
control, it retained the crucial spatial specificity of limiting hansgene 
expression to the acinar cells of the mouse pancreas. This model had 
potential limitations, as it would possibly allow expression of human 
cationic trypsinogen during foetal development, a consequence of which
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may be pathological changes in the pancreatic parenchyma seen from birth 
in the transgenic animals or potentially a fatal phenotype as seen in the 
spinkS null mice (Ohmuraya, Hirota et al. 2005). Although these findings 
would be of immense interest, further interrogation of the adult mouse 
pancreas would become limited. Due to these concerns the inducible 
model became our* primary strategy whilst the constitutive expression 
model was initially envisaged as a back up project.
Development and identification of founder animals for both the inducible 
and constitutive transgene expression models were completed during my 
tenure in the laboratory. Work to generate homozygous animals for each 
strain and then analyse the resultant phenotype, which developed both 
spontaneously and upon treatment with caerulein, took place after this 
period of time and is outside the scope of this thesis.
7.4 Trypsin Assay
Whilst generating a transgenic mouse model to analyse the role of human 
cationic trypsinogen in vivo, experiments were also undertaken to assess 
the enzymatic activity of wild type and mutant trypsin in vitro. Several 
pCEP-based expression constructs were generated to examine the 
expression and enzymatic activity of untagged and HA-tagged human 
cationic trypsinogen and the mutant alleles in vitro. This was a critical 
question, as transcription of the transgenic DNA and the confirmed
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presence of a protein product within the acinar cells of the murine pancreas 
could be no guarantor of an enzymatically functional protein. If eventual 
analysis of the transgenic mice revealed no difference in phenotype, 
compared to non-transgenic mice, then the question would be even more 
pertinent.
The pCEP-based expression constructs were initially used to transiently 
transfect HI299 cells and expression was analysed by western blot analysis 
using anti-HA antibody and an anti-PRSSl (13404) antibody. Even though 
expression of the PRSS1 proteins was detected, cellular lysate of these 
transfected cells did not seem to possess any enzymatic activity as I failed 
to detect any fluorescence indicating cleavage of the substrate BZiPAR 
using an in vitro trypsin activity assay. This failure to detect trypsin activity 
raised questions as to whether there was insufficient trypsin in the lysates 
to enable a detectable response in the assay, whether post-translational 
misfolding of the proteins abolished the enzymatic pocket, or if other 
proteins present in the cell lysate may have inhibited the enzymatic ability 
of cationic trypsin.
Whilst addressing these questions, a paper describing a cell line, human 
embryonic kidney 293T (HEK 293T), amenable to transient transfection 
with cationic trypsinogen, secreted the protein into the culture medium 
(Sahin-Toth, Kukor et al. 2006). We decided to adopt this method to
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investigate the enzymatic activity of cationic trypsin and the two mutant 
alleles.
The pCEP-based plasmids were again used to transiently transfected 
human embryonic kidney 293T cell, which appeared to secrete the protein 
into the tissue culture medium. The culture medium/supematant was 
harvested for the assay. The modified assay demonstrated cleavage of the 
BZiPAR substrate by the wtPRSSIHA protein, thus confirming for the 
first time, both the expression and enzymatic activity of the construct. 
However, when comparing the activity of the wt protein to the two mutant 
alleles, we found that PRSS1HA R122H appeared to be more efficient at 
cleaving BZiPAR whilst PRSS1HA N29I had a reduced efficiency. The 
bands corresponding to the proteins on the western blots were of similar 
intensity suggesting that there was no significant difference in the relative 
quantities of each protein. No previous reports assessing the properties of 
cationic trypsinogen and the two mutant alleles had found any difference in 
their activity (Sahin-Toth 2001). However, an early paper investigating the 
properties of the N29I mutation had found that wt human cationic 
trypsinogen was activated 2-fold faster than the N29I mutant by bovine 
enterokinase (Sahin-Toth 2000). The implications of this finding were not 
discussed in the paper and it was not raised again in the future studies 
reported by the group.
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These findings led us to speculate whether the HA-tag, placed on the C- 
teiminus of the three trypsinogen proteins to aid identification, was having 
an influence on the enzymatic activity of one or more of the proteins. To 
resolve this issue we sort to repeat the experiments using the pCEP based 
constructs without the HA-tag, which were therefore faithful replications 
of cationic trypsinogen and its two common mutations as found in humans.
The assay showed that wtPRSSl and PRSS1 R122H had similar levels of 
fluorescence indicating a similar ability to cleave the BZiPAR substrate 
whilst PRSS1 N29I appeared to be not as efficient. A significant difference 
in the level of fluorescence was seen with respect to each protein when the 
experiments were conducted at pH 5 or pH 8. The acidic conditions 
reduced the level of fluorescence of the wtPRSSl and the PRSS1 R122H 
proteins almost 20-fold at 60 minutes, whilst fluorescence of the PRSS1 
N29I protein was reduced almost 100-fold. This is consistent with findings 
that an acidic pH stabilises pancreatic zymogens (Colomb and Figarella 
1979)
The results from the assay analysing the untagged proteins were similar to 
those reported in the literature (Sahin-Toth and Toth 2000; Sahin-Toth 
2001) though the reduced activity of the N29I mutant is not adequately 
explained. An early report investigating the influence of the N29I mutation 
on human cationic trypsinogen had found that it resulted in a 2-fold 
reduction in activation by bovine enterokinase (Sahin-Toth 2000).
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However the catalytic activity was found to be similar to the wt human 
cationic trypsin and the focus of the paper turned to the increased 
autoactivation of the N29I mutant protein in acidic conditions. This has 
become accepted as the mechanism underlying the pathophysiology of 
acute pancreatitis seen in patients carrying the N29I mutation.
Our findings of a decrease in the ability of PRSS1 N29I to cleave the 
substrate BZiPAR in comparison to wtPRSSl and PRSS1 R122H raises 
the prospect that the N29I mutation may reduce enzymatic activity. 
Alternatively, the effect may be due in part to a decreased activation of 
PRSS1 N29I by human enterokinase resulting in a time lag reflected by 
reduced levels of fluorescence. However, as a mechanism for causing 
hereditary pancreatitis the role of this finding is not clear and further work 
is required to delineate whether the reduced activity is real or an artefact.
Interestingly, all the untagged proteins achieved a higher level of 
fluorescence at 60 minutes then seen with the HA-tagged proteins. This 
suggested that the HA-tag may influence the enzymatic activity of each of 
the proteins, and though the ability to cleave the substrate BZiPAR was 
reduced in those proteins with the HA tag it was not completely abolished.
This finding may have an influence on the eventual phenotype of the 
transgenic mice developed during this project, as reduced activity of the
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enzymes may manifest as a mild insult to the acinar cells of the murine 
pancreas that may or may not be amenable to clinical characterisation.
7.5 Discussion & Future work
Despite numerous set backs and difficulties, we were finally able to 
generate and positively identify founder animals for both the inducible 
mouse model and the constitutive expression model of hereditary 
pancreatitis. The transgenes were successfully integrated into the murine 
genome and further generations of positive animals were generated.
The in vitro trypsin assay demonstrated that the PRS SI-based transgenes,
with the HA tag, were expressed in cultured human cell lines and were also
functionally active enzymes capable of cleaving the substrate BZiPAR.
Interestingly, there was an unexpected difference in the apparent enzymatic
activity of the wild type PRSS1HA compared to the two mutant alleles.
We consistently observed that the mutant PRSS1HA R122H was more
active than the wild type protein whilst the mutant PRSS1HA N29I
appeared to be less active. The difference in activity observed may be due
to subtle differences in the relative concentrations of the individual proteins
present in the assayed supernatant, though this should have become
apparent from successive replications of the assay. Another possibility is
the addition of the HA tag, intended to aid protein identification from
amongst the native murine trypsinogens in the mouse pancreas, results in
minor alterations of the tertiary structure of the zymogens based on the
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interactions of the HA tag in combination with the wild-type or mutated 
amino acids. These modifications may lead to the variation in enzymatic 
activity as seen in the experiments involving the cleavage of the substrate 
BZiPAR.
When the experiments were repeated with human cationic trypsinogen or 
the mutant proteins without the HA-tag, wtPRSSl and PRSS1 R122H 
demonstrated a similar ability to cleave the BZiPAR substrate under 
various conditions. However, PRSS1 N29I appeared to have a reduced 
ability to cleave BZiPAR under similar conditions, as had been seen in the 
experiments analysing the proteins with the HA-tag.
The finding that the level of fluorescence detected from the cleavage of the 
BZiPAR substrate was reduced in proteins with the HA-tag raised 
questions regarding the potential implications this may exert in the 
transgenic animals. Though there are multiple permutations that can be 
described with regards to the possible effects on the phenotype of the 
transgenic animals, the primary concern was that a reduced level of 
enzymatic activity may significantly ameliorate the pathological insult on 
the acinar cells of the murine pancreas. The animals may demonstrate no 
evidence of pancreatitis or only a mild phenotype. Alternatively, the 
enzymatic activity may still be sufficient that if the zymogens are 
inappropriately activated within the acinar cells, then inflammatory 
pathways are activated leading to acute and/or chronic pancreatitis.
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The biochemical kinetics, previously described by Sahin-Toth and 
colleagues (Sahin-Toth 2001) when describing the R122H and N29I 
mutations, would also be amenable to investigation using the trypsin assay. 
This would allow analysis of autoactivation and autolysis of recombinant 
human cationic trypsinogen, and the R122H and N29I mutants, transcribed 
and processed by cultured human cells as opposed to E.Coli. The previous 
work carried out by Sahin-Toth et al in characterising the biochemical 
properties of these proteins relied on transcription and post-translational 
modification of the proteins in E. Coli and then refolding the protein in 
vitro after extraction by sonication. There exists the real possibility that the 
final proteins are similar but not identical to human expressed cationic 
trypsinogen, rendering a discrepancy in the biochemical findings.
The trypsin assay was developed to examine the ability of our antibodies in 
detecting expression of cationic trypsinogen and indeed demonstrate that 
the plasmids generated were able to allow expression of the genes in 
transiently transfected cells in vitro. Once expression of the proteins had 
been verified, we sought to confirm that the proteins were functional as 
enzymes before moving onto interrogation of the transgenic animals. 
Further experiments to understand the biochemistry of the proteins had to 
take a minor role to the primary aim of generating and analysing the 
transgenic animals. However, this work deserves greater emphasis in the
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near future to determine whether there is a real difference in the enzymatic 
activity of wild cationic trypsinogen and the mutant alleles.
With regards to the genetically modified mice, all positively identified 
animals from both the inducible and constitutive expression models are due 
to be extensively backcrossed to generate a large pool of transgenic 
animals for each of the individual strains. Eventually, compound mice 
would be generated for the inducible model, canying the pBEG OptrtTA 
transgene and one of the PRSS1-based transgenes. In the event of 
continued difficulties arising from the pBEG OptrtTA animals, we would 
look to import a similar transgenic animal that had been validated 
(Baumann, Wagner et al. 2007), as part of collaboration with another 
laboratory. Animals from both models would be dated at birth and 
eventually analysed at different time points to determine whether they 
develop a phenotype, either spontaneously or after a pharmacological 
challenge, characteristic of pancreatitis.
No group had developed a transgenic animal with expression of wild type 
human cationic trypsinogen or contested this against animals canying the 
common hereditary pancreatitis associated mutations at the onset of this 
work and this remains the case at the time of writing. One group has, 
however, during the course of our work, described a transgenic mouse 
model expressing human cationic trypsinogen carrying the R122H 
mutation (Selig, Sack et al. 2006). What are the consequences, if any, of
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expressing human cationic trypsinogen in the murine acinar cell? Would 
there be a different phenotype between the wild type and mutant forms of 
human cationic tiypsinogen, or would the model simply result in over­
expression of trypsin regardless of the mutations? Ultimately, would our 
hopes of seeing the full spectrum of hereditary pancreatitis in these 
transgenic animals be a naive assumption?
The evidence from previous studies of transgenic animals has taught us 
that the pathophysiological response to a genetic modification rarely gives 
the expected phenotype. Given the species variation and the redundancy 
built into cellular pathways that has now become apparent, this is not a 
surprise. The initial attempts to understand the role of p53 in epithelial 
cancer led to the development of a transgenic mouse model over­
expressing mutant alleles of p53 (Lavigueur, Maltby et al. 1989). The 
transgenic animals were found to have a high risk of lymphomas and 
sarcomas rather than the expected epithelial cancers. Other groups have 
sort to assess the function of a particular gene or protein by generating a 
knock out mouse, only to find that the genetic modification leads to a lethal 
phenotype (Ohmuraya, Hirota et al. 2005).
These concerns were part of the reason that we opted to develop an 
inducible model to allow temporal, as well as spatial, control of transgene 
expression. In this way we could assess if there were effects on the 
pancreas at the time of birth of the transgenic animals, or indeed if
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transgene expression was a lethal condition, whilst also having the option 
of activating expression of the transgene in an adult mouse to study the 
resultant phenotype. As we were using the elastase promoter, expression of 
the transgene in the constitutive model could begin at embryonic day 14, 
consistent with expression of the elastase protein (Omitz, Hammer et al. 
1987).
The importance of transgenic human cationic trypsinogen is found in its 
propensity to autoactivate relative to trypins from other species (Buck, Bier 
et al. 1962; Colomb and Figarella 1979). The transgenic mice carrying the 
wild type human cationic trypsinogen may not only function as a control 
group to assess the impact of the disease associated mutants, but may 
provide a new model for experimental acute and/or chronic pancreatitis. 
Though there is a wide range of models available to interrogate the cellular 
mechanisms leading to pancreatitis, none have proven fruitful in the face of 
developing effective preventative or therapeutic strategies (Steinberg and 
Schlesselman 1987). A study comparing the outcomes of therapeutic 
studies in animal models of acute pancreatitis found that 81% of the 25 
animal protocols studied had a positive outcome with respect to survival 
whilst only 7.7% of the resulting 13 human studies demonsfrated a positive 
outcome (Steinberg and Schlesselman 1987). Many investigators believe 
that the fundamental problem lies in the artificial methods employed to 
induce pancreatitis in these animal models. A model that has a spectrum of
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disease closely mimicking that seen in human pancreatitis may be an 
avenue to developing successful preventative and therapeutic medicines.
Though it is impossible to predict the phenotype that will eventually be 
exhibited by these transgenic animals, it is still possible to speculate and 
rationalise the potential of the model. In an ideal world the model would 
recapitulate the full spectrum of disease as seen in human patients with 
hereditary pancreatitis. In this scenario, the transgenic animal carrying the 
R122H or N29I mutant alleles would develop acute pancreatitis early in 
life, with a large proportion developing histological evidence of chronic 
pancreatitis with increasing age and ultimately a significant number then 
exhibiting pancreatic adenocarcinoma. It almost goes without saying that 
such a model would be highly sought after amongst the research 
community as a very powerful tool for dissecting the pathways underlying 
the disease mechanisms and driving the progression from acute to chronic 
pancreatitis and cancer.
On the other hand, the simple presence of human cationic trypsinogen, 
whether wild type or mutant may be a significant insult to the murine 
pancreas and result in either recurrent episodes of acute pancreatitis or 
chronic pancreatitis. In this respect, the constitutive expression model may 
show little or no significant difference between the phenotype of the three 
strains of transgenic animal, in effect behaving like an overexpression 
model of trypsinogen. This model would have great utility in studying the
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role of trypsinogen as an early player in the pathogenesis of pancreatitis 
and aid understanding of the cellular response to excess trypsinogen and 
how this influences cell fate with regards to apoptosis or necrosis. The 
inducible model would be a powerful tool in this setting, as it would allow 
precise control of trypsinogen expression for a defined time period, after 
which the animals could be analysed. Temporal control of trypsinogen 
expression could allow investigators to identify the site of trypsinogen 
activation, mechanism of injury, induction of inflammatory mediators and 
quantify the efforts of a cell’s protective machineiy to limit the subsequent 
injury. These models would sit alongside the current models of 
experimental acute pancreatitis, and allow interrogation of the earliest 
events in acute pancreatitis from a different standpoint. Recent work, 
utilising a CMV driven construct expressing a mutant trypsinogen that was 
activated by an intracellular protease, PACE (paired basic amino acid 
cleaving enzyme), demonstrated that expression of intracellular trypsin 
induced apoptosis and did not activate the inflammatory mediator NF-kB 
(Ji, Gaiser et al. 2009). Indeed, the extracellular presence of trypsin proved 
to be a powerful inducer of NF-kB. This study claimed to be the first direct 
evidence of the biological effects of intracellular trypsin activity on 
pancreatic acinar cells, and if validated in our research may yield some 
interesting results.
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There is a reasonable probability that the transgenic animals fail to produce 
a spontaneous or pharmacologically induced phenotype. The underlying 
reason for this may range from human cationic trypsinogen and the mutant 
alleles being veiy well tolerated and therefore not pathological in the 
murine pancreas through to inadequate expression of the transgenes to 
allow a phenotype to develop. The only model to date that describes 
integration of a mutant human cationic trypsinogen transgene into the 
murine genome appears to have suffered from a problem with low 
transgene expression levels (Selig, Sack et al. 2006). The cellular response 
to an injurious fans genic human cationic trypsinogen may be to down 
regulate the gene and thus prevent further damage or initiate apoptosis, 
limiting the acinar population to cells with low transgene expression. In 
this scenario, it would be difficult to demonstrate whether the transgenes 
may have had a pathological impact given strong expression. There may be 
an opportunity to compare the constitutive expression model against the 
inducible model to analyse whether transgene expression levels are a 
temporally dependent phenomenon. As discussed above, Ji et al 
demonstrated that intracellular trypsin resulted in acinar cell apoptosis and 
did not activate an inflammatory response via NF-kB (Ji, Gaiser et al. 
2009). The in vivo implication of these findings when extrapolated to our 
models may mean that no phenotype consistent with acute or chronic 
pancreatitis is identified, and instead we see animals with various degrees 
of pancreas atrophy.
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The only successful genetically modified mouse model to date, that has 
attempted to assess the in vivo effects of the R122H mutation showed an 
early onset of acinar cell injury and inflammatory cell infiltration, 
progressing to pancreatic fibrosis with increasing age (Archer, Jura et al. 
2006). Despite showing that persistent pancreatic injmy may be linked to 
chronic pancreatitis, it was not clear from the data whether the injmy was 
related to the R122H mutation introduced into one of the murine 
tiypsinogens or a consequence of trypsinogen overexpression that 
overwhelmed the acinar cell’s protective mechanisms. It certainly had little 
to say with regards to how the murine pancreas may handle the presence of 
human cationic trypsinogen and therefore limits the potential implications 
for our models.
Invariably, once analysis of the transgenic mouse models is underway there 
will be surprise findings that one could not anticipate, which lead to new 
and unexpected avenues of research. It will be interesting to see what 
future research tells us about the role of cationic trypsinogen in the early 
events of acute pancreatitis and how this leads to chronic pancreatitis and 
in particular it will be interesting to see how the genetically modified 
animals generated in this thesis are used to answer these questions.
221
References
Almoguera, C., D. Shibata, et al. (1988). "Most human carcinomas of the 
exocrine pancreas contain mutant c-K-ras genes." Cell 53(4): 549- 
54.
Amann, S. T., L. K. Gates, et al. (2001). "Expression and penetrance of the 
hereditary pancreatitis phenotype in monozygotic twins." Gut 
48(4): 542-7.
Apple, S. K., J. R. Hecht, et al. (1999). "Imnumohistochemical evaluation 
of K-ras, p53, and HER-2/neu expression in hyperplastic, 
dysplastic, and carcinomatous lesions of the pancreas: evidence for 
multistep carcinogenesis." Hum Pathol 30(2): 123-9.
Archer, H., N. Jura, et al. (2006). "A mouse model of hereditary 
pancreatitis generated by transgenic expression of R122H 
trypsinogen." Gastroenterology 13116): 1844-55.
Arduino, C., P. Salacone, et al. (2005). "Association of a new cationic 
trypsinogen gene mutation (V39A) with chronic pancreatitis in an 
Italian family." Gut 54(11): 1663-4.
Argent, B. E., R. M. Case, et al. (1982). "The effects of manganese, cobalt 
and calcium on amylase secretion and calcium homeostasis in rat 
pancreas." J Physiol 323: 353-75.
Bardeesy, N. and R. A. DePinho (2002). "Pancreatic cancer biology and 
genetics." Nat Rev Cancer 21121: 897-909.
Baron, U., M. Gossen, et al. (1997). "Tetracycline-controlled transcription 
in eukaryotes: novel transactivators with graded transactivation 
potential." Nucleic Acids Res 25(14): 2723-9.
Barton, C. M., S. L. Staddon, et al. (1991). "Abnormalities of the p53 
tumour suppressor gene in human pancreatic cancer." Br J Cancer 
64(6): 1076-82.
Baumann, B., M. Wagner, et al. (2007). "Constitutive IKK2 activation in 
acinar cells is sufficient to induce pancreatitis in vivo." J Clin 
Invest 1X7161: 1502-13.
Bayerdorffer, E., H. Streb, et al. (1984). "Characterization of calcium 
uptake into rough endoplasmic reticulum of rat pancreas." JMembr 
Biol 81(1): 69-82.
Bayliss, W. M. and E. H. Starling (1905). "On the relation of enterokinase 
to trypsin." J Physiol 32(2): 129-36.
Bell, S. M., C. Bennett, et al. (1998). "Evidence for a common mutation in 
hereditary pancreatitis." Mol Pathol 51: 115-7.
222
Bernardino, A. L., D. R. Guarita, et al. (2003). "CFTR, PRSS1 and 
SPINK 1 mutations in the development of pancreatitis in Brazilian 
patients." JOP 4(5): 169-77.
Bhatia, E., G. Choudhuri, et al. (2002). "Tropical calcific pancreatitis: 
strong association with SPINK1 trypsin inhibitor mutations." 
Gastroenterology 123(4): 1020-5.
Bottinger, E. P., J. L. Jakubczak, et al. (1997). "Expression of a dominant­
negative mutant TGF-beta type II receptor in transgenic mice 
reveals essential roles for TGF-beta in regulation of growth and 
differentiation in the exocrine pancreas." EMBO J 16(10): 2621-33.
Bradford, M. M. (1976). "A rapid and sensitive method for the quantitation 
of microgram quantities of protein utilizing the principle of protein- 
dye binding." Anal Biochem 72: 248-54.
Bradley, A., M. Evans, et al. (1984). "Fonnation of germ-line chimaeras 
from embryo-derived teratocarcinoma cell lines." Nature 
309(5965): 255-6.
Brady, M., S. Christmas, et al. (1999). "Cytokines and acute pancreatitis." 
Baillieres Best Pract Res Clin Gastroenterol 13(2): 265-89.
Brinster, R. L., H. Y. Chen, et al. (1981). "Somatic expression of heipes 
thymidine kinase in mice following injection of a fusion gene into 
eggs." Ceh 27(1 Pt 2): 223-31.
Buchholz, F., P. O. Angrand, et al. (1998). "Improved properties of FLP 
recombinase evolved by cycling mutagenesis." Nat Biotechnol 
16(7): 657-62.
Buck, F. F., M. Bier, et al. (1962). "Some properties of human trypsin." 
Archives of Biochemistry and Biophysics 98(3): 528-530.
Burim, R. V., R. Canalle, et al. (2004). "Polymorphisms in glutathione S- 
transferases GSTM1, GSTT1 and GSTP1 and cytochromes P450 
CYP2E1 and CYP1 Al and susceptibility to cirrhosis or pancreatitis 
in alcoholics." Mutagenesis 19(4): 291-8.
Caldas, C., S. A. Hahn, et al. (1994). "Frequent somatic mutations and 
homozygous deletions of the pi6 (MTS1) gene in pancreatic 
adenocarcinoma." Nat Genet 8(1): 27-32.
Cancela, J. M., F. Van Coppenolle, et al. (2002). "Transformation of local 
Ca2+ spikes to global Ca2+ transients: the combinatorial roles of 
multiple Ca2+ releasing messengers." EMBO J 21(5): 909-19.
Cano, D. A., S. Sekine, et al. (2006). "Primary cilia deletion in pancreatic 
epithelial cells results in cyst formation and pancreatitis." 
Gastroenterology 131161: 1856-69.
Caro, L. G. and G. E. Palade (1964). "Protein Synthesis, Storage, and 
Discharge in the Pancreatic Exocrine Cell. An Autoradiographic 
Study." J Cell Biol 20: 473-95.
Casanova, M. L., A. Bravo, et al. (1999). "Exocrine pancreatic disorders in 
transsgenic mice expressing human keratin 8." J Clin Invest 
103(11): 1587-95.
223
Casey, G., Y. Yamanaka, et al. (1993). "p53 mutations are common in 
pancreatic cancer and are absent in chronic pancreatitis." Cancer 
Lett 69(3): 151-60.
Chandak, G. R., M. M. Idris, et al. (2002). "Mutations in the pancreatic 
secretoiy trypsin inhibitor gene (PSTI/SPINK1) rather than the 
cationic trypsinogen gene (PRSS1) are significantly associated with 
tropical calcific pancreatitis." J Med Genet 39(5): 347-51.
Chari, S. T., C. L. Leibson, et al. (2005). "Probability of pancreatic cancer 
following diabetes: a population-based study." Gastroenterology 
129(2): 504-11.
Chamley, R. M. (2003). "Hereditary pancreatitis." World J Gastroenterol 
9(1): 1-4.
Chen, J. M. and C. Ferec (2009). "Chronic pancreatitis: genetics and 
pathogenesis." Annu Rev Genomics Hum Genet 10: 63-87.
Chen, J. M., Z. Kukor, et al. (2003). "Evolution of trypsinogen activation 
peptides." Mol Biol Evol 20(11): 1767-77.
Chen, J. M., C. Le Marechal, et al. (2003). ""Loss of function" mutations in 
the cationic trypsinogen gene (PRSS1) may act as a protective 
factor against pancreatitis." Mol Genet Metab 79(1): 67-70.
Chen, J. M., A. Piepoli Bis, et al. (2001). "Mutational screening of the 
cationic trypsinogen gene in a large cohort of subjects with 
idiopathic chronic pancreatitis." Clin Genet 59(3): 189-93.
Chepovalnikov (1899). Maly's Jhrsh: 378.
Cohn, J. A., K. J. Friedman, et al. (1998). "Relation between mutations of 
the cystic fibrosis gene and idiopathic pancreatitis." N Engl J Med 
339(10): 653-8.
Cohn, J. A., J. P. Neoptolemos, et al. (2005). "Increased risk of idiopathic 
chronic pancreatitis in cystic fibrosis earners." Hum Mutat 26(4): 
303-7.
Colomb, E. and C. Figarella (1979). "Comparative studies on the 
mechanism of activation of the two human trypsinogens." Biochim 
Biophvs Acta 571(2): 343-51.
Colomb, E., C. Figarella, et al. (1979). "The two human trypsinogens. 
Evidence of complex formation with basic pancreatic trypsin 
inhibitor-proteolytic activity." Biochim Biophvs Acta 570(2): 397- 
405.
Colomb, E., O. Guy, et al. (1978). "The two human trypsinogens: catalytic 
properties of the corresponding trypsins." Biochim Biophvs Acta 
525(1): 186-93.
Comfort, M. W. and A. G. Steinberg (1952). "Pedigree of a family with 
hereditary chronic relapsing pancreatitis." Gastroenterology 21(1): 
54-63.
Corfreld, A. P., M. J. Cooper, et al. (1985). "Acute pancreatitis: a lethal 
disease of increasing incidence." Gut 26(7): 724-9.
224
Costantini, F. and E. Lacy (1981). "Introduction of a rabbit beta-globin 
gene into the mouse germ line." Nature 294(5836): 92-4.
Coughlin, S. S., E. E. Calle, et al. (2000). "Predictors of pancreatic cancer 
mortality among a large cohort of United States adults." Cancer 
Causes Control 11(10): 915-23.
Craik, C. S., C. Largman, et al. (1985). "Redesigning trypsin: alteration of 
substrate specificity." Science 228(4697): 291-7.
Creighton, J., R. Lyall, et al. (1999). "Mutations of the cationic trypsinogen 
gene in patients with chronic pancreatitis, (see Pane 405)." Lancet 
354: 42-3.
Criddle, D. N., J. V. Gerasimenko, et al. (2007). "Calcium signalling and 
pancreatic cell death: apoptosis or necrosis?" Cell Death Differ 
14(7): 1285-94.
Criddle, D. N., E. McLaughlin, et al. (2007). "The pancreas misled: signals 
to pancreatitis." Pancreatology 7(5-6): 436-46.
Cuzzocrea, S., E. Mazzon, et al. (2002). "Absence of endogenous 
interleukin-6 enhances the inflammatory response during acute 
pancreatitis induced by cerulein in mice." Cytokine 18(5): 274-85.
Davies, M. G. and P. O. Hagen (1997). "Systemic inflammatory response 
syndrome." Br J Surg 84(7): 920-35.
Delezenne 119011 C.R.Soc.de Biol LIII: 1161.
Denham, W., J. Yang, et al. (1997). "Gene targeting demonstrates additive 
detrimental effects of interleukin 1 and tumor necrosis factor during 
pancreatitis." Gastroenterology 113(5): 1741-6.
Douglas, W. W. and R. P, Rubin (1961). "Mechanism of nicotinic action at 
the adrenal medulla: calcium as a link in stimulus-secretion 
coupling." Nature 192: 1087-9.
Durie, P. R., G. Kent, et al. (2004). "Characteristic multiorgan pathology of 
cystic fibrosis in a long-living cystic fibrosis transmembrane 
regulator knockout murine model." Am J Pathol 164(4): 1481-93.
Edlund, H. (2002). "Pancreatic organogenesis—developmental mechanisms 
and implications for therapy." Nat Rev Genet 3(7): 524-32.
Emi, M., Y. Nakamura, et al. (1986). "Cloning, characterization and 
nucleotide sequences of two cDNAs encoding human pancreatic 
trypsinogens." Gene 41(2-3): 305-10.
Etemad, B. and D. C. Whitcomb (2001). "Chronic pancreatitis: diagnosis, 
classification, and new genetic developments." Gastroenterology 
120(3): 682-707.
Evans, M. J. and M. H. Kaufman (1981). "Establishment in culture of 
pluripotential cells from mouse embryos." Nature 292(5819): 154- 
6.
Ferec, C., O. Raguenes, et al. (1999). "Mutations in the cationic 
trypsinogen gene and evidence for genetic heterogeneity in 
hereditary pancreatitis." J Med Genet 36: 228-32.
225
Fernandez-Salazar, M. P., P. Pascua, et al. (2004). "Basolateral anion 
transport mechanisms underlying fluid secretion by mouse, rat and 
guinea-pig pancreatic ducts." J Physiol 556(Pt 2): 415-28.
Figarella, C., F. Clemente, et al. (1969). "On zymogens of human 
pancreatic juice." FEES Lett 3(5): 351-353.
Figarella, C., B. Miszczuk-Jamska, et al. (1988). "Possible lysosomal 
activation of pancreatic zymogens. Activation of both human 
trypsinogens by cathepsin B and spontaneous acid. Activation of 
human trypsinogen 1." Biol Chem Hoppe Sevier 369 Suppl: 293-8.
Figarella, C, G. A. Negri, et al. (1975). "The two human trypsinogens. 
Inhibition spectra of the two human trypsins derived from their 
purified zymogens." Eur J Biochem 53(2): 457-63.
Fiunya, N., S. Kawa, et al. (1997). "Long-term follow-up of patients with 
chronic pancreatitis and K-ras gene mutation detected in pancreatic 
juice." Gastroenterology 113(2): 593-8.
Gaboriaud, C., L. Serre, et al. (1996). "Crystal structure of human trypsin 
1: unexpected phosphorylation of TyiT51." J Mol Biol 259(5): 995- 
1010.
Ganong, W. F. (2001). Digestion. Review of Medical Physiology. McGraw 
Hill: 481-483.
Gerber, B. (1963). "Hereditary Pancreatitis." Archives of Surgery 87: 70- 
80.
Gilmore, T. D. (2006). "Introduction to NF-kappaB: players, pathways, 
perspectives." Oncogene 25(51): 6680-4.
Goldacre, M. J., C. J. Wotton, et al. (2008). "Liver cirrhosis, other liver 
diseases, pancreatitis and subsequent cancer: record linkage study." 
Eur J Gastroenterol Hepatol 20(5): 384-92.
Gordon, J. W. and F. H. Ruddle (1981). "Integration and stable germ line 
transmission of genes injected into mouse pronuclei." Science 
214(4526): 1244-6.
Gordon, J. W., G. A. Scangos, et al. (1980). "Genetic transformation of 
mouse embiyos by microinjection of purified DNA." Proc Natl 
AcadSciUSA77(12): 7380-4.
Gorelick, F. S. and L. M. Matovcik (1995). "Lysosomal enzymes and 
pancreatitis." Gastroenterology 109(2): 620-5.
Gorry, M. C., D. Gabbaizedeh, et al. (1997). "Mutations in the cationic 
trypsinogen gene are associated with recurrent acute and chronic 
pancreatitis." Gastroenterology 113(4): 1063-8.
Gossen, M. and H. Bujard (1992). "Tight control of gene expression in 
mammalian cells by tetracycline-responsive promoters." Proc Natl 
AcadScilLSA 89(12): 5547-51.
Gossen, M., S. Freundlieb, et al. (1995). "Transcriptional activation by 
tetracyclines in mammalian cells." Science 268(5218): 1766-9.
Grieshammer, U., M. Lewandoski, et al. (1998). "Muscle-specific cell 
ablation conditional upon Cre-mediated DNA recombination in
226
transgenic mice leads to massive spinal and cranial motoneuron 
loss.” Dev Biol 197(2): 234-47.
Gross, J. (1958). "Some recent developments pertaining to the pancreas." 
Annals of Internal Medicine 49: 796-836.
Gross, J. and M. W. Comfort (1957). "Hereditary Pancreatitis: Report on 
two additional families." Gastroenterologv 32: 829-54.
Gross, J., J. Ulrich, et al. (1962). Further observations on the hereditary 
form of pancreatitis. CIBA foundation symposium. London, 
Churchill: 278-309.
Gu, H., J. D. Marth, et al. (1994). "Deletion of a DNA polymerase beta 
gene segment in T cells using cell type-specific gene targeting." 
Science 265(51681: 103-6.
Guerra, C., A. J. Schuhmacher, et al. (2007). "Chronic pancreatitis is 
essential for induction of pancreatic ductal adenocarcinoma by K- 
Ras oncogenes in adult mice." Cancer Cell 11(3): 291-302.
Guy, O., D. Lombardo, et al. (1978). "Two human trypsinogens. 
Purification, molecular properties, and N-terminal sequences." 
Biochemistry 17(9): 1669-75.
Hahn, S. A., M. Schutte, et al. (1996). "DPC4, a candidate tumor 
suppressor gene at human chromosome 18q21.1." Science 
271(5247): 350-3.
Halangk, W., B. Kruger, et al. (2002). "Trypsin activity is not involved in 
premature, intrapancreatic trypsinogen activation." Am J Physiol 
Gastrointest Liver Physiol 282(2): G367-74.
Halangk, W. and M. M. Lerch (2005). "Early events in acute pancreatitis." 
Clin Lab Med 25(1): 1-15.
Halangk, W., M. M. Lerch, et al. (2000). "Role of cathepsin B in 
intracellular trypsinogen activation and the onset of acute 
pancreatitis." J Clin Invest 106(6): 773-81.
Harding, H. P., H. Zeng, et al. (2001), "Diabetes mellitus and exocrine 
pancreatic dysfunction in perk-/- mice reveals a role for 
translational control in secretory cell survival." Mol Cell 7(6): 
1153-63.
Hemandez-Munoz, I., A. Skoudy, et al. (2008), "Pancreatic ductal 
adenocarcinoma: cellular origin, signaling pathways and stroma 
contribution." Pancreatology 8(4-5): 462-9.
Hezel, A. F., A. C. Kimmelman, et al. (2006). "Genetics and biology of 
pancreatic ductal adenocarcinoma." Genes Dev 20(10): 1218-49.
Hingorani, S. R., E. F. Petricoin, et al. (2003). "Preinvasive and invasive 
ductal pancreatic cancer and its early detection in the mouse." 
Cancer Cell 4(61:437-50.
Hingorani, S. R., L. Wang, et al. (2005), "Trp53R172H and KrasG12D 
cooperate to promote chromosomal instability and widely 
metastatic pancreatic ductal adenocarcinoma in mice." Cancer Cell 
7(5): 469-83.
227
Hooper, M., K. Hardy, et al. (1987). "HPRT-deficient (Lesch-Nyhan) 
mouse embryos derived from germline colonization by cultured 
cells." Nature 326(6110): 292-5.
Howes, N., W. Greenhalf, et al. (2001). "A new polymorphism for the 
RI22H mutation in hereditary pancreatitis." Gut 48(2): 247-250.
Howes, N., W. Greenhalf, et al. (2005). "Cationic trypsinogen mutations 
and pancreatitis." Clin Lab Med 25(1): 39-59.
Howes, N., M. M. Lerch, et al. (2004). "Clinical and genetic characteristics 
of hereditary pancreatitis in Europe." Clin Gastroenterol Hepatol 
2(3): 252-61.
Howes, N. and J. P. Neoptolemos (2002). "Risk of pancreatic ductal 
adenocarcinoma in chronic pancreatitis." Gut 51(6): 765-6.
Hraban, R. H. and N. V. Adsay (2009). "Molecular classification of 
neoplasms of the pancreas." Hum Pathol 40(5): 612-23.
Hruban, R. H., N. V. Adsay, et al. (2001). "Pancreatic intraepithelial 
neoplasia: a new nomenclature and classification system for 
pancreatic duct lesions." Am J Sure Pathol 25(5): 579-86.
Iglesias, A., M. Murga, et al. (2004). "Diabetes and exocrine pancreatic 
insufficiency in E2F1/E2F2 double-mutant mice." J Clin Invest 
113(10): 1398-407.
Jemal, A., R. Siegel, et al. (2009). "Cancer statistics, 2009." CA Cancer J 
Clin 59(4): 225-49.
Ji, B., S. Gaiser, et al. (2009). "Intracellular trypsin induces pancreatic 
acinar cell death but not NF-kappaB activation." J Biol Chem 
284(26): 17488-98.
Johnson, C. D., R. Chamley, et al. (2005). "UK guidelines for the 
management of acute pancreatitis." Gut 54 Suppl 3: iiil-9.
Kattwinkel, J., A. Lapey, et al. (1973). "Hereditary pancreatitis: three new 
kindreds and a critical review of the literature." Pediatrics 51: 55- 
69.
Keiles, S. and A. Kammesheidt (2006). "Identification of CFTR, PRSS1, 
and SPINK1 mutations in 381 patients with pancreatitis." Pancreas 
33(3): 221-7.
Keim, V., N. Bauer, et al. (2001). "Clinical characterization of patients 
with hereditary pancreatitis and mutations in the cationic 
trypsinogen gene." Am J Med 111(8): 622-6.
Keim, V., N. Teich, et al. (2000). "Trypsinogen mutations in hereditary 
pancreatitis: which nomenclature is convenient?" Gut 46(6): 873.
Kim, S. K. and M. Hebrok (2001). "Intercellular signals regulating 
pancreas development and function." Genes Dev 15(2): 111-27.
Kingsnorth, A. and D. O'Reilly (2006). "Acute pancreatitis." BMJ 
332(7549): 1072-6.
Kiraly, O., A. Boulling, et al. (2007). "Signal peptide variants that impair 
secretion of pancreatic secretory trypsin inhibitor (SPINK1) cause
228
autosomal dominant hereditary pancreatitis." Hum Mutat 28(5): 
469-76.
Kiraly, O., L. Guan, et al. (2006). "Expression of human cationic 
trypsinogen with an authentic N terminus using intein-mediated 
splicing in aminopeptidase P deficient Escherichia coli." Protein 
ExprPurif 48(1): 104-11.
Kistner, A., M. Gossen, et al. (1996). "Doxycycline-mediated quantitative 
and tissue-specific control of gene expression in transgenic mice." 
Proc Natl Acad Sci U S A 93(20): 10933-8.
Koller, B. H., L. J. Hagemann, et al. (1989). "Germ-line transmission of a 
planned alteration made in a hypoxanthine 
phosphoribosyltransferase gene by homologous recombination in 
embryonic stem cells." Proc Natl Acad Sci U S A 86(22): 8927-31.
Konzen, K. M.} J. Perrault, et al. (1993). "Long-term follow-up of young 
patients with chronic hereditary or idiopathic pancreatitis." Mayo 
Clin Proc 68: 449-53.
Kozuka, S., S. Nagasawa, et al. (1982). "DNA content of pancreatic duct 
hyperplasia and carcinoma." Gann 73(1): 119-23.
Kuehn, M. R., A. Bradley, et al. (1987). "A potential animal model for 
Lesch-Nyhan syndrome through introduction of HPRT mutations 
into mice." Nature 326(6110): 295-8.
Kukor, Z., J. Mayerle, et al. (2002). "Presence of cathepsin B in the human 
pancreatic secretoiy pathway and its role in trypsinogen activation 
during hereditary pancreatitis." J Biol Chem 277(24): 21389-96.
Kukor, Z., M. Toth, et al. (2002). "Human cationic trypsinogen. Arg(117) 
is the reactive site of an inhibitory surface loop that controls 
spontaneous zymogen activation." J Biol Chem 277(8): 6111-7.
Kukor, Z., M. Toth, et al. (2003). "Human anionic trypsinogen: properties 
of autocatalytic activation and degradation and implications in 
pancreatic diseases." Eur J Biochem 270(9): 2047-58.
Lakso, M., B. Sauer, et al. (1992). "Targeted oncogene activation by site- 
specific recombination in transgenic mice." Proc Natl Acad Sci U S 
A 89(14): 6232-6.
Lavigueur, A., V. Maltby, et al. (1989). "High incidence of lung, bone, and 
lymphoid tumors in transgenic mice overexpressing mutant alleles 
of the p53 oncogene." Mol Cell Biol 9(9): 3982-91.
Le Bodic, L., J. D. Bignon, et al. (1996). "The hereditary pancreatitis gene 
maps to long arm of chromosome 7." Hum Mol Genet 5(4): 549- 
54.
Le Bodic, L., M. Schnee, et al. (1996). "An exceptional genealogy for 
hereditary chronic pancreatitis." Dig Pis Sci 41(7): 1504-10.
Le Marechal, C., J. F. Bretagne, et al. (2001). "Identification of a novel 
pancreatitis-associated missense mutation, R116C, in the human 
cationic trypsinogen gene (PRSS1)." Mol Genet Metab 74(3): 342- 
4.
229
Le Marechal, C., J. M. Chen, et al. (2004). "Two novel severe mutations in 
the pancreatic secretory trypsin inhibitor gene (SPINK 1) cause 
familial and/or hereditary pancreatitis." Hum Mutat 23(2): 205.
Le Marechal, C., J. M. Chen, et al. (2001). "Discrimination of three 
mutational events that result in a disruption of the R122 primary 
autolysis site of the human cationic trypsinogen (PRSS1) by 
denaturing high performance liquid chromatography." BMC Genet 
2: 19.
Leach, S. D., I. M. Modlin, et al. (1991). "Intracellular activation of 
digestive zymogens in rat pancreatic acini. Stimulation by high 
doses of cholecystokinin." J Clin Invest 87(1): 362-6.
Lee, S. P., J. F. Nicholls, et al. (1992). "Biliary sludge as a cause of acute 
pancreatitis." N Engl J Med 326(9): 589-93.
Lengyel, Z., G. Pal, et al. (1998). "Affinity purification of recombinant 
trypsinogen using immobilized ecotin." Protein Expr Purif 12(2): 
291-4.
Lerch, M. M., W. Halangk, et al. (2000). "The role of cysteine proteases in 
intracellular pancreatic serine protease activation." Adv Exp Med 
Bid 477: 403-11.
Levine, A. J. (1997). "p53, the cellular gatekeeper for growth and 
division." Cell 88(3): 323-31.
Levine, A. J., W. Hu, et al. (2006). "The P53 pathway: what questions 
remain to be explored?" Cell Death Differ 13(6): 1027-36.
Li, D., K. Xie, et al. (2004). "Pancreatic cancer." Lancet 363(9414): 1049- 
57.
Lin, T. P. (1966). "Microinjection of mouse eggs." Science 151(708): 333-
7.
Longnecker, D. S., H. Shinozuka, et al. (1980). "Focal acinar cell dysplasia 
in human pancreas." Cancer 45(3): 534-40.
Lowenfels, A. B., P. Maisonneuve, et al. (1993). "Pancreatitis and the risk 
of pancreatic cancer. International Pancreatitis Study Group." N 
End J Med 328(201: 1433-7.
Lowenfels, A. B., P. Maisonneuve, et al. (1997). "Hereditary pancreatitis 
and the risk of pancreatic cancer. International Hereditary 
Pancreatitis Study Group." J Natl Cancer Inst 89: 442-446.
Lowenfels, A. B,, P. Maisonneuve, et al. (2000). "Risk factors for cancer in 
hereditary pancreatitis. International Hereditary Pancreatitis Study 
Group." Med Clin North Am 84(3): 565-73.
Lowenfels, A. B., P. Maisonneuve, et al. (2001). "Cigarette smoking as a 
risk factor for pancreatic cancer in patients with hereditaiy 
pancreatitis." JAMA 286(2): 169-70.
Luttges, J., B. Schlehe, et al. (1999). "The K-ras mutation pattern in 
pancreatic ductal adenocarcinoma usually is identical to that in 
associated normal, hyperplastic, and metaplastic ductal 
epithelium." Cancer 85181: 1703-10.
230
Madsen, O. D., J. Jensen, et al. (1996). "Pancreatic development and 
maturation of the islet B cell. Studies of pluripotent islet cultures." 
Eur J Biochem 242(3): 435-45.
Malumbres, M. and M. Barbacid (2003). "RAS oncogenes: the first 30 
year's." Nat Rev Cancer 3(6): 459-65.
Margaritis, T. and F. C. Holstege (2008). "Poised RNA polymerase II gives 
pause for thought." Cell 133(4): 581-4.
Marrache, F., S. P. Tu, et al. (2008). "Overexpression of interleukin-1 beta 
in the murine pancreas results in chronic pancreatitis." 
Gastroenterology 135(4): 1277-87.
Masson, E., J. M. Chen, et al. (2008). "Association of rare 
chymotrypsinogen C (CTRC) gene variations in patients with 
idiopathic chronic pancreatitis." Hum Genet 123(1): 83-91.
Matthaei, K. I. (2007). "Genetically manipulated mice: a powerful tool 
with unsuspected caveats." J Physiol 582(Pt 2): 481-8.
McGaughran, J. M., R. Kimble, et al. (2004). "Hereditary pancreatitis in a 
family of Aboriginal descent." J Paediatr Child Health 40(8): 487- 
9.
McKay, C. J., S. Evans, et al. (1999). "High early mortality rate from acute 
pancreatitis in Scotland, 1984-1995." Br J Sure 86(10): 1302-5.
Mellanby, J. and V. J. Woolley (1912). "The fennents of the pancreas: Part 
I. The generation of trypsin from trypsinogen by enterokinase." J 
Physiol 45(5): 370-88.
Mithofer, K., C. Femandez-del Castillo, et al. (1998). "Subcellular kinetics 
of early trypsinogen activation in acute rodent pancreatitis." Am J 
Physiol 274(1 Pt 1): G71-9.
Mogami, H., K. Nakano, et al. (1997). "Ca2+ flow via tunnels in polarized 
cells: recharging of apical Ca2+ stores by focal Ca2+ entry through 
basal membrane patch." Cell 88(1): 49-55.
Mogami, H., A. V. Tepikin, et al. (1998). "Tennination of cytosolic Ca2+ 
signals: Ca2+ reuptake into intracellular stores is regulated by the 
free Ca2+ concentration in the store lumen." Embo J 17(2): 435-42.
Moir, C. R., K. M. Konzen, et al. (1992). "Surgical therapy and long-term 
follow-up of childhood hereditary pancreatitis." J Pediatr Surg 27: 
282-6; discussion 286-7.
Moskaluk, C. A., R. H. Hmban, et al. (1997). "pi6 and K-ras gene 
mutations in the intraductal precursors of human pancreatic 
adenocarcinoma." Cancer Res 57(11): 2140-3.
Muallem, S. and P. A. Loessberg (1990). "Intracellular pH-regulatory 
mechanisms in pancreatic acinar cells. I. Characterization of H+ 
and HC03- transporters." J Biol Chem 265(22): 12806-12.
Mukherjee, R., D. N. Criddle, et al. (2008). "Mitochondrial injury in 
pancreatitis." Cell Calcium 44111: 14-23.
Nagy, A. (2000). "Cre recombinase: the universal reagent for genome 
tailoring." Genesis 26(2): 99-109.
231
Nathan, J. D., J. Romac, et al. (2005). "Transgenic expression of pancreatic 
secretory trypsin inhibitor-I ameliorates secretagogue-induced 
pancreatitis in mice." Gastroenterology 128(3): 717-27.
Nemoda, Z. and M. Sahin-Toth (2005). "The tetra-aspartate motif in the 
activation peptide of human cationic trypsinogen is essential for 
autoactivation control but not for enteropeptidase recognition." J 
Biol Chem 280(33): 29645-52.
Nemoda, Z. and M. Sahin-Toth (2006). "Chymotrypsin C (caldecrin) 
stimulates autoactivation of human cationic trypsinogen." J Biol 
Cheni 281(17): 11879-86.
Neoptolemos, J. P., E. A. Kemppainen, et al. (2000). "Early prediction of 
severity in acute pancreatitis by urinary trypsinogen activation 
peptide: a multicentre study." Lancet 355(9219): 1955-60.
Neoptolemos, J. P., M. Raraty, et al. (1998). "Acute pancreatitis: the 
substantial human and financial costs." Gut 42(6): 886-91.
Neoptolemos, J. P., D. D. Stocken, et al. (2004). "A randomized trial of 
chemoradiotherapy and chemotherapy after resection of pancreatic 
cancer." New England Journal of Medicine 350(T2k 1200-1210.
Neurath, H. and K. A. Walsh (1976). "Role of proteolytic enzymes in 
biological regulation (a review)." Proc Natl Acad Sci U S A 73(11): 
3825-32.
Nishimori, L, M. Kamakura, et al. (1999). "Mutations in exons 2 and 3 of 
the cationic trypsinogen gene in Japanese families with hereditary 
pancreatitis." Gut 44(2): 259-63.
Norman, J., J. Yang, et al. (1997). "Severity and mortality of experimental 
pancreatitis are dependent on interleukin-1 converting enzyme 
(ICE)." J Interferon Cytokine Res 17f2k 113-8.
Norman, J. G., G. Fink, et al. (1996). "Active interleukin-1 receptor 
required for maximal progression of acute pancreatitis." Ann Surg 
223(2): 163-9.
Northrop, J. H. and M. Kunitz (1932). "Crystalline Trypsin: I. Isolation and 
Tests of Purity." J. Gen. Phvsiol. 16(2): 267-294.
Nyaruhucha, C. N., M. Kito, et al. (1997). "Identification and expression of 
the cDNA-encoding human mesotrypsin(ogen), an isoform of 
trypsin with inhibitor resistance." J Biol Chem 272(16): 10573-8.
O'Gorman, S., D. T. Fox, et al. (1991). "Recombinase-mediated gene 
activation and site-specific integration in mammalian cells." 
Science 251(4999): 1351-5.
Ohmuraya, M., M. Hirota, et al. (2006). "Enhanced trypsin activity in 
pancreatic acinar cells deficient for serine protease inhibitor kazal 
type 3." Pancreas 3311): 104-6,
Ohmuraya, M., M. Hirota, et al. (2005). "Autophagic cell death of 
pancreatic acinar cells in serine protease inhibitor Kazal type 3- 
deficientmice." Gastroenterology 129(2): 696-705.
232
Orci, L., M. Ravazzola, et al. (1987). "The condensing vacuole of exocrine 
cells is more acidic than the mature secretory vesicle." Nature 
326(6108): 77-9.
Omitz, D. M., R. E. Hammer, et al. (1987). "Promoter and enhancer 
elements from the rat elastase I gene function independently of 
each other and of heterologous enhancers." Mol Cell Biol 7(10): 
3466-72.
Omitz, D. M., R. E. Hammer, et al. (1987). "Pancreatic neoplasia induced 
by SV40 T-antigen expression in acinar cells of fransgenic mice." 
Science 238(4824): 188-93.
Palade, G. (1975). "Intracellular Aspects of the Process of Protein 
Synthesis." Science 189(4206): 867.
Palmiter, R. D. and R. L. Brinster (1986). "Germ-line transformation of 
mice." Annu Rev Genet 20: 465-99.
Pandol, S. J. (2005). "Acute pancreatitis." Cun- Opin Gastroenterol 21(5): 
538-43.
Pandya, A., S. H. Blanton, et al. (1996). "Linkage studies in a large kindred 
with hereditary pancreatitis confirms mapping of the gene to a 16- 
cM region on 7q." Genomics 38(2): 227-30.
Parkin, D. M., F. Bray, et al. (2005). "Global cancer statistics, 2002." CA 
Cancer J Clin 55(2): 74-108.
Pastor, C. M. and J. L. Frossard (2001). "Are genetically modified mice 
useful for the understanding of acute pancreatitis?" FASEB J 15(6): 
893-7.
Pavlov, I. The work of the digestive glands.
Perrault, J. (1994). "Hereditary pancreatitis." Gastroenterol Clin North Am 
23: 743-52.
Petersen, O. H., O. V. Gerasimenko, et al. (1998). "The calcium store in 
the nuclear envelope." Cell Calcium 23(2-3): 87-90.
Pezzilli, R. (2009). "Etiology of chronic pancreatitis: has it changed in the 
last decade?" World J Gastroenterol 15(38): 4737-40.
Pfutzer, R., E. Myers, et al. (2002), "Novel Cationic trypsinogen (PRSS1) 
N29T and R122C mutations cause autosomal dominant Hereditary 
Pancreatitis." Gut 50: 271-2.
Pfutzer, R. H., M. M. Barmada, et al. (2000). "SPINK1/PSTI 
polymorphisms act as disease modifiers in familial and idiopathic 
chronic pancreatitis." Gastroenterology 119(3): 615-23.
Postic, C., M. Shiota, et al. (1999). "Dual roles for glucokinase in glucose 
homeostasis as determined by liver and pancreatic beta cell-specific 
gene knock-outs using Cre recombinase." J Biol Chem 274(1): 
305-15.
Quaife, C. J., C. A. Pinkert, et al. (1987). "Pancreatic neoplasia induced by 
ras expression in acinar cells of transgenic mice." Cell 48(6): 1023- 
34.
233
Raimondi, S., A. B. Lowenfels, et al. (2010). "Pancreatic cancer in chronic 
pancreatitis; aetiology, incidence, and early detection." Best Pract 
Res Clin Gastroenterol 24(3): 349-58.
Raraty, M., J. Ward, et al. (2000). "Calcium-dependent enzyme activation 
and vacuole formation in the apical granular region of pancreatic 
acinar cells." Proc Natl Acad Sci U S A 971241: 13126-31.
Raraty, M. G., S. Connor, et al. (2004). "Acute pancreatitis and organ 
failure: pathophysiology, natural history, and management 
strategies." Curr Gastroenterol Rep 6(2): 99-103.
Rebours, V., M. C. Boutron-Ruault, et al. (2009). "The natural histoiy of 
hereditary pancreatitis: a national series." Gut 58(1): 97-103.
Rebours, V., M. C. Boutron-Ruault, et al. (2008). "Risk of pancreatic 
adenocarcinoma in patients with hereditary pancreatitis: a national 
exhaustive series." Am J Gastroenterol 103(1): 111-9.
Rinderknecht, H. (1986). "Activation of pancreatic zymogens. Normal 
activation, premature intrapancreatic activation, protective 
mechanisms against inappropriate activation." Dig Pis Sci 31(3): 
314-21.
Rinderknecht, H., N. F. Adham, et al. (1988). "A possible zymogen self- 
destruct mechanism preventing pancreatic autodigestion." Int J 
Pancreato!3(l): 33-44.
Rinderknecht, H., E. R. Engeling, et al. (1974). "A sensitive assay for 
human enterokinase and some properties of the enzyme." Clin 
Chim Acta 54(2): 145-60.
Rinderknecht, H., I. G. Renner, et al. (1984). "Mesotrypsin: a new 
inhibitor-resistant protease from a zymogen in human pancreatic 
tissue and fluid." Gastroenterology 86(4): 681-92.
Rinderknecht, H., I. G. Renner, et al. (1979). "Trypsinogen variants in 
pancreatic juice of healthy volunteers, chronic alcoholics, and 
patients with pancreatitis and cancer of the pancreas." Gut 20(10): 
886-91.
Riordan, J. R., J. M. Rommens, et al. (1989). "Identification of the cystic 
fibrosis gene: cloning and characterization of complementary 
DNA." Science 245(4922): 1066-73.
Robertson, E., A. Bradley, et al. (1986). "Germ-line transmission of genes 
introduced into cultured pluripotential cells by retroviral vector." 
Nature 323(6087): 445-8.
Rosendahl, J., H. Witt, et al. (2008). "Chymotrypsin C (CTRC) variants 
that diminish activity or secretion are associated with chronic 
pancreatitis." Nat Genet 40(1): 78-82.
Rowen, L., B. F. Koop, et al. (1996). "The complete 685-kilobase DNA 
sequence of the human beta T cell receptor locus." Science 
272(5269): 1755-62.
234
Rowen, L., E. Williams, et al. (2005). 11Interchromosomal segmental 
duplications explain the unusual structm*e of PRSS3, the gene for 
an inhibitor-resistant trypsinogen." Mol Biol Evol 22(8): 1712-20.
Rozenblum, E., M. Schutte, et al. (1997). "Tumor-suppressive pathways in 
pancreatic carcinoma." Cancer Res 57(9): 1731-4.
Sahin-Toth, M. (2000). "Human cationic trypsinogen. Role of Asn-21 in 
zymogen activation and implications in hereditary pancreatitis." J 
Biol Chem 275(30): 22750-5.
Sahin-Toth, M. (2001). "The pathobiochemistry of hereditaiy pancreatitis: 
studies on recombinant human cationic trypsinogen." 
Fancreatologv 1(5): 461-5.
Sahin-Toth, M. (2005). "Human mesotrypsin defies natural trypsin 
inhibitors: from passive resistance to active destruction." Protein 
PeotLett 12(5): 457-64.
Sahin-Toth, M. (2006). "Biochemical Models of Hereditary Pancreatitis." 
Endocrine And Metabolic Clinics of North America 35(2): 303- 
312.
Sahin-Toth, M., L. Graf, et al. (1999). "Trypsinogen stabilization by 
mutation Argll7~>His: a unifying pathomechanism for hereditaiy 
pancreatitis?" Biochem Biophvs Res Commun 264(2): 505-8.
Sahin-Toth, M., Z. Kukor, et al. (2006). "Human cationic trypsinogen is 
sulfated on TyiT54." Febs J 273(22): 5044-50.
Sahin-Toth, M. and M. Toth (2000). "Gain-of-function mutations 
associated with hereditary pancreatitis enhance autoactivation of 
human cationic trypsinogen." Biochem Biophvs Res Commun 
278(2): 286-9.
Saluja, A., S. Hashimoto, et al. (1987). "Subcellular redistribution of 
lysosomal enzymes during caerulein-induced pancreatitis." Am J 
Phvsiol 253(4 Pt 1): G508-16.
Saluja, A., I. Saito, et al. (1985). "In vivo rat pancreatic acinar cell function 
during supramaximal stimulation with caemlein." Am J Phvsiol 
249(6 Pt 1): G702-10.
Sato, T. and Y. Saito (1974). "Familial chronic pancreatitis associated with 
pancreatic lithiasis." Am J Sum 127(5): 511-7.
Sauer, B. and N. Henderson (1989). "Cre-stimulated recombination at 
loxP-containing DNA sequences placed into the mammalian 
genome." Nucleic Acids Res 17rik 147-61.
Scheele, G., D. Bartelt, et al. (1981). "Characterization of human exocrine 
pancreatic proteins by two-dimensional isoelectric focusing/sodium 
dodecyl sulfate gel electrophoresis." Gastroenterology 80(3): 461- 
73.
Schneider, A., M. M. Barmada, et al. (2004). "Transforming growth factor- 
beta 1, interleukin-10 and interferon-gamma cytokine 
polymorphisms in patients with hereditaiy, familial and sporadic 
chronic pancreatitis." Pancreatology 4(6): 490-4.
235
Schutte, M., R. H. Hmban, et al. (1996). "DPC4 gene in various tumor 
types." Cancer Res 56(11): 2527-30.
Selig, L., U. Sack, et al. (2006). "Characterisation of a transgenic mouse 
expressing R122H human cationic trypsinogen." BMC 
Gastroenterol 6: 30.
Sharer, N., M. Schwarz, et al. (1998). "Mutations of the cystic fibrosis gene 
in patients with chronic pancreatitis." N Engl J Med 339(10): 645- 
52.
Sharpless, N. E. (2005). "INK4a/ARF: a multifunctional tumor suppressor 
locus." Mutat Res 576(1-2): 22-38.
Sherwood, M. W., I. A. Prior, et al. (2007). "Activation of trypsinogen in 
large endocytic vacuoles of pancreatic acinar cells." Proc Natl Acad 
Sci U S A 104(13): 5674-9.
Shields, J. M., K. Pruitt, et al. (2000). "Understanding Ras: 'it ain't over 'til 
it’s over'." Trends Cell Biol 10(4): 147-54.
Sibert, J. R. (1978). "Hereditary pancreatitis in England and Wales." J Med 
Genet 15: 189-201.
Simon, P., F. U. Weiss, et al. (2002). "Hereditary pancreatitis caused by a 
novel PRSS1 mutation (Arg-122 —> Cys) that alters autoactivation 
and autodegradation of cationic trypsinogen." J Biol Chem 277(7): 
5404-10.
Siimatamby, C. (2000). Abdomen. Last's Anatomy: Regional And Applied. 
London, Churchill Livingston.
Sossenheimer, M. J., C. E. Aston, et al. (1997). "Clinical characteristics of 
hereditary pancreatitis in a large family, based on high-risk 
haplotype. The Midwest Multicenter Pancreatic Study Group." Am 
J Gastroenterol 92: 1113-1116.
Southern, E. M. (1975). "Detection of specific sequences among DNA 
fragments separated by gel electrophoresis." J Mol Biol 98(3): 503- 
17.
Steer, M. L. and J. Meldolesi (1988). "Pathogenesis of acute pancreatitis." 
Annu Rev Med 39: 95-105.
Steinberg, W. M. and S. E. Schlesselman (1987). "Treatment of acute 
pancreatitis. Comparison of animal and human studies." 
Gastroenterology 93(6): 1420-7.
Stuenkel, E. L., T. E. Machen, et al. (1988). "pH regulatory mechanisms in 
rat pancreatic ductal cells." Am J Physiol 254(6 Pt 1): G925-30.
Sutton, R., D. Griddle, et al. (2003). "Signal transduction, calcium and 
acute pancreatitis." Pancreatology 3(6): 497-505.
Szilagyi, L., E. Kenesi, et al. (2001). "Comparative in vitro studies on 
native and recombinant human cationic trypsins. Cathepsin B is a 
possible pathological activator of trypsinogen in pancreatitis." J 
Biol Chem 276(27): 24574-80.
236
Szmola, R., Z. Kiikor, et al. (2003). "Human mesotrypsin is a unique 
digestive protease specialized for the degradation of trypsin 
inhibitors." JBiol Chem 278(49): 48580-9.
Szmola, R. and M. Sahin-Toth (2007). "Chymotrypsin C (caldecrin) 
promotes degradation of human cationic trypsin: identity with 
Rinderknecht's enzyme Y." Proc Natl Acad Sci USA 104(27): 
11227-32.
Tautemiami, G., H. Ruebsamen, et al. (2001). "R116C mutation of cationic 
trypsinogen in a Turkish family with recurrent pancreatitis 
illustrates genetic microheterogeneity of hereditary pancreatitis." 
Digestion 64(4): 226-32.
Teich, N., N. Bauer, et al. (2002). "Mutational screening of patients with 
nonalcoholic chronic pancreatitis: identification of further 
trypsinogen variants." Am J Gastroenterol 97(2): 341-6.
Teich, N., H. Bodeker, et al. (2002). "Cathepsin B cleavage of the 
trypsinogen activation peptide." BMC Gastroenterol 2:16.
Teich, N., A. Hoffmeister, et al. (2000). "Nomenclature of trypsinogen 
mutations in hereditary pancreatitis." Hum Mutat 15(2): 197-8.
Teich, N., C. Le Marechal, et al. (2004). "Interaction between trypsinogen 
isoforms in genetically determined pancreatitis: mutation E79K in 
cationic trypsin (PRSS1) causes increased transactivation of 
anionic trypsinogen (PRSS2)." Hum Mutat 23(1): 22-31.
Teich, N., J. Mossner, et al. (1998). "Mutations of the cationic trypsinogen 
in hereditary pancreatitis." Hum Mutat 12(1): 39-43.
Teich, N., J. Mossner, et al. (1999). "Screening for mutations of the 
cationic trypsinogen gene: are they of relevance in chronic 
alcoholic pancreatitis?" Gut 44(3): 413-6.
Teich, N., J. Ockenga, et al. (2000). "Chronic pancreatitis associated with 
an activation peptide mutation that facilitates trypsin activation." 
Gastroenterology 119: 461-5.
Teich, N., J. Ockenga, et al. (2000). "Chronic pancreatitis associated with 
an activation peptide mutation that facilitates trypsin activation." 
Gastroenterology 119(2): 461-5.
Thomas, K. R. and M. R. Capecchi (1990). "Targeted disruption of the 
murine int-1 proto-oncogene resulting in severe abnormalities in 
midbrain and cerebellar development." Nature 346(6287): 847-50.
Thompson, S., A. R. Clarke, et al. (1989). "Genu line transmission and 
expression of a conected HPRT gene produced by gene targeting in 
embryonic stem cells." Cell 56(2): 313-21.
Thom, P., O. Gerasimenko, et al. (1994). "Cyclic ADP-ribose regulation of 
ryanodine receptors involved in agonist evoked cytosolic Ca2+ 
oscillations in pancreatic acinar cells." EMBQ J 13(9): 2038-43.
Toh, S. K., S. Phillips, et al. (2000). "A prospective audit against national 
standards of the presentation and management of acute pancreatitis 
in the South of England." Gut 46(2): 239-43.
237
Torres, R. J. and J. G. Puig (2007). "Hypoxanthine-guanine 
phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan 
syndi*ome." Orphanet J Rare Pis 2: 48.
Tnminger, K., R. W. Ammann, et al. (2001). ’’Genetic aspects of chronic 
pancreatitis: insights into aetiopathogenesis and clinical 
implications." Swiss Med Wklv 131(39-40): 565-74.
Tsunoda, Y., E. L. Stuenkel, et al. (1990). "Characterization of sustained 
[Ca2+]i increase in pancreatic acinar cells and its relation to 
amylase secretion." Am J Phvsiol 259(5 Pt 1): G792-801.
Uhl, W., A. Warshaw, et al. (2002). 'TAP Guidelines for the Surgical 
Management of Acute Pancreatitis." Pancreatology 2(6): 565-73.
Ulrich, C. D., 2nd, E. Kopras, et al. (2000). "Hereditary pancreatitis: 
epidemiology, molecules, mutations, and models." J Lab Clin Med 
136(4): 260-74.
van Acker, G. J., G. Perides, et al. (2006). "Co-localization hypothesis: a 
mechanism for the intrapancreatic activation of digestive enzymes 
during the early phases of acute pancreatitis." World J 
Gastroenterol 12(13): 1985-90.
Yitone, L. J., W. Greenhalf, et al. (2006). "The inherited genetics of 
pancreatic cancer and prospects for secondary screening." Best 
Pract Res Clin Gastroenterol 20(2): 253-83.
Wagner, E. F,, T. A. Stewart, et al. (1981). "The human beta-globin gene 
and a functional viral thymidine kinase gene in developing mice." 
Proc Natl Acad Sci U S A 78(8): 5016-20.
Wagner, T. E., P. C. Hoppe, et al. (1981). "Microinjection of a rabbit beta- 
globin gene into zygotes and its subsequent expression in adult 
mice and their offspring." Proc Natl Acad Sci U S A 78(10): 6376- 
80.
Watanabe, O., F. M. Baccino, et al. (1984). "Supramaximal caemlein 
stimulation and ultrastructure of rat pancreatic acinar cell: early 
morphological changes during development of experimental 
pancreatitis." Am J Phvsiol 246(4 Pt 1): G457-67.
Weiss, F. U., P. Simon, et al. (2005). "Complete cystic fibrosis 
transmembrane conductance regulator gene sequencing in patients 
with idiopathic chronic pancreatitis and controls." Gut 54(10): 
1456-60.
Whitcomb, D. C. (1999). "Hereditary pancreatitis: new insights into acute 
and chronic pancreatitis." Gut 45: 317-22,
Whitcomb, D. C. (2001). "Hereditary pancreatitis: a model for 
understanding the genetic basis of acute and chronic pancreatitis." 
Pancreatology 1(6): 565-70.
Whitcomb, D. C. (2004). "Mechanisms of disease: Advances in 
understanding the mechanisms leading to chronic pancreatitis." Nat 
Clin Pract Gastroenterol Hepatol 1(1): 46-52.
238
Whitcomb, D. C. (2004). "Value of genetic testing in the management of 
pancreatitis." Gut 53(11): 1710-7.
Whitcomb, D. C., M. C. Goixy, et al. (1996). "Hereditary pancreatitis is 
caused by a mutation in the cationic trypsinogen gene." Nat Genet 
14(2): 141-5.
Whitcomb, D. C. and M. E. Lowe (2007). "Human pancreatic digestive 
enzymes." Dig Pis Sci 52(T): 1-17.
Whitcomb, D. C., R. A. Preston, et al. (1996). "A gene for hereditary 
pancreatitis maps to chromosome 7q35." Gastroenterology 110(6): 
1975-80.
Williams, J. A. (2006). "Regulation of pancreatic acinar cell function." 
Cult Opin Gastroenterol 22(5): 498-504.
Williams, J. A. and M. J. Dimagno (2009). "Can too much acid sour your 
pancreas?" Gastroenterology 137(3): 779-82.
Wilson, P. G., M. Manji, et al. (1998). "Acute pancreatitis as a model of 
sepsis." J Antimicrob Chemother 41 Suppl A: 51-63.
Witt, H., W. Luck, et al. (1999). "A signal peptide cleavage site mutation 
in the cationic trypsinogen gene is strongly associated with chronic 
pancreatitis." Gastroenterology 117(1): 7-10.
Witt, H., W. Luck, et al. (1999). "A signal peptide cleavage site mutation 
in the cationic trypsinogen gene is strongly associated with chronic 
pancreatitis." Gastroenterology 117(1): 7-10.
Witt, H., W. Luck, et al. (2001). "Mutation in the SPINK1 trypsin inhibitor 
gene, alcohol use, and chronic pancreatitis." JAMA 285(21): 2716- 
7.
Witt, H., W. Luck, et al. (2000). "Mutations in the gene encoding the serine 
protease inhibitor, Kazal type 1 are associated with chronic 
pancreatitis." Nat Genet 25(2): 213-6.
Witt, H., M. Sahin-Toth, et al. (2006). "A degradation-sensitive anionic 
trypsinogen (PRSS2) variant protects against chronic pancreatitis." 
Nat Genet 38f6L 668-73.
Yadav, D., R. H. Hawes, et al. (2009). "Alcohol consumption, cigarette 
smoking, and the risk of recurrent acute and chronic pancreatitis." 
Arch Intern Med 169Q L): 1035-45.
Yadav, D. and A. B. Lowenfels (2006). "Trends in the epidemiology of the 
first attack of acute pancreatitis: a systematic review." Pancreas 
33(4): 323-30.
239
